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FOREWORD 
 
The School of Pharmacy and Pharmaceutical Sciences, Cardiff University, is the only 
school of pharmacy in Wales and is one of the top schools of pharmacy in the UK, 
currently being ranked first in The Guardian league table. Our students graduate well-
prepared and satisfied, as seen by the consistently high pass rate in the pharmacist 
registration examination and high ranking in the National Student Survey respectively. 
 
In addition to supporting individual pharmacists in their initial and ongoing education and 
development, the School is active in research that has been independently judged to be 
predominantly of international standing, more than half of which is recognised as world-
leading or internationally excellent and with many interdisciplinary and external 
collaborators. Research at the School encompasses medicinal chemistry, drug delivery 
and microbiology, pharmacology and physiology, and pharmacy practice and clinical 
pharmacy, and it impacts on healthcare and pharmaceutical sciences throughout the UK 
and the world. Further information on the School’s research activities and degree 
programmes, along with contact details for academic staff can be found at 
http://www.cardiff.ac.uk/phrmy. 
 
At the Cardiff School of Pharmacy and Pharmaceutical Sciences, the combination of these 
strengths allows us to successfully deliver research-led learning and teaching. All of our 
MPharm students undertake a significant, independent Masters level research project in 
the final year of the four year degree, and present and defend their research. The large 
numbers of well-qualified UK, EU and international students that we attract to our 
postgraduate diplomas and degrees also contribute significantly to our research output. 
 
This is the 13th year in which we have published the abstracts of our students’ research. 
Within this publication the student is the first named author, and collaborators and 
supervisors follow. An alphabetical list of authors appears in the index. 
 
Many thanks to my colleagues for their assistance in collating this book, most especially Dr 
Keith Brain. 
 
Rebecca Price-Davies 
July 2013 
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Antimicrobial activity and surface structure of silver nanoparticles coated surfaces 
prepared by Metal Plasma Immersion Ion Implantation and Deposition (MePIIID) 
Izyan Abdul Samad and P Prokopovich 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Silver nanoparticles is shown to have effective antibacterial activity1,2 and is used for coatings of medical 
devices2. In this project, we are investigating the antibacterial properties of five silver nanoparticles coating 
samples prepared by Metal Plasma Immersion Ion Implantation and Deposition (MePIIID) against Gram-
negative bacterium Escherichia coli (E. coli) and Gram-positive bacterium Staphylococcus aureus (S. 
aureus) at two different incubation time, 5 and 24 hours. We are also measuring the surface roughness and 
analyzing the surface morphology of the prepared samples by observing the Atomic Force Microscope 
(AFM) images of each sample. The coating method used, MePIIID is a combination of plasma immersion ion 
implantation and deposition of metals3,4. The main aims of this experiment are to prove MePIIID 
methodology of silver nanoparticles coating preparation produce an effective antimicrobial activity, observing 
difference in activity against two types of bacteria at two incubation time, and observing if there is any 
correlation between sample surface roughness and antimicrobial activity.   
The experiment involves plating of bacteria on agar plate to count the number of colonies form, in order to 
determine the viable count per area sample of 1cm2. The samples are firstly incubated with dilute bacteria 
suspension in a 24-well plate for either 5 or 24 hours, and later undergo steps like washing and vortexing.  
Lower mean viable count/cm2 of silver-coated samples compared to control showing that there is 
antibacterial activity but it is considered weak and not effective activity due to a high number of surviving 
bacteria remaining. There is greater activity against E. coli than S. aureus and no correlation found between 
surface roughness and antimicrobial activity.  
In conclusion, weak antibacterial activity could be due to ineffective silver coating preparation, suggesting 
that silver nanoparticles coating method by MePIIID as prepared in this project is less effective in producing 
profound antibacterial activity. 
1. Kim JS, Kuk E, Yu KN, et al. Antimicrobial effects of silver nanoparticles. Nanomedicine : nanotechnology, biology, and medicine. 
2007; 3(1):95-101. 
2. Sondi I, Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative 
bacteria. Journal of Colloid and Interface Science. 2004; 275(1):177-82. 
3. Anders A. Metal plasma immersion ion implantation and deposition: a review. Surface and Coating Technology. 1997; 93(2-3):158 -
67. 
4. Kang BS, Sul YT, Jeong Y, et al. Metal plasma immersion ion implantation and deposition (MePIIID) on screw-shaped titanium 
implant: The effects of ion source, ion dose and acceleration voltage on surface chemistry and morphology. Medical engineering & 
physics. 2011; 33(6):730-8. 
 
Learning Outcomes as a tool to explore final year MPharm undergraduate students’ 
perceptions of preparedness for pharmacy practice 
Moushumi Shaila Ahmed and E Mantzourani 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Every year almost 3000 pharmacy students graduate from the UK but it is unknown how many of these feel 
equipped with the necessary competencies for pharmacy practice.1 There is limited published research 
around whether the degree is effective in preparing students for the workplace environment.2 This study aims 
to determine the perception of final year Cardiff MPharm students’ preparedness for pharmacy practice 
measured against curriculum assessments and GPhC learning outcomes. 
School ethics approval was granted from the university research committee. Purposive sampling was used to 
recruit 19 participants; characteristics considered during sampling were gender, ethnicity and nationality.3 
Two focus groups and nine semi-structured interviews were conducted. Each focus group and interview was 
audio-taped with consent, then transcribed (ad verbatim) before being analysed using the code and retrieve 
method, producing a thematic framework. Themes identified were used to inform the development of a 
questionnaire.4 
Participants identified their perceptions of preparedness using GPhC learning outcomes and assessment 
show cards. The findings showed participants had a high level of perceived preparedness for pharmacy 
practice and on whole met the GPhC and curriculum outcomes. However the extent of preparedness differed 
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amongst students. Those who had experience outside of university felt more prepared with respect to 
dispensing, over the counter (OTC) supply and working with other healthcare disciplines. Students felt 
assessments were useful to assess competence but thought they did not provide an accurate measurement 
of their actual performance as a pharmacist due to time constraints and artificial environment setting. 
The Cardiff MPharm degree provides students with the knowledge for pharmacy practice but the variance in 
the preparedness of students needs to be reduced. This study advocates more time dedicated to OTC 
supply, dispensing and hospital placements. This should result in qualified pharmacists from accredited 
GPhC degrees starting at a higher more uniform level. 
1. Willis SC, Hassell K, Seston EM, Hann M. Using learning outcomes for undergraduate pharmacy education to assess final-year 
students' perceptions of their preparedness for pharmacy practice. International Journal of Pharmacy Practice. 2009; 17: 351-358. 
2. Wilson K et al. MPharm Programmes: Where Are We Now? London: Royal Pharmaceutical Society of Great Britain. 2005. 
3. Wengraf T. Qualitative research interviewing: biographic narrative and semi-structured methods. London: Sage 2001. 
4. Bloor M, Frankland J, Thomas M, Robson K. Focus groups in social research sage publications. London: Sage. 2001. 
 
Investigating the relationship between polar surface area and skin penetration of 
topical medications 
Jumanah Altabtabai and AW White  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Skin penetration of topical medication is an important challenge to drug delivery.¹ Polar surface area (PSA) is 
the sum of polar surfaces, particularly nitrogen and oxygen, including the attached hydrogen atoms.² This 
can be an important indicator how successfully a topical drug in permeates the skin. This can be assessed 
by investigating the relationship between topographical polar surface area (tPSA) and skin permeation (J). 
Depending on the results of the evaluation, it would lead to a decision whether PSA can be applied as a rule 
of thumb for predicting successful topical medication candidates. 
Relevant literature reporting skin penetration of topical medication was obtained. The reported compounds 
and derivatives were drawn using chemical structure drawing software to automatically calculate tPSA 
values. The value was then plotted against reported J-values using Microsoft Excel to enable the generation 
of charts to determine the relationship, if any, between tPSA and J to test the project hypothesis.  
The results were found to indicate some good R² values, which demonstrates the linearity of the relationship. 
However, the best data available included only seven compounds, which is still a low number.  
Further investigation of the relationship is required. This can be achieved by calculating PSA of 3D 
structures, and laboratory experimentation of skin penetration. After completing the research, it was 
concluded that there is an inverse relationship between tPSA and skin penetration. However, more work 
needed as there was a limited number of compounds and lack of time supplied.  
1. Lane ME. Skin penetration enhancers. International journal of pharmaceutic. 2013; 447(1-2): 12-21. 
2. Williams A. Transdermal and topical drug delivery: From theory to clinical practice, Pharmaceutical Press, London, 2003. 
 
Characterising changes in the numerical competence and confidence of students 
between MPharm I and MPharm II 
Farah Arikat, DN John and SA Coulman 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Diagnostic numeracy tools are valuable in testing inherent numeracy skills of incoming university students.1 
The study aims were to use a diagnostic numeracy tool to establish if the numerical competence and 
confidence of MPharm students at Cardiff School of Pharmacy and Pharmaceutical Sciences (CSPPS) 
improved after one year in higher education and to determine the factors which govern numeracy skills. 
In October 2011, CSPPS MPharm I students (N=140) sat a contextualised diagnostic numeracy test and one 
year later (on entering MPharm II) sat exactly the same test. Statistical analyses were conducted using 
SPSS. 
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Score (p<0.001) and confidence (p<0.001) significantly increased between Year 1 (score=20.3±4.33; 
confidence=18.2±6.17) and Year 2 (score=22.2±3.36; confidence=21.5±4.61). Students principally educated 
in Malaysia had higher scores and greater confidence. This was also true for students whose highest 
mathematics qualification was A level compared to those without A level. Scores and confidence did not 
differ significantly between males and females. The most incorrectly and least confidently answered 
questions involved unit conversions and multi-step calculations. 
Feedback after test 1 and MPharm I pharmaceutical calculations teaching may have contributed to the 
significant improvement in numeracy skills between the two study time points. Different countries’ teaching 
methods2 can impact on numeracy skills and MPharm students with A level mathematics have previously 
demonstrated stronger numeracy skills than those without.3 This study supports those observations. The lack 
of difference between males and females does not agree with the literature4 relating to students in other 
scientific disciplines. However, males made up only 24% of the study group. A limitation of the study is that 
students from only one School of Pharmacy were involved. Future research could see the involvement of 
other Schools of Pharmacy.  
1. Sharif S, Gifford LA, Morris GA, Barber J. Diagnostic testing of first year pharmacy students: a tool for targeted student support. 
Pharmacy Education. 2007; 7:215-221. 
2. Hitch G, West D, Jee R, Foulsham R, Pearce B. A novel visually-displayed test for assessing numerical skills in pharmacy 
undergraduates. Pharmacy Education. 2010; 10:144-148. 
3. Lee S, Browne R, Dudzic S, Stripp C. Understanding the UK Mathematics Curriculum Pre-Higher Education: a guide for Academic 
Members of Staff. Leicestershire: The Higher Education Engineering Subject Centre; 2010. 
4. Tariq VN, Qualter P, Roberts S, Appleby Y, Barnes L. Mathematical literacy in undergraduates: role of gender, emotional 
intelligence and emotional self-efficacy. Int J Math Educ Sci Tech. 2013; [accessed 10 Mar 2013]. Available from: 
http://www.tandfonline.com/doi/pdf/10.1080/0020739X.2013.770087. 
 
Imaging and analysis of bacterial pulpal tooth infection and its effect on pulpal cells 
Jessica Arneil, J Roberts and J-Y Maillard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Streptococcus anginosus is recognised as one of the earliest colonisers involved in pulpal infection1 which 
can lead to pulp necrosis and irreversible tissue damage.2 Triclosan could potentially be an alternative 
treatment option to a root canal, as it has both antibacterial and anti-inflammatory properties essential for 
healing pulpal tissue.3 This study aims to use confocal microscopy to obtain 3D images of how S. anginosus 
grows into pulpal tissue and to test the effects 300 µg/ml triclosan against the growth of S. anginosus. 
S. anginosus bacteria were standardised to 105 cfu/ml, stained with 1% FDA solution, and resuspended into 
a DMEM + 10% BHI co-culture media with a 0.22 µm filter. Triclosan was dissolved in 100% DMSO before 
diluting with the bacterial filtrate to create a concentration of 300 µg/ml. Two ml of this suspension was then 
used to inoculate 2 mm thick rat tooth slices anaerobically (5% CO2) at 37ºC for 24 hours. Samples were 
stained with Hoechst then viewed with a confocal laser scanning microscope at X20 magnification using two 
different protocols.  
The images produced showed S. anginosus growth in scattered colonies throughout pulpal tissue with co-
localisation between bacterial and pulpal cells. The bacteria were present at least 100 µm into the pulpal 
tissue as viewed with a z-stack image. Triclosan reduced the growth of S. anginosus in the pulp compared to 
samples incubated without triclosan. 
Although clear trends were observed demonstrating that triclosan reduced the growth of S. anginosus in 
pulpal tissue, it was not possible to collect enough images to conduct a statistical analysis. Despite providing 
a promising future for the use of triclosan as an alternative treatment to a root canal in the presence of a 
pulpal infection, the experiment needs repeating to produce images clear enough to be counted. 
1. Love RM, Jenkinson HF. Invasion of Dentinal Tubules by Oral Bacteria. Critical Reviews in Oral Biology & Medicine. 2002; 
13(2):171-83. 
2. Suda H, Ikeda H. The Circulation of The Pulp. Seltzer and Bender's Dental Pulp. Illinois, USA: Quintessence Publishing. p. 2002; 
123-50. 
3. Kjaerheim V, Skaare A, Barkvoll P, Rolla G.. Antiplaque, antibacterial, and anti-inflammatory properties of triclosan mouthrinses in 
combination with zinc citrate or polyvinylmethylether maleic acid (PVM-MA) copolymer. European Journal of Oral Sciences. 1996; 
104(5-6):529-34. 
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Evaluating intra- and inter- individual variability in capsule puncture within dry 
powder inhalers 
Zahra M Atrah,1 F Diez,2 BE Jones1,2 and SA Coulman1 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK and 2Qualicaps Europe, Alcobenas, Madrid, Spain 
Dry powder inhalers (DPI) are a commonly used form of pulmonary drug delivery. Gelatin capsules have 
been used in single unit dose DPI since their introduction in 1971.1,2 However more recently hypromellose 
(HPMC) capsules have become available for use in DPI, with some reports claiming they have better 
puncturing properties than gelatin capsules.3 There has been little research into the inter- and intra- 
individual variability in capsule penetration. The aim of this study is to characterise the puncture performance 
of HPMC and gelatin capsules when perforated by a single pin DPI, operated by a member of the public. 
Following informed consent participants (n=36) were supplied with a Plastiape® monodose inhaler and 
instruction sheet before being handed, in random sequence, five HPMC and five gelatin size 3 capsules, 
which had been conditioned in desiccators over a saturated solution of calcium chloride (RH 33%). 
Participants were provided with a questionnaire to collect demographic data. Punctured capsules were 
imaged using a light microscope and the puncture area of both the cap and body was measured using Image 
J® software. 
The punctures in HPMC capsules (cap mean 1.58 ± 0.80, body mean 1.72 ± 0.79) were smaller and less 
variable than gelatin capsules (cap mean 3.21 ± 1.98, body mean 2.89 ± 1.34). Puncture appearance and 
flap condition were also more consistent in HPMC capsules than gelatin capsules. In agreement with 
previous publications, gelatin capsules appeared more brittle.3 
To conclude, the punctures created by a 2-pin inhaler in HPMC capsules appear to be more reproducible 
than those in gelatin capsules. Patient factors, such as age and previous inhaler experience, had no 
noticeable impact on the area of the puncture or the condition of the flap for both HPMC and gelatin 
capsules.  
1. Bell JH et al. Dry powder aerosols I: A new powder inhalation device. Journal of Pharmaceutical Sciences. 1971; 60(10):1559-1564. 
2. Broeders ME et al. The ADMIT series--issues in inhalation therapy. 2. Improving technique and clinical effectiveness. Prim Care 
Respir J. 2009; 18(2):76-82. 
3. Birchall JC et al. A comparison of the puncturing properties of gelatin and hypromellose capsules for use in dry powder 
inhalers.Drug Dev Ind Pharm. 2008; 34:870-876. 
4. Qualicaps. 2013. Pharmaceutical Capsules Quali-V [Online]. Qualicaps. Available at: 
http://www.qualicaps.com/pharmcaps/qualiv.aspx [Accessed: 4 February 2013].  
 
A study to determine the in vitro activity of antimicrobial peptides against various 
bacteria 
Jonathan Ayer and L Baillie  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The emergence of antibiotic resistant bacterial strains has caused clinicians to search for other sources of 
antimicrobials.1 Antimicrobial peptides (AMPs) are polyproteins isolated from various multicellular organisms. 
Resistance has been noted to develop slower to AMPs than to existing antibiotics.2,3 We determined the 
activity of a range of commonly derived AMPs against a panel of clinically and environmentally relevant 
bacteria in vitro to which resistance to classical antibiotics has been noted.4 This study investigates the 
activity of 6 AMPs: IL-37, IL-37 Scrambled, Bee defensin-1, Melittin, Pep 14 and Pep 15 against 6 different 
bacteria: Staphylococcus aureus, Escherichia coli, Mycobacterium smegmatis, M. abcessus, Paenibacillus 
larvae and Clostridium difficile. 
Serial dilutions generated 6 peptide concentrations ranging from 100, 75, 50, 25,10 and 5 (ug/ml). 1ml of a 1 
in 100 dilution of overnight broth culture of each bacterium was spread across the surface of agar 
appropriate for each bacterium before various concentrations of each peptide were spotted in 10ul drops. An 
appropriate antibiotic was used as a positive control for each bacterial strain. Plates were then incubated for 
24 hours at 37oC and the diameter of the resulting zones of inhibition were measured in millimetres to 
determine the minimum inhibitory concentrations (MICs). 
MPharm 
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Only two peptides demonstrated activity compared to the controls; melittin which was active against both S. 
aureus and P. larvae (MICs were 50ug/ml and 100ug/ml respectively), and bee defensin which was active 
against both C. difficile and P. larvae (5 ug/ml). 
AMPs seem to be good candidates for further investigation as future antimicrobials. If introduced, this would 
allow for a decrease reliance on classical antibiotics. Further investigation will increase understanding of the 
relationship between naturally derived peptides and the microbial challenge of the natural environment from 
which they are isolated.  
1. WHO. Containing Antimicrobial Resistance: Review of the Literature and Report of a WHO Workshop on the Development of a 
Global Strategy for the Containment of Antimicrobial Resistance. Geneva, Switzerland: World Health Organisation; 1999. 
2. Brogden NK, Brogden KA. Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals? Int J 
Antimicrob Agents. 2011;38(3):217-25. 
3. Laverty G, Gorman SP, Gilmore BF. The potential of antimicrobial peptides as biocides. Int J Mol Sci. 2011;12(10):6566-96. 
4. Giedraitienė A, Vitkauskienė A, Naginienė R, Pavilonis A. Antibiotic resistance mechanisms of clinically important bacteria. Medicina 
(Kaunas). 2011;47(3):137-46. 
 
6-chloro-penciclovir phosphate prodrugs as new anti-HIV agents 
Ruth Barry,1 C McGuigan,1 M Derudas,1 J Balzarini,2 L Margolis,3 and C Vanpouille3 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales, UK, 2Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10, B-3000 Leuven, 
Belgium, 3Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of 
Health, Bethesda, Maryland 20892 
Acyclovir has shown anti-HIV activity in patients co-infected with HSV and HIV.1 It was discovered that 
acyclovir could inhibit HIV reverse transcriptase1 due to its activation in co-infected patients by thymidine 
kinase.2 ProTides of acyclovir were synthesised and found to be active against HIV, however they were 
found to be cytotoxic3. In previous work, virtual screening of nucleoside analogues was carried out modifying 
the nucleoside base and/or the sugar moiety,3 among these 6-chloro-penciclovir showed a good profile and 
therefore was chosen for this project. Phosphate prodrugs have been synthesised to improve delivery of the 
drug as the monophosphate cannot be directly administered.4  
A ProTide, a cyclic phosphoramidate and a diamidate were designed and synthesised from 6-chloro-
penciclovir. A bis-protide and a bis-diamidate were also produced. Due to the presence of two hydroxyl 
groups, the synthesis of the mono-diamidate of 6-chloro-penciclovir was not achieved; therefore the 
monoacetylated 6-chloro-penciclovir was produced allowing synthesis of the diamidate. A 6-chloro-
monoacetylated ProTide was also synthesised.  
Enzyme tests using carboxypeptidase  in acetone-D6 and a trizma buffer were undertaken on CF3583, 
CF3584 and CF3596 to understand if the prodrugs could be activated. The compounds were sent for 
biological testing for their ability to inhibit HIV-1 (MT-4) cells. The EC50, CC50, and IC50 of the compounds 
were established. The nucleoside analogue, 6-chloro-penciclovir was inactive. All prodrugs produced were 
found to have a degree of anti-HIV activity. However they were also found to be cytotoxic. CF3595 showed 
promising results with a low EC50 and no cytotoxicity.  
Six phosphate prodrugs and two nucleoside analogues were synthesised. The aim of the project was 
achieved as prodrugs were synthesised to release a monophosphate drug to inhibit HIV-RT. All compounds 
showed activity, except the parent nucleoside. Most compounds were cytotoxic. CF3595 is currently being 
retested to confirm the results.  
1. Lisco A, Vanpouille C, Tchesnokov EP et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected 
human tissues. Cell Host Microbe. 2008;4(3):260-70. 
2. Vanpouille C, Lisco A, Introini A et al. Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV 
isolates and potentiation of the activity by ribavirin. Antimicrob Agents Chemother. 2012;56(5):2604-11. 
3. Derudas M. Design, Synthesis and Biological Evaluation of Novel Bioactive Nucleosides and Nucleotides. Cardiff: Cardiff University; 
2009. 
4. McGuigan C, Madela K, Aljarah M et al. Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug 
discovery: application to anti-HCV agents. J Med Chem. 201;54(24):8632-45. 
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Locating natriuretic peptide receptors in the rat myocardium 
Sarah Bergdoelmo, DS Burley, JS Bice and GF Baxter 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Myocardial ischaemia-reperfusion (I-R) injury is the paradoxical injury which occurs following reperfusion of 
ischaemic tissues. Following myocardial infarction, 50% of final infarct size is caused by I-R injury1 but at 
present, there are no effective treatments for this injury. Natriuretic peptides have been shown to reduce 
infarct size2, 3 by interacting with natriuretic peptide receptors and are believed to trigger signalling pathways 
leading to cGMP production, a cardioprotective second messenger.4 There is currently limited evidence to 
show that natriuretic peptide receptors are expressed at functional levels in the myocardium. We 
hypothesised that NPR-A, NPR-B and NPR-C would be present in rat ventricles and in isolated 
cardiomyocytes. 
Samples taken from naïve left and right ventricle tissue (n=4) were analysed using Western blotting to detect 
the three natriuretic peptide receptors: NPR-A, NPR-B and NPR-C. Cardiomyocytes were isolated by 
enzymatic digestion of left ventricle samples (n=4) and also analysed for the receptors using Western 
blotting. Reverse transcriptase polymerase chain reaction was used to determine whether mRNA for each of 
the receptors was present in the isolated cardiomyocytes. 
Western analysis showed that all three receptors were expressed in ventricle samples. Expression of NPR-A 
and NPR-B was shown to be higher in right ventricle samples than in left ventricle samples, while NPR-C 
was expressed more in left ventricle samples than in right ventricle samples. NPR-B and NPR-C were both 
expressed in isolated cardiomyocytes but results for NPR-A expression were inconclusive due to poor 
antibody specificity. RT-PCR results showed that transcripts for all three natriuretic peptide receptors were 
present in cardiomyocytes. 
Confirming the presence of natriuretic peptide receptors in the myocardium means that they could be 
potential targets for novel therapeutic strategies to reduce myocardial I-R injury. Further investigation is 
needed to examine the signalling pathways that are triggered by activation of these receptors. 
1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007 Sep;357(11):1121-35. 
2. Kitakaze M, Asakura M, Kim J et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute 
myocardial infarction (J-WIND): two randomised trials. Lancet. 2007 Oct;370(9597):1483-93. 
3. Hobbs A, Foster P, Prescott C, Scotland R, Ahluwalia A. Natriuretic peptide receptor-C regulates coronary blood flow and prevents 
myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide. Circulation. 
2004 Sep;110(10):1231-5. 
4. Burley DS, Ferdinandy P, Baxter GF. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and 
obstacles for survival signaling. Br J Pharmacol. 2007 Nov;152(6):855-69. 
 
A framework to support pharmacist-patient consultations through the medium of 
Welsh  
Rhodri Bevan and DH James  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The Medication-Related Consultation Framework (MRCF) is a tool providing pharmacists with a patient-
centered consultation structure to assist in identifying medication-related issues,1 and has recently been 
translated into Welsh. Pharmacies in Wales have a duty to consider the linguistic needs of the Welsh-
speaking public.2 The study aimed to explore pharmacy students’ and practitioners’ views about using a 
framework to support pharmacist-patient consultations in Welsh. 
The Welsh MRCF was distributed to ten pharmacy students and twenty practitioners from all areas of Wales. 
Semi-structured interviews plus one focus group were held with the participants. Written feedback forms 
were also used to aid in capturing feedback. Interviews were transcribed verbatim and two separate thematic 
analyses were carried out on the students’ and pharmacists’ data.  
Seven pharmacy students and thirteen pharmacy practitioners were interviewed. Overall, participants, 
thought that the Welsh MRCF was worthwhile and highlighted the significance of the Welsh language in 
establishing a good therapeutic pharmacist-patient relationship. Many had difficulty understanding the 
formality of the language used and did not believe that the current framework would make individuals feel 
confident about conducting consultations in Welsh. 
MPharm 
9 
Pharmacy students and practitioners liked the concept of having a framework in place but the formality of the 
language used in the current Welsh MRCF needs simplifying so that it can be understood by all levels of 
Welsh-speakers. Although it could be useful to provide structure to a consultation, further work would be 
needed to make it ‘fit for purpose’. 
1. Abdel-Tawab R, James D et al. Development and validation of the Medication-Related Consultation Framework (MRCF). Patient 
Education and Counselling. 2011; 83(3):451-457 
2. Hughes ML et al. The Role of the Welsh language in community pharmacy service provision in Wales. Pharmacy Practice Research 
Trust, London. 2008. 
 
Does cilengitide increase overall survival for patients with glioblastoma multiforme? 
A systematic review 
Olivia Bishop and M Smith 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Glioblastoma multiforme (GBM) is a highly aggressive and vascularised brain tumour that affects mostly the 
elderly with median survival of around 12 months following standard therapy of surgical resection followed by 
radiotherapy and temozolomide.1,2 Due to the fatality of this cancer and lack of established treatment for 
recurrent patients, there is need for further research to increase survival rates. A promising candidate 
cilengitide which is a cyclic arginine-glycine-aspartic acid peptide that antagonises integrins which play an 
important role in the growth of GBM.3 The primary aim of the project was to find out whether cilengitide 
increases overall survival and this was done by looking at studies that compared two doses 
(500mg/2000mg) and also looked at patients who received standard therapy alone and those who received it 
with cilengitide. 
Following a literature search, 77 potentially relevant articles were identified. The abstracts of these papers 
were analysed against inclusion/exclusion criteria. Four articles were identified against the inclusion criteria. 
Analysis of the papers was done by extracting individual hazard ratios and where this was not possible 
extracting survival curves and then generating summary statistics using Review Manager and Graphpad 
Prism.4 
The data shows there is an increase in overall survival for patients taking 2000mg compared to those taking 
500mg with hazard ratio of 0.42(95%CI,0.34-0.51) p < 0.00001. However, there was no significant increase 
in overall survival for patients taking 500mg cilengitide with radiotherapy and temozolomide compared to 
radiotherapy and temozolomide alone with hazard ratio of 0.81(95%CI,0.59-1.13) p > 0.05.  
Cilengitide shows some benefit and a high safety profile when given at a high dose (2000mg) for patients 
with Glioblastoma. However clinical trials need to be conducted to assess the effect of 2000mg cilengitide 
with radiotherapy and temozolomide. 
1. Huse JT et al. Glioblastoma: molecular analysis and clinical implications. Annu Rev Med. 2013; 64: 59-70. 
2. Dobelbower MC et al. USA Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. Journal 
of Medical Imaging and Radiation Oncology. 55: 77-81. 
3. Reardon DA et al. Randomized Phase II Study of cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in 
Recurrent Glioblastoma Multiforme. 2008; 26(34). 
4. Parmar et al. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 
England. 1998. 
 
The role of Wnt signalling in the pathogenesis of Alzheimer’s disease 
Orla Bonnar, RS Thomas, M Hvoslef-Eide and EJ Kidd 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Alzheimer’s disease (AD) is an irreversible, neurodegenerative disorder that leads to severe memory loss 
and cognitive decline.1 An accumulation of amyloid-β (Aβ) (cleaved from amyloid precursor protein (APP)) is 
thought to contribute to the pathology seen in AD.2 The London mutation mouse model used in these 
experiments overexpressed APP and consequently expressed Aβ with increasing age. Canonical Wnt 
signalling is thought to be dysfunctional in AD with debate surrounding its exact role.3 Most current studies 
suggest that pharmacologically upregulating Wnt signalling could be a viable treatment option in AD.3 This 
study investigated if there were any differences in canonical Wnt signalling between young, middle-aged and 
old wild-type (WT) and transgenic (TG) mice. 
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Cortices from WT and TG mice were extracted and levels of APP and Aβ determined. Levels of Wnt proteins 
total β-catenin, active β-catenin and Lef present were also investigated.  
Overexpression of APP was confirmed in TG mice of all ages, however, increased levels of Aβ were 
detected only in old TG mice. The findings in this study suggested that Wnt signalling was upregulated in 
young TG mice (as determined by increased levels of active β-catenin in young TG animals). At middle age 
there was no difference in Wnt signaling between WT and TG animals suggesting an interaction between 
APP and Wnt in young mice that is no longer present at middle age. Results suggested that Wnt signaling 
was again increased in old TG mice. 
It is probable that this suggested increase in Wnt signalling in old TG mice was in response to increased 
levels of Aβ. This increase implies that further upregulating the Wnt pathway may not be a feasible treatment 
option for AD and could potentially have detrimental effects. This study is important to help ascertain the 
eligibility of the Wnt pathway as a future pharmacological target.  
1. Di Carlo M, Giacomazza D, San Biagio PL. Alzheimer's disease: biological aspects, therapeutic perspectives and diagnostic tools. J 
Phys Condens Matter. 2012;24(24):244102. 
2. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-5. 
3. Boonen RA, van Tijn P, Zivkovic D. Wnt signaling in Alzheimer's disease: up or down, that is the question. Ageing Res Rev. 
2009;8(2):71-82. 
 
Calcium oxalate precipitate – a risk to parenteral nutrition patients? 
Rebecca Brain and R Price-Davies 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Parenteral nutrition (PN) is a method of feeding via the intravenous route.1 Throughout this research it has 
been the degradation product of the least stable component of PN, (vitamin C) that has been of interest. It 
has been theorised that the final breakdown product (oxalic acid) is able to form a practically insoluble 
precipitate of calcium oxalate (0.67mg/100ml water) in the presence of calcium.2 The aim was to find out the 
maximum amount of vitamin C that can be present with no calcium oxalate precipitate formation. 
Various concentrations of oxalic acid were added to calcium chloride until a precipitate was detected. 
Samples were visually inspected, turbidity and pH measurements were also recorded. Experiments were 
carried out at pH 5-7, 2-8°C, room temperature and 35°C. The next step was to react vitamin C with calcium 
chloride. 
Calcium oxalate solubility increased at lower pH and higher temperatures. In the reaction between ascorbic 
acid (0.96mg/100ml water) and calcium chloride at room temperature a precipitate was observed after 24 
hours. However, at 2-8°C no precipitate was observed for 96 hours.  
These experiments were carried out under conditions to drive the reaction; in the presence of oxygen and 
water allowing for oxidation and hydrolysis to occur. A catalyst was also present. Under clinical conditions 
procedures are put in place to minimise these. The use of multi-layered bags which are impermeable to 
oxygen have been shown to prevent against oxidative degradation.3,4 Providing PN is stored in these multi-
layered bags the commonly used levels of ascorbic acid is safe and unlikely to cause harm to PN patients. 
1. National Institute for Health and Care Excellence, 2013. When and how to give parenteral nutrition. NICE pathway. London: 
National Institute for Health and Care Excellence 
2. Das Gupta V. Stability of vitamins in total parenteral nutrient solutions. American Journal of Hospital pharmacy. 1986; 43(9):2138-
43. 
3. Berger M. Vitamin C Requirements in Parenteral Nutrition. Gastroenterology. 2009; 137:70-8. 
4. Munoz G, Sanchez M, Gonzalvez N et al. Stability of vitamins in parenteral nutrition: a comparison of multi-layer and EVA bags. 
Nutr Hosp. 1996; 11(5):259-64 
 
Prostate cancer cell exosomes are endocytosed by fibroblast cells 
Edel Brown, AT Jones, E Sayers and A Clayton1 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK and 1Velindre Hospital, Whitchurch, Cardiff CF14 2TL, Wales, UK 
Exosomes are nanosized vesicles secreted by many cells including tumours.1 Modified exosomes have 
shown potential as a mode of selective delivery to a target cell and this has led to growing clinical interest in 
exosomes, as possible drug delivery vehicles.2,3 In addition, current dogma suggests cancer exosomes 
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deliver TGF-ß to stromal fibroblast cells, which leads to their differentiation into myofibroblasts, resulting in 
the establishment of tumour tissue.4 There are however, significant gaps in our understanding of the physical 
interaction between cancer cell exosomes and fibroblast cells. Our aim was to develop a method of direct, 
fluorescent labelling of prostate cancer cell exosomes that would allow tracking of interactions with 
fibroblasts by confocal microscopy. 
Exosomes were purified from prostate cancer cells using the sucrose cushion isolation method and labelled 
using the fluorophore, Alexa Fluor® 488 C5 Maleimide. Fibroblasts were exposed to labelled exosomes 
and/or Dextran Alexa Fluor® 647 and/or Transferrin Alexa Fluor® 633 Conjugate at 4oC or 37oC. 
Colocalization was observed on the confocal microscope. 
Labelled exosomes were taken up by lung fibroblasts and significant colocalization with Dextran occurred as 
well as some colocalization with Transferrin. Exosome uptake was shown to be an active process and 
prostate cancer cell exosomes were taken up by endocytosis. A proportion of exosomes ended up in 
terminal lysosomes and some colocalized with the transferrin pathway.  
Although a proportion of exosomes are degraded in terminal lysosomes, some exosomes go to other cell 
compartments. In the future, it would be useful for us to mathematically quantify the colocalisation, to further 
investigate the potential of exosomes as drug delivery vehicles. In addition, knockdown of key proteins 
involved in endocytosis, such as AP2, clathrin and flotillin-1could help to further understand uptake 
mechanisms. This new information makes an exciting contribution to knowledge on the dynamics of 
exosomes in cancer. 
1. Clayton A, Mason MD. Exosomes in Tumour Immunity. 2009;16(3):46-9. 
2. van Dommelen SM, Vader P, Lakhal S et al. Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug 
delivery. J Control Release. 161. Netherlands: 2011 Elsevier B.V; 2012. p. 635-44. 
3. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted 
exosomes. Nat Biotechnol. 2011;29(4):341-5. 
4. Webber J, Steadman R, Mason MD, Tabi Z, Clayton A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer 
Res. 2010;70(23):9621-30. 
 
Examining the impact of video instructions on the forces used by members of the 
public to apply “dummy” microneedle patches 
Joshua Bugajski, DN John, JC Birchall and SA Coulman 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Microneedle devices are progressing rapidly towards the clinic with micron scale devices now in clinical trial. 
Minimal research has been conducted to examine the potential for self-administration of microneedles. The 
force required to apply a microneedle is a critical feature of microneedle penetration. Some microneedle 
designs, e.g.hollow silicon microneedles, exhibit a 5-fold safety margin between needle insertion and fracture 
force.1 This study aims to characterise the application forces used by members of the public to apply 
“dummy” microneedle patches after watching an instructional video, and to compare them to baseline data 
i.e. without an instructional video. 
The ethics committee at Cardiff School of Pharmacy and Pharmaceutical Sciences approved the study. An 
instructional video on microneedle application was developed. Demographic information (age, gender, any 
medical education and any experience of using needles) was recorded for each participant (n=41). 
Partcipants watched the information video before applying a force to the dummy microneedle patch, located 
both on the forearm and deltoid of themselves and the researcher, using a hand-held force gauge. Each 
measurement was repeated 3 times. Comments and observations were recorded. T-tests were used to 
analyse significance of results. 
The average force used was 20.70+/-13.8 (standard deviation) N. Results varied from 2.45N to 74.85N, a 
30-fold difference. This was comparable to the baseline data (n=50, mean=18.3+/-12.4N), which captured 
the intuitive forces used. Men (n=24, mean=25.4+/-15.0N) applied more force than women (n=17, 
mean=14.5+/6.8N) (P=0.004). Self-application forces (mean=25.42+/-14.8N) were significantly greater 
(P=0.004) than application to another person (mean=15.42+/- 11.1N).  
The study concluded that video instruction did not impact on the reproducibility of forces applied by 
participants. To reduce the inter-patient variability in self-application forces it will be necessary to use an 
applicator or manufacture microneedles that can perform safely and consistently over the recorded force 
range. 
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1. Davis SP, Landis BJ, Adams ZH, Allen MG, Prausnitz MR. Insertion of microneedles into skin: measurement and prediction of 
insertion force and needle fracture force. J Biomech. 2004 ; 37:1155–1163. 
 
Stability assessment of the new generation lipid emulsion, SMOFlipid®, in the 
presence of glucose and oxygen 
Rebecca L Carpenter, SE Emery and AG Cosslett 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The use of a mixed oil lipid emulsion containing fish oils rich in omega-3 fatty acids has been sought after to 
replace the more traditional pure soybean emulsions in parenteral nutrition.1 The third generation lipid 
emulsion, SMOFlipid®, was designed in an attempt to increase the ω-6: ω-3 ratio and improve patient 
outcome, however, uncertainty surrounding its potential increased oxidation risk has hindered its use in 
clinical nutrition support.2 The aim of this study was to generate pharmaceutical stability data for SMOFlipid® 
in the presence of glucose and oxygen, using a pure soybean emulsion, Intralipid®, for comparison. 
Laser diffraction (LD) and optical microscopy were carried out to measure globule size changes and related 
to results from visual inspection, pH and dissolved oxygen (DO) analysis. Two studies were carried out in 
succession, the first measuring the effect of a range of glucose concentrations (0 to 16%w/v) on emulsion 
stability, and the second analysing the effect of an oxygen rich environment on stability. In the latter, the 
hypothesis suggesting temperature affects DO levels was also investigated.3 Half of the samples were stored 
at 36°C, and the remainder at 4°C with calcium ions used as an agent to accelerate destabilisation.4 
For both emulsions, glucose alone at high concentrations managed to cause an increase in maximum 
globule size, which was then emphasized by the addition of calcium. Changes in pH correlated well with 
observed variations in the globule size changes however data from microscopy and LD did not always 
correlate. DO testing samples tested in the presence of oxygen, particularly stored in a cold environment, 
had expected increased in levels of DO. SMOFlipid® generally displayed a higher level of stability across all 
methods. 
The comparison of these two emulsions revealed the superiority of SMOFlipid® in the presence of both 
glucose and oxygen. Results suggest encouragement towards more frequent use of SMOFlipid® in current 
parenteral nutrition formulations. 
1. Koch T, Heller A. Beneﬁts of x-3 fatty acids in parenteral nutrition. Clinical Nutrition Supplements. 2005;1:17-24. 
2. Grimm H. A balanced lipid emulsion - A new concept in parenteral nutrition. Clinical Nutrition Supplements. 2005;1:25-30. 
3. Sun Y et al. Autoxidation of Unsaturated Lipids in Food Emulsion. Critical Reviews in Food Science and Nutrition. 2011; 5:1453-466. 
4. Washington C. The stability of intravenous fat emulsions in total parenteral nutrition mixtures. International Journal of 
Pharmaceutics. 1990;66: 1-21. 
 
Development of an algorithm for converting the Dermatology Life Quality Index 
(DLQI) into EQ-5D utility values using historical data 
Sue Wei Chong, AY Finlay1 and MS Salek  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK and 1Department of Dermatology and Wound Healing, School of Medicine, Cardiff University, UK 
The Dermatology Life Quality Index (DLQI) and EQ-5D are two instruments used to measure patient health-
related quality of life (HRQoL). The DLQI is a widely used dermatology-specific measure with high internal 
consistency and test-retest reliability.1 The EQ-5D on the other hand is a generic utility measure preferred by 
NICE for the purpose of obtaining utility values for economic analysis.2 DLQI scores can be mapped onto 
EQ-5D utility values in order to obtain utilities from studies where the EQ-5D was not used. Although there is 
an existing mapping model created by linear regression,3 this has several weaknesses. 
The aim of the study was to construct an improved algorithm to predict EQ-5D utility values from DLQI 
scores. Historical data was obtained from the University Hospital of Wales (n=256). Ordinal logistic 
regression, which has been used for mapping on previous occasions,4,5 was used to estimate the probability 
that a respondent will select any given level of response on the EQ-5D dimensions. Results were compared 
to predicted utilities obtained using the existing linear method.  
The ordinal model predicted over 40% of cases accurately while the linear model predicted none. However, 
the ordinal model was associated with higher mean squared error (MSE) and mean absolute error (MAE) 
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than the linear model, for both internal and external validation data sets. For both models, errors in prediction 
decreased as utility values increased, indicating that they perform poorly in poor health states. 
The findings indicate that the ordinal model is inconclusive for prediction of utility values in the data set used. 
The ordinal model may be useful for non-UK samples as it can be used with the country-specific EQ-5D 
scoring tariff. It provides more detailed information on patients’ health states than the linear model. It is 
recommended that this approach be repeated using a larger sample size to reduce standard errors and 
improve the model performance. 
1. Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994–2007: a comprehensive review of 
validation data and clinical results. British Journal of Dermatology 2008;159: 997–1035. 
2. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: National 
Institute for Health and Care Excellence; 2008. 
3. Currie CJ, Conway P. Evaluation of the association between EQ-5D utility and Dermatology Life Quality Index (DLQI) score in 
patients with psoriasis [Online]. Value in Health 2007; A470: PSK11. Abstract only. Available at: 
http://www.valueinhealthjournal.com/article/S1098-3015(10)65617-3/fulltext [Accessed: 5 February 2013] 
4. Gray AM, Rivero-Arias O, Clarke PM. Estimating the association between SF-12 responses and EQ-5D utility values by response 
mapping. Medical Decision Making 2006;26(1): 18-29. 
5. Rivero-Arias O, Ouellet M, Gray A, et al. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) 
health outcome. Medical Decision Making 2010;30(3): 341-354. 
 
Characterisation of new antihormone resistant breast cancer models developed 
from ER+/HER2- cells 
Samantha J Clitheroe, L Farrow, S Kyme, P Finlay, H Mottram, C Dutkowski, D Barrow and JMW Gee 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
MCF7-derived breast cancer models have revealed EGFR and HER2 cross-talk with oestrogen receptor 
(ER) in anti-hormone resistance,1 however promising preclinical targeting of these pathways alongside anti-
hormones is not always translated into clinic.2,3 The aim was to begin to characterize acquired resistant cells 
recently derived by continuous anti-hormone treatment of a further ER+ model, EFM19, as this may help 
clarify why some patients do not respond to combination therapies. 
A panel of continuously cultured control EFM19 (CONT), faslodex (FAS), tamoxifen (TAM) and oestrogen 
deprivation (SFCS, X) resistant cell lines were characterized for growth and EGFR (1μM gefitinib) or HER2 
(100nM Herceptin) inhibitor impact using Coulter Counting (n=3). A further experiment examined ER 
blockade (Faslodex 10-7M). Migration studies used Boyden Chambers (n=2) and ER expression and activity 
(PR, phospho-ER), EGFR and HER2 profiled using immunocytochemistry with HScoring (n=6 fields from two 
coverslips). 
While FAS resistant growth was slower (p=0.003), SFCS, X and TAM growth was equivalent to CONT. 
Migration decreased substantially in FAS, SFCS and X but increased in TAM by 205%. ER was decreased in 
FAS (p=0.002) but increased in SFCS and X (p=0.002) and was equivalent in TAM vs. CONT. PR decreased 
in all resistant lines (p=0.002) but phospho-ER remained detectable and TAM, SFCS and X were Faslodex 
growth-sensitive. EGFR (p=0.002) and HER2 increased in all resistant cells. TAM, SFCS and X were 
gefitinib sensitive and SFCS and X were Herceptin sensitive.  
TAM was the most aggressive model in keeping with superior clinical benefit of further anti-hormones vs. 
tamoxifen. All resistant models were ER dependent and second-line anti-hormone responsiveness is 
common clinically.4 Despite EGFR/HER2 increases, FAS were insensitive to EGFR and HER2 blockade and 
TAM to HER2 blockade, mirroring disappointing trial results for such agents.3 Continued study of these 
models could clarify why some patients fail on combination therapy.  
1. Britton D, Hutcheson I, Knowlden J, et al. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates 
tamoxifen-resistant growth. Breast Cancer Res Treat. 2006;96:131-46. 
2. Nicholson R, Staka C, Boyns F, Hutcheson I, Gee J. Growth factor-driven mechanisms associated with resistance to estrogen 
deprivation in breast cancer: new opportunities for therapy. Endocr Relat Cancer. 2004; 11:623-41. 
3. Carlson R, O’Neill A, Vidaurre T, Gomez H, Badve S, Sledge G. A randomised trial of combination anaztrazole plus gefitinib in the 
treatment of postmenopausal women with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat. 2012; 133: 
1049-56 
4. Mauriac L, Pippen J, Quaresma Albano J, Gertler S, Osborne C. Fulvestrant (Faslodex) versus anastrozole for the second-line 
treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined 
results from two multicentre trials. Eur J Cancer. 2003;39(9):1228-33. 
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What are the factors that motivate pharmacy undergraduate students in relation to 
the MPharm degree? 
Michael Compton, SA Coulman and DN John 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Motivation is the process by which individuals are driven to act in order to achieve a goal. Greater levels of 
motivation often lead to higher levels of academic performance.1 The aim of this study was to explore the 
views of first and fourth year of the MPharm students at Cardiff University, in relation to their motivation for 
choosing to study pharmacy, their motivation for choosing to study pharmacy at Cardiff University and from 
where they derive their ongoing motivation for the MPharm degree. This could highlight ways in which 
motivation for the MPharm degree could be improved. 
Non-probability (purposive and convenience) sampling was used to identify and recruit a variety of students. 
Recruitment methods included email, personal approach and workshop announcements. The study was 
conducted using semi-structured, one-to-one, audio-recorded. The topic guide was developed following a 
literature review. Transcribed interviews were analysed using content analysis. 
Ten fourth year students and seven first year MPharm students at Cardiff University were recruited. Students 
interviewed listed various motivating factors, also identified by others.2,3 Such factors included external 
influences, the nature and content of the pharmacy degree, personal drive, university lecturing staff, 
feedback on assessed work, career opportunities, placements and end goals. Factors that negatively 
affected individuals’ motivation were also identified.  
Implications for recruitment to the Cardiff MPharm and for students while enrolled were identified during the 
interviews. The impact that staff can have upon student motivation was highlighted. Findings of this study 
have identified opportunities for further investigation within Cardiff and more widely.  
1. Kirk K. 2012. Motivating Students. [Online]. Available at: http://serc.carleton.edu/NAGTWorkshops/affective/motivation.html 
[Accessed April 19th 2013] 
2. Wilson K et al. 2006. Pharmacy Undergraduate Students: Career Choices & Expectations Across A Four-Year Degree Programme. 
Report commissioned by the Pharmacy Practice Research Trust. [Online]. Available at: 
http://www.pprt.org.uk/documents/publications/pharmacy_undergraduate_students_career_choices_and_expectations.pdf 
[Accessed April 19th 2013] 
3. Huitt W. 2011. Motivation to learn: An overview [Online]. Educational Psychology Interactive. Valdosta, GA: Valdosta State 
University. Available at: http://www.edpsycinteractive.org/topics/motivation/motivate.html [Accessed April 19th 2013] 
 
Haptic drug design: simulating the induced fit effect 
Thomas Coughlin and A Brancale 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Computer aided drug design exists is an integral part of drug discovery. Its ability to dramatically decrease 
time spent during initial development stages makes it a valuable tool. In spite of this, errors do exist, and can 
result in costly setbacks. This is partly due to failure of the technology to accurately simulate ligand/receptor 
interactions. This is partly because of induced fit. This is a process whereby when a ligand approaches a 
receptor, it modifies the structure of the active site.1 Modern computer software generally fails to incorporate 
induced fit.2 This project aims to tackle this issue, with use of novel software that is capable of protein 
flexibility that is able to mimic the effects of included fit. The aim of the project is to deduce whether or not 
this new approach is able to more accurately reflect ligand/ receptor interactions, through comparisons with 
crystallised structures.  
Two major protein families were tested with a variety of ligands. Initially, a protein was prepared without a 
ligand in the active site as a template. Then using a haptic device in conjunction with the computer software, 
the ligand was manually placed inside the active site as accurately as possible. With the use of molecular 
operating environment (a popular protein manipulation software) the results could be compared to the crystal 
structure for accuracy. 
CDK produced results that differed little from traditional automatic software, with no significant protein 
movement. With HIV, being a larger protein (and therefore more susceptible to induced fit), the flexible 
software appeared superior and was able to move pocket residues to mimic induced fit (although this was 
not exact and protein distortion was a problem).  
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The investigation deduced that haptic software, operated via computer software with protein flexibility has 
potential for further development, particularly when used with larger proteins.  
1. Weikl TR, von Deuster C.. Selected-fit versus induced-fit protein binding: kinetic differences and mutational analysis. Proteins. 2010; 
75 (1):104-10 
2. Xu M, Lil MA. Induced fit docking, and the use of QM/MM methods in docking. Drug Discovery Today: Technologies. 2011; 55 (6): 
110-121 
 
Evaluation and characterisation of two directly compressible paracetamol powders 
used in the manufacture of immediate release tablets 
Bethan Crewe, BE Jones and JC Birchall  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Direct compression is the preferred method of tablet manufacture as it requires fewer processing steps and 
excipients, resulting in lower production costs.1,2 Despite this, few drugs possess the required properties 
needed for the process. Pure paracetamol is widely known for its poor flow and compressibility rendering it 
unsuitable for use in direct compression, however many paracetamol formulations have been developed to 
overcome this.3,4 The aim of this study was to manufacture tablets from two different directly compressible 
paracetamol powders, Compap L (CL) and Compap Coarse L (CCL), and to evaluate and compare their 
mechanical properties. The powders were also characterised based on their flow properties and surface 
morphology to observe how differences affected tablet manufacture. Addition of magnesium stearate to 
powders was also investigated to observe effects on tablet properties.  
Tablets were produced at different compression forces and their weight, thickness, crushing strength and 
friability were determined. Dissolution testing was carried out according to the British Pharmacopoeia 
method and ANOVA was used to analyse dissolution data. SEM analysis of powders was used to examine 
particle size and shape. Powder flow was investigated using compressibility index, Hausner ratio and flow 
time measurements.  
Pure PAR showed poor flow properties whilst both directly compressible powders showed improved 
flowability and produced suitably hard compacts. CCL showed the best flowability, resulting in lower tablet 
weight variation; however both formulations met uniformity of weight requirements. CL tablets displayed 
higher crushing strength but also a higher friability. CCL tablets showed faster dissolution and reached a 
higher percentage of drug dissolution at 45 minutes. Magnesium stearate delayed drug release from tablets 
for the first 15 minutes of the test.  
These findings show that CCL powder exhibits the best properties for direct compression tableting, however 
both powders produce good quality tablets which comply with pharmacopoeial requirements. 
1. Gohel M. A review of co-processed directly compressible excipients. Journal of Pharmacy and Pharmaceutical Science. 
2005;8(1):76-93. 
2. Jivraj M, Mertini L, Thomson C. An overview of the different excipients useful for the direct compression of tablets. Pharmaceutical 
Science & Technology Today. 2000;3(2):58-63. 
3. Joiris E, Di Martino P, Berneron C, Guyot-Hermann A, Guyot J. Compression Behavior of Orthorhombic Paracetamol. 
Pharmaceutical Research. 1998;15(7):1122-30. 
4. Krycer I, Pope D, Hersey J. The prediction of paracetamol capping tendencies. Journal of Pharmacy and Pharmacology. 
1982;34(12):802-4. 
 
Can the Theory of Planned Behaviour (TPB) predict pharmacists’ engagement with 
Continuing Professional Development (CPD)? 
Rachel Davies and DH James 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Practising pharmacists are legally obliged to complete CPD as a condition of their registration with the 
Regulator.1 The TPB, a psychological theory used in the study of health-related behaviours states that the 
strongest predictor of behaviour is ones’ behavioural intention, which is a function of their attitude, subjective 
norm (SN) and perceived behavioural control (PBC).2 This study investigates whether or not the TPB can 
quantify pharmacists’ views and engagement with CPD. 
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A questionnaire based on the TPB was distributed to 300 registered pharmacists, whom were either staff or 
postgraduate students of Cardiff School of Pharmacy and Pharmaceutical Sciences. Based on previous 
qualitative findings,3 views and engagement in CPD were measured as two separate behaviours i.e. 
undertaking and recording CPD. Quantitative data relating to pharmacists’ views and engagement with 
undertaking and recording CPD were analysed using SPSS® software. 
A response rate of 54.7% (146/267) resulted from two mailings. Overall, pharmacists’ views i.e. attitudes 
(MD=11.74, t=18.02, df=119, p<0.01), SN (MD=0.78, t=6.92, df=119, p<0.01) and PBC (MD=4.97, t=13.60, 
df=119, p<0.01) were more positive towards undertaking than recording CPD. Pharmacists reported that 
they undertake CPD more frequently than they record CPD. In 2011, patterns of recording did not meet the 
minimum Regulatory requirement in 27.3% of cases. No correlation was seen between self-reported 
undertaking and recording behaviours (rho=-0.092, p>0.05). Attitude (rho=0.218, p<0.05), SN (rho=0.233, 
p<0.05) and intention (rho=0.830, p<0.01) were significant predictors of undertaking CPD, whereas, attitude 
(rho=0.268, p<0.01), SN (rho=0.184, p<0.01) and PBC (rho=0.231, p<0.05) were significant predictors of 
recording behaviour. 
The TPB was more effective at explaining pharmacists’ recording behaviour than undertaking CPD 
behaviour. Pharmacists’ views and engagement with undertaking CPD were more favourable than recording 
CPD. Strategies to improve pharmacists’ approaches towards recording CPD should focus on the TPB 
constructs with the aim of removing barriers that impede the translation of intentions to record into actual 
CPD recording behaviour. 
1. General Pharmaceutical Council. 2011a. Framework for continuing professional development [Online]. Available at: 
http://www.pharmacyregulation.org/sites/default/files/CPD%20framework%20g.pdf [Accessed: 4th March 2013]. 
2. Ajzen I. From intentions to actions: A Theory of Planned Behaviour. In: Kuhl, J and Beckman, J.eds. Action –control: From Cognition 
to Behaviour. 1985. 11-39. 
3. James D, Miles R. Posters: 0026 Engagement with Continuing Professional Development (CPD): Can the Theory of Planned 
Behaviour be used to describe pharmacists’ attitudes? International Journal of Pharmacy Practice. 2012. 38-55. 
 
An evaluation of the current discharge advice letters used in Wales 
Kelly Davis, C Way1 and KL Hodson 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB and 1NHS Wales Informatics Service, Brunel House, 12th Floor, 2 Fitzalan Road, Cardiff, CF24 0HA Wales, UK 
A discharge advice letter (DAL) containing a summary of the clinical information and changes to the patient’s 
medication is used to transfer information to general practitioners (GPs) when patients are discharged from 
hospital. Currently DALs are not automatically sent to the community pharmacists (CPs). The aim of this 
study was to evaluate the current DALs used in hospitals across Wales, to identify whether they contain the 
required information, as outlined by the Royal College of Physicians (RCP)1 and the Royal Pharmaceutical 
Society (RPS)2 or any sensitive information3 . This would allow an assessment to be made on whether DALs 
are appropriate for CPs to review.  
Five hospitals in four Health Boards (HBs) in Wales participated in the study. Qualitative interviews (face-to-
face or telephone)4 were undertaken with participants who were considered best placed to provide 
information on the DALs used in each hospital (n=5). Each hospital’s DAL(s) (electronic +/- paper) was 
assessed against the RCP1 and RPS2 criteria. Subsequently, in 4 hospitals, systematic sampling was used 
to select 50-100 DALs from a representative sample of specialities, and their contents were analysed. 
The interviews uncovered that each hospital had a different system in place, although similarities were 
identified. No hospital fully meets the RCP1 and RPS2 guidance on DALs. Electronic DALs contained more of 
the criteria and the criteria were completed more frequently than on the paper copies. Sensitive information3 
was identified on 2% of the 286 DALs reviewed in the study. 
The study has identified a number of issues with DALs currently used; this will inform the further 
development of a new all Wales electronic discharge system currently being piloted. Further work must be 
done and amendments made to ensure GPs receive all the required information and the information is also 
made suitable for CPs to receive.  
1. The Royal College of Physicians. A Clinician’s Guide to Record Standards – Part 2: Standards for the structure and content of 
medical records and communications when patients are admitted to hospital (2008) London: the Digital and Health Information 
Policy Directorate. [Accessed 30th January 2013]. Available at: www.rcplondon.ac.uk/clinical-standards/hiu/medical-records 
2. Picton C. Keeping patients safe when they transfer between care providers – getting the medicines right (2011) London: Royal 
Pharmaceutical Society. [Accessed 30th January 2013]. Available at: http://www.rpharms.com/medicines-safety/getting-the-
medicines-right.asp 
3. NWIS. Highly sensitive test list. Wales: NWIS 2008. 
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4. Smith FJ. Conducting Your Pharmacy Practice Research Project. London; Pharmaceutical Press. 2005. 
 
The effect of caveolin-1 over-expression on amyloid precursor protein metabolism 
in Alzheimer’s disease 
Sarah-Jane Davis, RS Thomas and EJ Kidd 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
β-amyloid is a cleavage product of amyloid precursor protein (APP) which forms plaques and causes 
neurodegenerative effects in Alzheimer’s disease (AD). APP is a transmembrane protein which must be 
internalised to enter one of two metabolic pathways; amyloidogenic metabolism by β-secretase then γ-
secretase and non-amyloidogenic metabolism by α-secretase.1,2 Internalisation is primarily via clathrin-
mediated endocytosis, entering APP into the endosomal-lysosomal system.2 Caveolin-1, a lipid-raft protein, 
is over-expressed in AD brains, whilst depletion increases β-amyloid and neuronal loss.3,4 It is hypothesised 
that caveolin-1 influences APP metabolism. Possible mechanisms are via caveolin-1-mediated endocytosis 
in caveolae and caveolin-1-driven lipid-rafts mediating inclusion/exclusion at sites of internalisation.1,2 The 
role of caveolin-1 was investigated by in vitro over-expression and quantification of relevant protein levels. 
Astrocytoma (MOG-G-UVW) cells were transfected with caveolin-1 plasmid-DNA using Turbofectin8 as the 
transfection reagent. Western blots established the expression levels of caveolin-1, APP, caveolin-2, flotillin, 
clathrin, dynamin and glyceraldehyde 3-phosphate dehydrogenase (loading control; n=4). Sandwich ELISAs 
quantified the expression of APP and β-amyloid40 (n=3-4). Treatment groups were Media, transfection 
reagent (T.R.), or T.R. with caveolin-1 plasmid-DNA.  
Western blots confirmed a 6.2±1.5 over-expression of caveolin-1. APP expression levels were significantly 
decreased in cav-1 cells (37.2%±8.5) by ELISA, whilst β-amyloid levels showed no significant change. Three 
APP isoforms were resolved; expression of the 100kDa isoform was significantly reduced in caveolin-1 over-
expression cells. There was no change in expression levels of the 112kDa and 142kDa APP isoforms, 
caveolin-2, flotillin, clathrin or dynamin. 
Decreased APP levels suggest that caveolin-1 over-expression increased APP metabolism. Since β-amyloid 
levels were unchanged, it is likely that activity of the non-amyloidogenic pathway was increased. Caveolin-1 
overexpression appeared to differentially affect the metabolism of APP isoforms; this requires further work. 
The lack of significant changes in the expression of caveolin-independent endocytic proteins suggests a role 
for caveolin-1 in APP metabolic regulation.  
1. Ikezu T, Trapp B, Song K, Schlegel A, Lisanti M, Okamoto T. Caveolae, plasma membrane microdomains for alpha secretase-
mediated processing of the amyloid precursor protein.The Journal of Biological Chemistry. 1998; 273(17): 10485-95. 
2. Thomas R, Lelos M, Good M, Kidd L. Clathrin-mediated endocytic proteins are upregulated in the cortex of the Tg2576 mouse 
model of Alzheimer’s disease-like amyloid pathology Biochemical and Biophysical Research Communications. 2011;415(4): 656-
661.  
3. Gaudreault SB, Doris D, Poirier J. Increased caveolin-1 expression in Alzheimer’s disease brain Neurobiology of Aging. 2004; 25(6): 
753-759. 
4. Head BP, Peart JN, Panneerselvam M et al. Loss of caveolin-1 accelerated neurodegeneration and aging. PLoS One.  2010; 5(12): 
e15697. 
 
Ser275 is essential for ZIP7-dependent cytosolic zinc release in breast cancer cells 
Arianwen Denham and KM Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The expression of zinc transporter ZIP7 (SLA39A7) is highly upregulated in poorly prognostic breast 
cancers1 and is thought to mediate the release of free zinc into the cytosol from intracellular stores, leading 
to the activation of tyrosine kinases that promote cell proliferation through multiple pathways,2 thus 
contributing to the aggressive nature of breast cancer cells.3 Here, we investigated whether phosphorylation 
of evolutionarily conserved3 Ser275 in ZIP7 is required for zinc-mediated activation of tyrosine kinases and the 
downstream phosphorylation of AKT and MAPK indicative of signalling pathway activation. 
Through genetic manipulation, MCF-7 cells were transfected with ZIP7 wild-type (WT), S275A and S275D 
mutants and treated with exogenous zinc. The cells were probed with antibodies directed against pAKT, 
pMAPK and pZIP7 and results collected from densitometry images produced via the Western Blot technique. 
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We identified that inactivation of Ser275 in ZIP7 S275A mutant cells prevents activation of downstream 
signalling pathways that promote cell proliferation. Activation of AKT and MAPK was significantly decreased 
in ZIP7 S275A mutant cells compared with those in WT ZIP7 cells. We also investigated a constantly active 
Ser275 in the ZIP7 S275D mutant cells and its effect on zinc transporter function. 
The present results show that Ser275 in ZIP7 is required for zinc-mediated activation of tyrosine kinases that 
promote cell proliferation. Our mutations allowed for phosphorylation of Ser276, which is equally conserved 
among organisms3, therefore our results suggest that phosphorylation of Ser275 is required first to allow 
phosphorylation of Ser276 which then allows for full activation of ZIP7, leading to zinc-mediated cellular 
signalling. This evidence provides us with a better understanding of how ZIP7 is regulated and contributes to 
zinc homeostasis. Furthermore, our findings contribute to novel research working towards the prospect of 
targeting ZIP7 therapeutically in anti-hormone resistant breast cancer. 
1. Hogstrand C, Kille P, Nicholson RI, Taylor KM. Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase 
activation. Trends in Molecular Medicine. 2009;15(3):101-11 
2. Taylor KM. A distinct role in breast cancer for two LIV-1 family zinc transporters. Biochemical Society transactions. 2008;36:1247-51 
3. Taylor KM, Hiscox S, Nicholson RI, Hogstrand C, Kille P. Protein kinase CK2 triggers cytosolic zinc signaling pathways by 
phosphorylation of zinc channel ZIP7. Sci Signal. 2012;5(210):ra11 
 
Antimicrobial Silver-based Coatings for Biomedical Applications 
Kiran Dhadda, P Prokopovich and SP Denyer 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Biomedical devices today are an integral part in patient healthcare, however despite their uses, biomedical 
devices used in vivo are susceptible to biofilm formation, this can lead to a medical-device associated 
infection.1 Biofilms are increasingly becoming resistant to antibiotics.2 Silver is a useful alternative because it 
has broad-spectrum antimicrobial activity including against those that are antibiotic-resistant. Silver based 
polymers can protect the surfaces of medical devices against the attachment of microorganisms.3 Much 
research is underway on how the antimicrobial properties of nanocomposites can be improved. 
The aim of this study was to show how varying the power (50-150 watts) of the oxygen plasma treated silver 
nanocomposites can modify its surface properties by increasing surface roughness to prevent biofilm 
formation. Specifically E. coli (MG1655) and S. aureus (NCIMB9518) which are commonly associated with 
device-associated infections were investigated. Antibacterial tests were performed using five silver-coated 
samples of different concentrations. Atomic force microscopy was used to study the topography of the 
samples. Surface roughness of the pre-incubated silver samples increased with the increase in oxygen 
plasma power. Samples exposed to S. aureus for 24 hours showed a decrease in roughness with increase in 
power, however, samples exposed to E. coli showed no such correlation. 
Although some of the samples showed modest reduction in bacterial growth there was little correlation with 
oxygen plasma power and not one sample was consistently better than the other. The AFM images show 
that the topography across all samples was uneven and this could have affected the bacterial adhesion 
properties and hence the antimicrobial efficacy of the sample.  
This study demonstrates that oxygen plasma surface treatment on silver nanocomposites has the potential 
to inhibit bacterial biofilm formation, but further research is required as the samples have not shown sufficient 
antimicrobial properties, the samples and the plasma process conditions need further development.  
1. Monteiro DR, Gorup LF, Takamiya AS, Ruvollo-Filho AC, Camargo ER, Barbosa DB. The growing importance of materials that 
prevent microbial adhesion: antimicrobial effect of medical devices containing silver. International Journal of Antimicrobial Agents. 
2009; 34(2):103-10. 
2. Fortunati E, Mattioli S, Visai L et al. Combined Effects of Ag Nanoparticles and Oxygen Plasma Treatment on PLGA Morphological, 
Chemical, and Antibacterial Properties. Biomacromolecules. 2013; 14(3):626-36. 
3. Kim JS, Kuk E, Yu KN et al. Antimicrobial effects of silver nanoparticles. Nanomedicine-Nanotechnology Biology and Medicine. 
2007; 3(1):95-101. 
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Does the SK Channel protect BV-2 Cells against inflammation and oxidative stress? 
Ronak Dodhia, ZA Abdulkareem, CD Cox and KT Wann 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The link between neurodegeneration and neuroinflammation is growing.1 Neuroinflammation is brought 
about by activated microglia, resident immune cells of the CNS, and can be neuroprotective or neurotoxic. 
When neurotoxic, inflammatory mediators and reactive oxygen species (ROS) are released, the latter can 
lead to oxidative stress, another neurodegenerative trigger.1,2 Recent findings suggest SK channels (small 
conductance Ca2+-activated K+ channels) regulate Ca2+ homeostasis and microglia activation.1,2,3 We 
investigated if SK Channel modulation provides protection to BV-2 (primary mouse microglia) cells against 
lipopolysaccharide-induced inflammation and H2O2 -induced oxidative stress. 
RT-PCR and Inside-out patch clamping were carried out, the target being the SK channel. Cell proliferation 
assays were also carried out. On Day 1, cells were seeded in 96 well plate triplicates (10,000 cells / well, 
method 1) and 6 well plate duplicates (300,000 cells / well, method 2). On Day 2, the insult medium was 
applied. 24 hours later, both MTS Assay (method 1) and cell counting (method 2) were carried out. Statistical 
analysis used a one way ANOVA and suitable post hoc test.  
RT-PCR showed that SK4 channel mRNA was present. Patch-clamp confirmed presence of a Ca2+-sensitive 
K+ channel, activated by NS309 (SK4 activator), with a conductance of 37 pS consistent with SK4 (IK). MTS 
with BV-2 + LPS proved problematic, hence cell counting was adopted whilst BV-2 + H2O2 gave credible 
MTS results. LPS LD50 10 ng/ml; H2O2 LD50 30 µM. SK4 activation (NS309) or blockade (TRAM-34) afforded 
no protection against LPS or H2O2. DMSO was toxic at low concentrations. 
SK Channel modulation in non-neuronal cells, especially microglia cells is quite topical and represents a 
novel therapeutic strategy, protecting neurons, by reducing microglia activation.1,2,3 The results here were 
confounded by vehicle toxicity but were compared with the little data that currently exists in the literature.  
1. Perry VH et al. Microglia in neurodegenerative disease. Nature Reviews Neurology. 2010; 6:193-201. 
2. Dolga AM, Culmsee C. Protective Roles for Potassium SK/KCa2 Channels in Microglia and Neurons. Frontiers in Pharmacology. 
2012. 3(196):1-9. 
3. Adelman JP et al. Small-Conductance Ca2+-Activated K+ Channels: Form and Function. Annual Review of Physiology. 2012; 74: 
245-269. 
 
Aripiprazole and risperidone long-acting injection: 5-year outcomes in a 
retrospective naturalistic follow up study 
Matthew M Dwivedi, PN Deslandes1 and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales, UK and 1Pharmacy Department, Whitchurch Hospital, Whitchurch, Cardiff, UK. 
Aripiprazole and risperidone long acting injection (RLAI) are atypical antipsychotics used to treat 
schizophrenia. Their safety, tolerability and efficacy have been confirmed by randomised controlled trials, but 
these may not reflect clinical practice.1 Naturalistic studies have attempted to overcome this issue, however, 
few include aripiprazole or RLAI. The aim was to assess the clinical effectiveness, safety and tolerability of 
aripiprazole and risperidone long-acting injection in treating schizophrenia over the latter three years of a 5-
year follow up period.  
This study was conducted within the acute mental health service in Cardiff, (UK). A retrospective case note 
review was undertaken and previous clozapine treatment was noted as an indicator of treatment-resistance. 
The primary outcome measure was discontinuation of treatment; other real world outcome measures were 
also used. 
Twenty-seven patients on aripiprazole and 28 on RLAI were included in the study. Five patients were lost to 
follow up. Ten patients (38.5%) from the aripiprazole group and 11(45.8%) from the RLAI group discontinued 
treatment, the main reasons being non-compliance and side effects, respectively.  
There is a lack of previous studies that are directly comparable, due to the length of the follow up period and 
this substantiates the uniqueness of this study. Using comparable, analogous, intermediate time-points, 
results are similar to those in the CATIE study with 70% of patients discontinuing before 18 months,2 
compared to 69.5% in the present study; other outcomes also compared robustly.2-4 Despite the limitations of 
this study, such as small sample size, the results suggest that both RLAI and aripiprazole are moderately 
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effective in treating schizophrenia in a clinical setting. The 5-year attrition rate of 16%/year for aripiprazole 
and 16.8%/year for RLAI combined with the relatively low re-hospitalisation rates, low numbers of co-
prescribed antipsychotics and infrequent dose increases, suggests that both drugs appeared to be safe and 
well tolerated. 
1. Hodgson R, Bushe C, Hunter R. Measurement of long-term outcomes in observational and randomised controlled trials. The British 
journal of psychiatry. 2007;50:78.  
2. Lieberman JA, Stroup TS, McEvoy JP et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. 
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med. 2005; 353: 1209-23. 
3. Kahn RS, Fleischhacker WW, Boter H et al. EUFEST study group. Effectiveness of antipsychotic drugs in first-episode 
schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008; 29;371(9618):1085-97.  
4. Taylor DM, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V. Risperidone Long-Acting Injection: A Prospective 3-Year 
Analysis of Its Use in Clinical Practice. Journal of Clinical Psychiatry. 200; 70 (2): 196-200. 
 
Differential cytotoxic effects of disulfiram and disulfiram analogues on MCF-7 and 
MDA-MB-231 breast cancer cell lines 
Luned E Edwards, AT Jones and AD Westwell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Breast cancer is the most common form of cancer in the United Kingdom. Disulfiram (DSF) has been used 
for over half a century in the treatment of alcoholism as an inhibitor of aldehyde dehydrogenase.1 Recent 
studies suggest that DSF has a selective cytotoxicity against cancer cells in vitro.2 This project aims to 
investigate the cytotoxicity of disulfiram and structurally related novel analogues to investigate the structure 
activity relationship. 
Experiments were conducted on MCF-7 and MDA-MB-231 breast cancer cells due to their contrasting 
expression of major proteins. Cytotoxicity was determined using Cell-titer blue™ (CTB) viability assay after 4, 
24, 48 and 72 hour incubation. CTB is a fluorometric assay that estimates the number of viable cells via the 
reduction of resazurin into a fluorescent end product, resorufin. 
DSF and analogues displayed a cytotoxic effect upon both cell lines especially at the higher concentration of 
10-100 µM and after longer incubation. Statistically significant (p < 0.05) biphasic effect was seen in MCF-7 
between 1-10 µM after 48 and 72 hours incubation with disulfiram. Incubation of FS-01BM for 72 hours and 
FS-03EB for 4 and 24 hours produced a biphasic effect in MCF-7 cell line. Both MCF-7 and MDA-MB-231 
cell lines display a biphasic effect when FS-07PY was incubated for 24 hours. 
Degree of cytotoxicity is dependent upon the structure of the analogue tested. Extending the side chain 
produced an inactive analogue. By replacing the terminal groups of DSF with a pyrrolidine ring and OH 
group it decreases the viability of both cell lines and produced the greatest cytotoxicity profile. The data show 
that all compounds have some degree of cytotoxicity especially at higher concentrations of 10-100 μM 
against MCF-7 and MDA-MB-231 breast cancer cell lines. Data produced evidence of biphasic effect in 
some analogues which is a phenomenon that requires further research. 
1. Cvek B. The value of proteasome inhibition in cancer: Can the old drug disulfiram, have a bright new future as a novel proteasome 
inhibitor? Drug Discovery Today. 2008;13(15):716-722 
2. Brahemi G, Kona F, Fiasella A et al. Exploring the Structural Requirements of the Ubiquitin E3 Ligase Breast Cancer Associated 
Protein 2 (BCA2) as Treatment for Breast Cancer. J Med Chem. 2010; 53(7):2757-2765. 
 
Optimising treatment for ER-positive/Her2-positive breast cancer 
Jennifer Flatman and S Hiscox 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Luminal B breast cancers have a much poorer prognosis than luminal A cancers.1 Therefore, new treatments 
need to be developed so as to improve the outlook for those with luminal B tumours. The effects of 
endocrine (Faslodex), anti-Her2 (Herceptin) and Src inhibitor (AZD0530) agents were investigated as 
monotherapies and as combinations of Faslodex plus Herceptin (FH) and Faslodex plus AZD0530 (FA). 
Four cell lines were used; MCF7 and T47D (luminal A) and BT474 and MDA361 (luminal B). Changes in 
cellular growth following treatment with single and combination agents were assessed using MTT assays. 
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The effects of these treatments on protein expression and activity were subsequently determined through 
Western blotting and immunoprobing with phospho-specific antibodies. 
As a single agent, Faslodex produced the greatest cell growth inhibition overall. Herceptin was very effective 
at inhibiting BT474 cell growth but only minimally effective with the other cell lines. Src inhibition produced 
the greatest growth inhibition in MDA361 cells. Protein detection revealed that Faslodex induced Src and 
Herceptin induced Her2 in all cell lines except BT474. AZD0530 inhibited Src activity but had little effect on 
other proteins investigated. Combination treatments inhibited growth in the luminal A cells better than luminal 
B but only BT474 cells showed FA to be statistically better than FH. BT474 cells showed the same level of 
growth inhibition when treated with Herceptin and FH, suggesting that this combination treatment was not 
beneficial. Protein detection for the combination treatments provided little evidence as to why they were 
more effective growth inhibitors, suggesting that other signalling molecules not investigated in this study 
were involved. 
The data suggests that combination treatments were more effective than single treatments at inhibiting ER-
positive/Her2-positive tumour cell growth. Src shows great promise as a target for treating ER-positive/Her2-
positive breast cancer and AZD0530 has the potential for clinical use. 
1. Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res. 2011; 13(6): 221. 
 
Exploring the views of Cardiff pharmacy undergraduate students on evaluating their 
Velindre Hospital placements 
Ciara Griffiths, DN John, SA Coulman, R Poole1 and E Mantzourani 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales, UK and 1Pharmacy Dept., Velindre Cancer Centre, Cardiff  
For the first time, 20 final year students from Cardiff School of Pharmacy and Pharmaceutical Sciences 
attended a voluntary half day placement at Velindre Hospital, Cardiff. Therefore, the aim of the study was to 
seek students’ views on the value of the experience and to find out whether and how it could be improved for 
future students. 
The methodology for this study was qualitative due to its exploratory nature.2 Individual and group semi 
structured interviews were deemed to be the most appropriate for research into students’ perceptions and 
beliefs. School ethics approval was obtained. An initial pilot interview was conducted check that the 
proposed interview schedule gathered reliable and valid data effectively and efficiently.3 Each interview was 
audio recorded, which allowed ‘ad verbatim’ transcripts to be produced for thematic analysis.4  
In total 13 participants were interviewed. Seven main themes were identified: placement structure, 
educational approach, preparedness for Velindre placement, exposure to patients, personal development, 
multidisciplinary team and role models. All students felt it was a valuable experience that they would 
recommend to other pharmacy students. Students expressed a number of positive aspects of the placement, 
including the approach of the staff towards them and also towards patients and that the experience 
highlighted career options they had not previously considered. Conversely, two possible changes in future 
years were to increase the duration of the placement and to provide pre-placement reading. The study 
revealed the main link was with the oncology module in the third year and that the placement in year 3 of the 
MPharm would be more useful.  
The interviews were successful in identifying the views of those who took part in the voluntary placements. 
The findings will be disseminated to the School and to the placement supervisors at Velindre Hospital. 
Evaluation of any changes resulting from the study is recommended. 
1. Von Treueri K, Sturre V, Keele S et al. 2011. An integrated model for the evaluation of work placements. Asia – Pacific Journal of 
Cooperative Education [online]. Available at: http://www.apjce.org/files/APJCE_12_3_195_204.pdf [Accessed 1 April 2013]. 
2. Moore N. 2000. How to do research. London: Library Association Publishing.  
3. Smith F. 2005. Conducting your pharmacy research project. London: Pharmaceutical press. 
4. Denscombe M. 2012. The good research guide. Berkshire: Open University Press.  
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An evaluation of how quality training is implemented in Welsh NHS production 
areas; can online learning provide a role in this area? 
Daniel A Griffiths, CJ Talbot and AG Cosslett 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Online learning has revolutionised healthcare training and is fundamental for delivering high quality training 
to the National Health Service (NHS) workforce.1,2 Despite the widespread use of online learning in the NHS, 
its application in production staff training is limited to the Technical Specialist Education and Training (TSET) 
packages.3 To date, there has been no research to indicate how existing production staff training is delivered 
in Wales, and whether online learning could expand its presence here. The aim was to understand how 
quality training is delivered to NHS production personnel in Wales, and whether extending online learning 
here would be of any benefit. 
Using topics identified from the literature, a self-complete questionnaire was developed to gather data from 
the entire study population (n=154). The questionnaire and covering letter was emailed to all production 
personnel in Wales via an NHS administrator and production unit managers, a reminder email was sent 
three weeks after the initial invitation. Quantitative data were analysed using Microsoft® Excel; qualitative 
data were entered into a Microsoft® Word document. 
Questionnaires were returned from five participants; the response rate could not be calculated. The findings 
indicate that current training is delivered by various personnel and by several different methods. Participants 
agreed that online learning could play more of a role within their training at all staff grades, providing that it is 
supported by alternative learning formats, and that online learning material does not repeat what is already 
available from the TSET packages. 
This study has highlighted the need to develop online learning in the training of NHS production personnel in 
Wales. It has underlined that where online learning is used in production staff training; it should not exist as a 
lone entity, but be supported by other training approaches. Additionally, any online learning developed 
should extend its scope beyond that of the existing TSET packages. 
1. National Health Service. E-learning in NHS England 2013-14 and beyond. National Health Service: eLearning Leads Group; 2012. 
2. National Health Service. Commissioning e-learning resources in the NHS. National Health Service: eLearning Leads Group; 2012. 
3. Pharmaceutical Technical Specialists Education and Training. NHS TSET – Aseptic training programme. National Health Service: 
Pharmaceutical Technical Specialists Education and Training; 2009. 
 
Mucoadhesive chitosan/gelatin films for the sublingual and buccal delivery of 
punicalagin 
Shu Ling Guan and CM Heard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Apart from the peri-oral region, herpes infections can occur throughout the buccal cavity. The aim of this 
project was to develop mucoadhesive films that could deliver antivirals to the sublingual and buccal regions. 
The drug that was used in this study was total pomegranate tannins (TPT) – a purified form of pomegranate 
rind extract and comprised largely of punicalagin that previously demonstrated both antiviral and anti-
inflammatory activities.1 
TPT was isolated by fractionation of the rinds of pomegranates using Amberlite XAD-16 polymeric resin as 
stationary phase. This was formulated into mucoadhesive films based on chitosan and gelatin2 at 0.05, 0.2 
and 0.8% w/v. Firstly, moisture absorption studies were carried out to determine the water uptake ability. 
Next, spontaneous release and buccal membrane permeation experiments were conducted using glass 
Franz Diffusion cells. Each experimental set up was run with n=3 and over a period of 12 h; the samples 
obtained were analyzed by HPLC.1  
It was found that as the TPT concentration increased, the water uptake ability decreased. In both the 
spontaneous release study and permeation study, a maximum of approx. 2.6% of punicalagin was delivered 
from the films. Sublingual membrane showed significantly higher permeation in comparison to buccal 
membrane (p < 0.05).  
Novel mucoadhesive films were successfully prepared, although a combination of low spontaneous release 
and low permeation was indicative of an over-retentive dosage form (based on extensive ion pairing and 
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hydrogen bonding), rather than poor permeability across the membrane alone. However, the amount of 
punicalagin released at 12 h was determined to be approximately the same as the IC50 concentration against 
HSV-1 for TPT according to previous studies.1 Overall, this work has shown that these novel TPT films may 
have potential as a new treatment for HSV infections of the buccal mucosal membranes.  
1. Houston D. Towards a nanomedicine-based broad-spectrum topical virucidal therapeutic system. PhD thesis: Cardiff University: 
2011. 
2. Abruzzo A, Bigucci F, Cerchiara T, Cruciani F, Vitali B, Luppi B. Mucoadhesive chitosan/gelatin films for buccal delivery of 
propranolol hydrochloride. Carbohydrate Polymers. 2012; 87(1):581-8. 
 
Testing the virucidal activity of disinfectant surface wipes 
Samantha Haines, MR Saavedra, R Westgate and J-Y Maillard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Coxsackievirus B3 (CVB3) is among many easily transmissible viruses and the prevention of spread from 
surfaces is crucial. Many disinfectant wipes claim to be virucidal, however there is no current standardised 
test for evaluating the efficacy of a wipe. This study used a three-stage protocol, already proven successful 
with bacteria and endospores.1,2 
Three “virucidal” wipes (A-C) and one control wipe were tested. Stainless steel discs inoculated with CVB3 
and bovine serum albumin (BSA) were dried before wiping. Wipes were rotated for 10 s at 60 rpm under 150 
g pressure. Virus removal from surfaces and the transfer of viruses from wipes were subsequently 
measured. The efficacy of wipes was also measured with no mechanical action.  
The concentration of CVB3 dried on surfaces decreased by 4.9 log10 before any wipe treatment, which was 
taken into account when analysing the wipe results. The control wipe displayed a complete reduction in 
CVB3 (1.6 log10). Wipe A showed a 1.44 and 1.07 log10 reduction for the removal and static tests, 
respectively. Wipe B demonstrated a 0.934 log10 reduction in the static test and a complete removal (1.6 
log10) following wiping, while wipe C, produced a 1.55 log10 reduction following wiping but a 0.79 log10 
reduction in the static test. No virus was transferred to another surface by any wipes. The log10 reductions, 
after wipe usage, were statistically significantly different to the dried CVB3 titre. Only one wipe (C) had a 
significant difference between its removal and static tests. 
The mechanical wiping action is the most important factor in removal. The complete log10 reduction of CVB3 
seen following use of the moist control wipe is due to its ability to absorb liquid well. Wipes can be used on 
additional surfaces as they prevent transfer well. The three-stage protocol proved successful with 
coxsackievirus so is ideal for future experiments. 
1. Williams GJ, Denyer SP, Hosein IK, Hill DW, Maillard JY. The development of a new three-step protocol to determine the efficacy of 
disinfectant wipes on surfaces contaminated with Staphylococcus aureus. Journal of Hospital Infection. 2007; 67(4): 329-335. 
2. Siani H, Cooper C, Maillard JY. Efficacy of "sporicidal" wipes against Clostridium difficile. American Journal of Infection Control. 
2011. 39(3): 212-218. 
 
Characterisation of novel in vitro models derived from ER+HER2+ BT474 cells to 
investigate the contribution of ER, EGFR and HER2 signalling in Faslodex 
resistance 
Gareth Harris, S Kyme, P Finlay, L Farrow, C Dutkowski, H Mottram, D Barrow and JMW Gee 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Currently, the effectiveness of breast cancer treatment in oestrogen receptor (ER) positive patients is limited 
by the problem of antihormone resistance.1 Resistance to the antioestrogen Faslodex is poorly understood, 
particularly in ER+HER2+ disease.2 A novel panel of acquired resistant models has recently been developed 
by continuous antihormone culture of ER+/HER2+ BT474 cells. This project focuses on characterising 
resistance to Faslodex in the BT474 cells, aiming to investigate whether duration of Faslodex treatment 
influences resistant phenotype and if this phenotype differs from that of other antihormonal resistant states 
(Tamoxifen, oestrogen deprivation) with regards to growth and contribution of ER and EGFR/HER2 
signalling. 
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Coulter counting studies were performed to determine growth of Faslodex resistant BT474 cells compared 
with control cells cultured for equivalent timeframes (12 or 30 months). Growth impact of HER2 (Herceptin) 
or EGFR blockade (Gefitinib) was also evaluated. Immunocytochemical analysis was performed to monitor 
levels of ER, EGFR and HER2 to further characterise resistance mechanisms of the cells. 
Major findings included initial slow growth in short term Faslodex resistant cells followed by substantial 
growth recovery as a consequence of longer-term treatment. ER was substantially reduced in short term 
Faslodex resistant cells but completely lost by 30 months, contrasting increases in other antihormonal 
resistant states. Despite superior increases in HER2 and EGFR versus other models, there was complete 
loss of Herceptin effectiveness on Faslodex resistant growth although EGFR blockade remained effective.  
Our findings indicate long term Faslodex resistant BT474 cells undergo significant further phenotypic 
reprogramming versus shorter term resistance and versus additional antihormone resistant models. EGFR 
remains an important mitogenic pathway for Faslodex resistant cells in contrast to the HER2 pathway.3 
These findings have clinical implications for antihormone sequencing and also for interpreting trials currently 
examining EGFR or HER2 blockade alongside Faslodex in ER+HER2+ patients.  
1. Osborne CK, Schiff R. Mechanisms of Endocrine Resistance in Breast Cancer. Annual Review of Medicine. 2011; 62 (1):233-247. 
2. Robertson JFR, Steger GG, Neven P et al. Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Annals of 
Oncology. 2010; 21 (6): 1246-1253. 
3. Gee JMW, Shaw VE, Hiscox SE, McClelland RA, Rushmere NK, Nicholson RI. Deciphering antihormone-induced compensatory 
mechanisms in breast cancer and their therapeutic implications. Endocrine-Related Cancer. 2006; 13 (1): 77-88. 
 
Antimicrobial Activity of Silver-coated Nanoparticle Surfaces 
Haslina Hasan and P Prokopovich 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Silver have been widely used in implantable device coatings to prevent bacterial growth and ward off 
infection. Issues such as hospital-acquired infections, which are infections associated with urinary catheters, 
blood lines and heart bypass are on the rise. The catheters, tubes, and drains provide entry vehicles for 
bacteria and other pathogens regardless of the care taken by healthcare workers and the cleanliness of the 
facility. Due to many infections are tied to various types of tubing used medical and surgical treatments, 
therefore adding silver lining on the surfaces of devices is a wise alternative. The aim of this project was to 
determine whether silver nanoparticles coated surfaces of silica sample demonstrate a significant 
antimicrobial effect against E. coli and S. aureus by using plating method. 
Five silicone surfaces coated with silver nanoparticles were prepared by ion implantation, with three repeats 
of each sample. All samples were incubated with the Gram negative E. coli MG1655 and Gram positive S. 
aureus NCIMB 9518 for 5 hours and 24 hours. At the end of the contact period, the samples were removed 
and washed three times in 1 ml PBS solution. Surviving bacteria were removed by vortexing after the final 
wash. Eventually, serial dilution and plating method was carried out in order to determine the viable count of 
bacteria.  
Generally, the result obtained demonstrates that silver-coated nanoparticle surfaces showed antimicrobial 
effect, yet relatively weak. The silver-coated nanoparticles surfaces antimicrobial activity was less 
susceptible against S. aureus compared to E. coli. Besides, antimicrobial activity was more significant over 5 
hours compared to 24 hours incubation. Apart from that, the surface roughness was closely related to the 
antimicrobial effect of silver nanoparticles. 
The antimicrobial activity shown was relatively weak due to the formation of a less than monolayer coverage, 
insufficient concentration of silver and the silver particles were spread far apart. Apart from that, E. coli were 
more susceptible to silver ions S. aureus owing to the thicker cell walls of S. aureus that protect the cell from 
penetration of silver ions into the cytoplasm.  
1. Aguinaldo AM et al. Bactericidal properties of silica particles with silver islands located on the surface. International Journal of 
Antimicrobial Agents. 2007; 29:738-748. 
2. Furno F et al. Silver nanoparticles and polymeric medical devices: a new approach to prevention of infection? Journal of 
Antimicrobial Chemotherapy. 2004; 54:1019-1024. 
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An evaluation of staff attitudes to and satisfaction with Medicines Vending Units 
(MVUs) at ward level in Aneurin Bevan Health Board (ABHB) 
Fatoma Hassan, KL Hodson and C Powell1 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales, UK and 1Ysbyty Ystrad Fawr, Ystrad Fawr Way, Ystrad Mynach, Hengoed, Wales, UK 
Medicine Vending Units (MVUs) are automated storage devices, consisting of computer controlled drawers.1 
Such devices have replaced medicine cupboards on some wards in Aneurin Bevan Health Board (ABHB) in 
order to improve efficiency, use of space, security and wastage of medicines.2 The aim of this research was 
to assess staff attitudes to and satisfaction with MVUs and the automated control of ward stock at ABHB. 
The objectives were to identify ABHB staff’s perceived advantages and disadvantages of using MVUs, 
compared to the cupboard storage system, as well as identifying the facilitators and barriers that occurred 
during the installation of MVUs. 
In phase 1, a semi-structured interview was completed with 6 health care professionals (HCPs), two 
Advanced Nurse Practitioners, two pharmacists and two non-medical prescribers. Each participant was 
recruited using convenience sampling, after receiving an invitation letter, information leaflet and consent 
form. The interviews were audio-recorded, transcribed verbatim and thematically analysed.3 For phase 2, a 
structured interview was developed using the themes identified in phase 1. Convenience and snowball 
sampling was used and the structured interviews were conducted on 32 participants. Data was then 
descriptively analysed and tabulated.  
Majority of respondents at ABHB felt medicines cupboards were disorganised and a change was needed 
from the system. Positive aspects of the MVUs included ease-of-use, simplicity and efficiency. Problems 
identified with the MVUs were location, with some machines being sited too far from the wards. Another 
problem was software, with the system logging certain staff out. Also some staff stated the MVU training 
(N=8/32) was too short. Overall HCPs were willing to accept the MVUs and change in storage practice. 
Attitudes towards and satisfaction with MVUs was generally positive, as most staff (N=28/32) were willing to 
recommend the system to other hospitals. Further research would be to look at how other health boards view 
the MVU system.  
1. Omnicell® (2011) Supply Management. Available at <url: http://www.omnicell.com/Products/Supply_Management.aspx.> 
[Accessed: 13th April 2013] 
2. Ford D, Platt E (2009) The implementation of an automated medication storage and dispensing system within the Acute Medical 
Unit (AMU)- Ninewells Hospital, Dundee. Available at 
<http://www.knowledge.scot.nhs.uk/media/CLT/ResourceUploads/21471/S14.pdf> [Accessed: 13th April 2013] 
3. Denscombe M (2007) The Good Research Guide. Berkshire: Open University Press.  
 
The involvement of endocytosis in normal aging compared to Alzheimer's disease 
Suzanne R Hemming, RS Thomas, M Hvoslef-Eide and EJ Kidd 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterised by accumulation of 
beta-amyloid (Aβ) in plaques in the brain.1 The primary risk factor for AD is aging. Aβ is cleaved from 
amyloid precursor protein (APP) with most of the cleavage occurring along the clathrin-mediated endocytic 
(CME) pathway.2 CME is thus likely to be important in the production of Aβ. The present study investigated 
how the expression of CME proteins is altered by increasing age in wild-type mouse brains compared to a 
transgenic mouse model of amyloid pathology. 
Immunohistochemistry assays were performed on 3, 9 and 18 month old C57BL6 wild-type and transgenic 
mice expressing the London Mutation in APP (n=1-5). Microscopy images were taken of the cortex and 
hippocampal dentate gyrus, CA1, CA2 and CA3. The number of labelled cells were counted and protein 
expression analysed by one-way ANOVA and Tukey’s post-hoc tests or Student's t-test.  
In wild-type mice, the number of APP- and Clathrin-labelled cells significantly increased in all areas with age. 
PICALM-labelled cells showed a non-significant increase with age and SORLA-labelled showed no changes 
in the cortex or dentate gyrus but significantly increased in CA1, CA2 and CA3 regions with age. In 
transgenic mice, APP and Clathrin increased with age in all brain regions except the cortex where a 
significant decrease in Clathrin was observed. PICALM- and SORLA-labelled cells increased with a non-
significant trend in all regions with age. 
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As APP is predominantly internalised by CME, the general increase in APP, Clathrin and PICALM infers an 
age-related increase in CME in the brain. This age-related increase is also present in the transgenic mice, 
suggesting that the increases seen in CME proteins in normal aging are accelerated in AD. The increase in 
SORLA contradicts other findings on the role of SORLA in amyloid pathology3 and needs further work. 
1. Citron M. Strategies for disease modification in Alzheimer's disease Nature Reviews Neuroscience. 2004; 5:677-685. 
2. Doherty GJ, McMahon HT. Mechanisms of Endocytosis. Annual Review of Biochemistry. 2009; 78:857-902. 
3. Dodson SE, Andersen OM et al. Loss of LR11/SORLA Enhances Early Pathology in a Mouse Model of Amyloidosis: Evidence for a 
Proximal Role in Alzheimer’s disease. Journal of Neuroscience. 2008; 28(48):12877-12886. 
 
Characterising and optimising polymer microneedle penetration in human skin  
Amanda Hotston, X Zhao and JC Birchall 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Microneedles (MN) are an attractive alternative to conventional injection as they cause minimal damage and 
pain.1 MN performance is dependent on application parameters and MN array characteristics.2,3 Optimising 
penetration performance may impact future MN design, enabling improved drug delivery. Investigation of MN 
application to human skin in vivo offers a valid insight into MN performance as animal models and human 
skin models are limited.4 Optical Coherence Tomography (OCT) is a non-invasive technique allowing for 
real-time in vivo visualisation of microneedle (MN) penetration and skin behaviour. 
Polymer MNs with different heights and needle spacing were applied to excised human skin samples using a 
materials analyser to determine array characteristics and the application speed and velocity required for 
optimal MN penetration. Polymer MNs were also applied to in vivo human skin manually and imaged by OCT 
for assessment of MN performance and skin behaviour.  
Polymer MNs were found to penetrate the SC of in vivo human palm skin and ex vivo human breast tissue. 
Application velocity of 2000mm/min and a force of 80N allowed for the most successful MN penetration when 
arrays with 900µm MN length and 1.5mm MN pitch were applied to ex vivo human skin. 
MN success depends on application velocity and force, coupled with MN height and pitch. Application 
velocity had a greater impact on increasing penetration than force, although both parameters appear 
synergistic. Increased MN height and increased pitch resulting in greater penetration performance indicated 
that it is a combination of each of these that leads to better MN performance and potential drug delivery. 
Refinement of MN dimensions and further in vivo OCT investigation is required to assess these parameters 
fully. 
1. Prausnitz MR, Langer R. Transdermal drug delivery. Nature Biotechnology. 2008; 26(11):1261–1268. 
2. Davis SP et al. Insertion of microneedles into skin: measurement and prediction of insertion force and needle fracture force. Journal 
of Biomechanics. 2004; 37:1155-1163 
3. Ololade O et al. Influence of Array Interspacing on the force Required for Successful Microneedle Skin Penetration. Theoretical and 
Practical approaches. Journal of Pharmaceutical Sciences. 2013;102:1209-1221 
4. Coulman SA et al. In Vivo, In Situ Imaging of Microneedle Insertion into the Skin of Human Volunteers Using Optical Coherence 
Tomography. Pharmaceutical Research. 2011; 28: 66-81 
 
Medicines reconciliation – what errors and discrepancies occur upon admission to 
hospital and why? 
Natasha Huckerby, RE Deslandes and PN Deslandes 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
It is common for medication errors to occur on admission to hospital.1 Medicines reconciliation is a pharmacy 
service designed to ensure patients’ get the medication that they were on pre-admission.2 This study at 
Whitchurch Hospital aimed to identify what and why errors and discrepancies occur on admission, as well as 
recommend improvements to the service. 
Ethics approval was obtained from the Cardiff School of Pharmacy Research Ethics Committee. A data 
collection tool was used to assess medicines reconciliations both prospectively and retrospectively. 
Differences between inpatient drug charts and GP medication were split into two groups. Errors made by the 
healthcare professional (HCP) or discrepancies, which were instigated by the HCP. A severity scale (Level 1-
6) was used to quantify errors. Semi-structured interviews were conducted and audio recorded with written 
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consent, to establish the views of pharmacy staff on the medicines reconciliation service. Transcribing and 
thematic analysis was then carried out.  
160 patients were analysed, 109 were retrospective and 51 prospective. 14 patients were excluded due to 
insufficient information. Errors (n=129) and discrepancies (n=46) occurred for 50% of patients and ranged 
from 0-10 in number. Omission was the most common type (61.7%), whilst the most frequent cause was due 
to HCP error (53.1%). Many of the errors were level 3 (moderate) in severity (51.5%). Seven interviews were 
conducted three with pharmacists and four with pharmacy technicians. Although time consuming, the benefit 
of the service on patient care was identified. Communication barriers between multidisciplinary teams and 
integration into the daily routine were also discussed.  
The data collected highlighted how often errors occurred on admission due to the HCP. This is a patient 
safety issue as many of these errors could have caused harm. The interviews were a useful insight into 
participant’s views on the service. Recommendations were made to improve the current service, such as an 
education day for junior doctors on common medication errors on admission. 
1. Duguid M. The importance of medication reconciliation for patients and practitioners. Australian Prescriber. 2012; 35(1):15-19.  
2. National Institute of Clinical Excellence and National Patient Safety Agency (NICE and NPSA). 2007. Technical patient safety 
solutions for medicines reconciliation on admission of adults to hospital [Online]. Available at: http://guidance.nice.org.uk/PSG001 
[Accessed 15th November 2012] 
 
The light protective effect of lipid emulsions on retinol in Vitlipid® N Infant 
Ffion C Hughes, TI Ferguson, SE Emery and R Price-Davies 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Parenteral nutrition (PN) is the administration of nutrients via the intravenous route, where oral or enteral 
feeding cannot be established.1 Components of PN include glucose, lipids, amino acids, vitamins, 
electrolytes and trace elements. Vitamins are known to cause instability and degradation issues within PN 
and therefore only added shortly before infusion.2 Vitlipid is a multivitamin preparation containing a 
concentrated emulsion of lipid-soluble vitamins,3 including retinol, the most photosensitive component of PN 
admixtures. This study investigated the effect of lipid emulsions on the photodegradation of retinol within 
Vitlipid ® N Infant under different light conditions.  
Clear glass bottles were prepared, containing either 50 ml Vitlipid, or 10 ml Vitlipid with 40 ml lipid emulsion 
(either Intralipid or SMOFlipid). A sample of each mixture was exposed to natural sunlight and cool white 
light. At 0h, 1h, 2h, 3h, 4h and 24h, light intensity readings were recorded and samples taken for analysis. 
Retinol loss was assessed through HPLC analysis. 
All samples showed a similar trend in retinol photodegradation but to different extents. Both lipid emulsions 
greatly reduced retinol photodegradation, but no significant difference was observed between the protective 
effect of SMOFlipid or Intralipid as the lipid source. Retinol loss was much less under cool white light 
compared to sunlight. The majority of retinol loss usually occurred within the first hour. 
Light intensity and wavelength had a significant effect on the photodegradation rate of retinol. Lipid 
emulsions reduced the extent of retinol photodegradation by approximately 10% at each time, but their 
protection alone is not sufficient. 
1. Minton A. Studies on the stability of parenteral nutrition admixtures: Cardiff University; 1998. 
2. Allwood MC, Kearney MCJ. Compatibility and stability of additives in parenteral nutrition admixtures. Nutrition. 1998;14(9):697-706. 
3. Fresenius Kabi. Vitlipid N Infant Concentrate for emulsion for infusion. Australia: Fresenius Kabi; 2010[accessed February 2013]. 
Available from: http://www.fresenius-kabi.com.au/files/Vitalipid_N _CMI.pdf. 
 
Is the molecularly imprinted polymer ‘p(EGDMA-co-MAA)’ superior to other 
imprinted polymer systems? 
Philip James and CJ Allender 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Molecular imprinting is a concept derived from the ability of biological hosts to strongly and specifically bind a 
particular molecular structure. Many different methods for creating a molecularly imprinted polymer (MIP) 
exist, along with numerous combinations of functional monomer and cross-linker. So why then is the polymer 
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‘p(EGDMA-co-MAA)’ by far the most widely reported MIP? Could it simply be that it is better than other 
polymer systems? 
An extensive literature review of papers from the past few years was carried out, searching for papers that 
reported the use of an equilibrium batch rebinding assay and enough data to reconstruct a binding isotherm 
for the MIP, allowing the Binding capacity (Bmax) and affinity (Kd) to be determined. Raw data was normalised 
to a standard set of units and entered into the GraphPad software to produce the binding isotherm for each 
MIP. 
Of the large numbers of papers reviewed, only 34 papers contained enough relevant information. From this 
data, the mean Bmax and Kd values were determined for p(EGDMA-co-MAA) systems and other polymer 
systems. There was no significant difference between the means for the Bmax and Kd (with p-values of 0.8479 
and 0.8850 respectively). Following removal of binding isotherms which may produce misleading Bmax and Kd 
values, the mean values were again determined, and there was no significant difference between the means 
(with P-values of 0.5298 and 0.2273). 
A total of 28 MIPs (from 34 published papers) were initially compared, followed by the comparison of the 
remaining isotherms upon removal of data that may produce misleading values. Based on the results of this 
work, it was concluded that on the whole, the polymer system p(EGDMA-co-MAA) is not superior to other 
polymer systems.  
 
An evaluation of Interprofessional Education (IPE) sessions in 2012/13 between 
medicine and pharmacy undergraduate students at Cardiff University  
Andy Jenkins, SA Coulman, PA Routledge1 and DN John 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales and 1School of Medicine, Cardiff University, UHW Main Building, Heath Park, Cardiff CF14 4XN, Wales, UK 
IPE has been defined as when ‘two or more professionals learn with, from and about each other to improve 
collaboration and the quality of care’.1 IPE is a required element of both medicine and pharmacy 
undergraduate degrees.2,3 IPE was introduced in 2011 between pharmacists and medics at Cardiff 
University. Students work together on therapeutics and prescribing cases. Three IPE sessions were 
conducted in 2012/2013 between 3rd year medicine students and either 3rd or 4th year pharmacists. The aim 
of this study was to evaluate the views of the students who participated in the IPE sessions. 
An anonymous, self-completion two-part questionnaire, including 5-point Likert-scale and open-ended 
questions, was distributed using total population sampling at the end of each 2hr session. Quantitative data 
were analysed using SPSS. Kruskal-Wallis and Mann-Whitney U statistical tests were used to compare 
student groups. Semi-structured interviews were conducted to help explain questionnaire findings. Non-
probability (purposive and convenience) sampling was used to recruit 3 participants from each student 
group. Interview and qualitative data from questionnaires were analysed using content analysis. Ethics 
approval was obtained. 
A questionnaire response rate of 96.7% was achieved. Both professions were positive about the sessions. 
Students found IPE useful and enjoyable with medics having a significantly higher level of agreement. Over 
95% found working with a student from a different profession useful. Students (≥79%) also agreed more IPE 
should be conducted. The most frequently stated benefit was ‘working with another healthcare professional’ 
(n=212). The organisation of the session was identified by most students as needing improvement (n=73). 
Several suggestions were made in relation to the organisation of the session, particularly regarding the 
allocation to interprofessional partners. Interviews provided additional information on negatives and 
improvements such as ‘medics got more out of the session’.  
IPE sessions were beneficial and should be continued. Suggestions for change have already been made to 
the Schools. Evaluating the sessions as a result of any changes is recommended. 
1. CAIPE. 1997. Interprofessional Education – a definition. CAIPE Bulletin. Centre for Advancement of Interprofessional Education, 
London. 
2. General Medical Council. Outcomes and standards for undergraduate medical education. Tomorrows Doctors. General Medical 
Council. 2009;27-28. 
3. General Pharmaceutical Council. Future pharmacists: Standards for the initial education and training of pharmacists. General 
Pharmaceutical Council. London. 2011;18-22. 
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Comparison of the effect of speed during penetration of inhalation grade gelatin and 
hypromellose capsules used in dry powder inhalers 
Gareth Jenks,1 SA Coulman,1 F Diez2 and BE Jones1,2 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK and 2Qualicaps Europe, Alcobenas, Madrid, Spain 
There has been a revival in the use of Dry Powder Inhalers (DPI) based on capsules, because of their 
inherent simplicity of design and powder formulation. The uses for pulmonary delivery has recently expanded 
to the administration of more complex actives such as insulin.1 DPI are more patient friendly as they 
overcome the problem of patients’ poor coordination when using metered dose inhalers (MDI).2 Previous 
studies have shown that moisture content of capsules has an impact on capsule puncturing.3,4 This study 
was designed to test the effect of the speed of movement of DPI pins during puncturing; comparing 
inhalation grade gelatin and hypromellose capsules that had been pre-conditioned at different relative 
humidities. The objective of this study was to provide data to aid in improving DPI design.  
Angular pins from a 2-pin inhaler (Plastiape, Italy) were used in a Zwick materials testing machine to 
puncture the capsules over a range of speeds, from 20mm/min to 420mm/min. Tests were made at 
20mm/min intervals. For each test the following factors were measured, shell deformation at puncture and 
the force required, the circularity of the puncture hole and its visual morphology.  
The increase in the speed of puncturing had no significance effect on the results of each set of capsules. 
However, the results for the gelatin capsule that had been stored at a lower relative humidity showed a 
significant difference (P<0.05) compared to the others for all the recorded measurements. They showed 
significant damage; with pieces breaking off causing large irregular shaped punctures. The increase in the 
force to puncture these capsules correlated with previous studies, confirming that when gelatin capsules lose 
moisture they become more rigid and liable to fracture.3,4 
The study showed that HPMC capsules are a much more robust system for use in DPI with regards to 
puncturing as they are unaffected by moisture loss. However, more studies are needed to investigate the 
relationship between puncture hole size/shape and the release of powder from capsules. 
1. Kwon J, Lee B, Lee J, Kim C. Insulin microcrystal suspension as a long-acting formulation for pulmonary delivery. European Journal 
of Pharmaceutical Sciences. 2004; 22(2-3):107-116.  
2. Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H et al. Medication adherence issues in patients treated for COPD. Int J Chron 
Obstruct Pulmon Disease. 2008;3:371-384. 
3. Birchall JC, Jones BE, Morrissey A, Jones BE. A Comparison of the Puncturing Properties of Gelatin and Hypromellose Capsules 
for Use in Dry Powder Inhalers. Drug Development and Industrial Pharmacy. 2008: 34:870-876. 
4. Coulman SA, Torrisi BM, Birchall JC, Jones B, Diez F. Charaterising penetration of hard shell capsules in dry powder inhalers. 2013 
in preparation. 
 
Residues S275 and S276 participate in the activation of the ZIP7 transporter in MCF-7 
breast cancer cells 
Bethan Jones and KM Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Zinc is an essential trace element and a second messenger in a non-genomic signalling pathway.1 Cytosolic 
zinc levels rise within minutes of exogenous zinc stimulation in breast cancer cells.2 Zinc is released from the 
ER intracellular store via ZIP7 efflux transporters located on its membrane.3 It is postulated that ZIP7 is 
activated following phosphorylation of serine residues, S275 and S276, by CK2. Zinc inhibits tyrosine 
phosphatases which causes prolonged activation of tyrosine kinases and downstream effector molecules 
AKT and MAPK and subsequent cell proliferation and metastasis4. We hypothesised that residues S275 and 
S276 participate in the activation of ZIP7 in MCF-7 breast cancer cells.  
Wild-type (WT), null mutant (AA) and phosphomimetic mutant (DD) ZIP7 transporters were created and 
transfected into MCF-7 breast cancer cells. Serine residues were mutated to evaluate their contribution to 
transporter activation. Cells were stimulated with exogenous zinc at 0, 2, 5, 10, 15 and 20 minutes and then 
lysed. 12% SDS-PAGE and western blotting analysis were used to separate proteins. To assess ZIP7 
activation, pZIP7 and activated downstream pMAPK and pAKT were measured using pZIP73-1-1, 
pMAPKT202/Y204 and pAKTS473 antibodies. Protein activation was quantified with densitometry.  
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MAPK and AKT were activated downstream of ZIP7 phosphorylation in wild-type cells, where S275 and S276 
were retained, proving that downstream activation was ZIP7-dependent. This response was lost in the AA 
mutant, suggesting that S275 and S276 participate in ZIP7activation. The activation of MAPK and AKT was 
examined in cells expressing DD mutant. 
In conclusion, residues S275 and S276 participate in the activation of ZIP7 and downstream signalling causing 
proliferation and metastasis in breast cancer cells. We demonstrate a potential to target S275 and S276 with 
small molecule inhibitors to halt zinc signalling, at the point of zinc release, in the treatment of breast cancer. 
1. Yamasaki S et al. Zinc is a novel intracellular second messenger. The Journal of Cell Biology. 2007;177(4):637-45. 
2. Hogstrand C, Kille P, Nicholson R, Taylor K. Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase 
activation. Trends in Molecular Medicine. 2009; 15(3):101-11. 
3. Taylor K, Gee J, Kille P. Zinc and cancer. In: Rink, L. ed. Zinc in Human Health. IOS Press, Amsterdam; 2011: 283-304. 
4. Taylor K, Hiscox S, Nicholson R, Hogstrand C, Kille P. Protein kinase CK2 triggers cytosolic zinc signaling pathways by 
phosphorylation of zinc channel ZIP7. Science Signaling. 2012; 5(210): 11 
 
Honey as a source of antimicrobial phytochemicals with activity against MRSA 
Emma Jones, J Hawkins and L Baillie 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Honey has been used for centuries for its medicinal properties. Research has identified the main 
antimicrobial components of honey; low pH, high sugar content and hydrogen peroxide.1 However honey is a 
rich source of phytochemicals, some of which may become potential drug development lead compounds to 
combat the threat of increasing antibiotic resistance. The aim of this study was to test a range of honey 
samples from local bee-keepers for antimicrobial activity against methicillin-resistant Stapphylococcus 
aureus (MRSA) and identify novel honey derived antimicrobial phytochemicals which inhibit the growth of 
MRSA. 
A range of honey samples were screened for their ability to inhibit the growth of MRSA using agar diffusion 
and broth based assays, the most promising honey samples were extracted with three different solvents (n-
hexane, ethyl acetate and methanol). The compounds present in each extraction were separated using thin 
layer chromatography (TLC). The TLC plates were then over-layed with MRSA to assess whether any of the 
TLC bands showed antimicrobial activity. 
Of the six honey samples tested, four produced zones of inhibition that were significantly greater (p<0.05) 
than those produced by the positive control (phenol 5%w/v) during the agar diffusion assay. One particular 
honey also retained antimicrobial activity when methylglyoxal, hydrogen peroxide and bee defensin-1 were 
neutralised, three known antimicrobial compounds present in honey1, suggesting the presence of novel 
antimicrobial phytochemicals. Screening the TLC bands from the solvent extractions resulted in nine TLC 
bands showing the ability to inhibit the growth of MRSA.  
This study has discovered honey derived phytochemicals that have antimicrobial activity against MRSA, with 
further research these compounds could now be identified and act as potential drug development leads for 
new antibiotics.  
1. Kwakman P et al. How honey kills bacteria. FASEB J. 2010; 24:2576-82. 
 
Investigation towards the surface imprinting of amlodipine 
Frances Joslin, J Bowen, E Loizidou and CJ Allender 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Based upon the complimentary binding sites between a template and target molecule, molecular imprinting 
enforces recognition for a chosen molecule onto a polymer matrix. Initial “bulk” imprinting methods are 
flawed; with the template dispersed throughout the polymer matrix it is difficult to remove and reintroduction 
of the molecule is problematic.1 Now, more sophisticated methods isolate imprinting of the template onto the 
surface of the polymer allowing easy access to binding sites and quick removal of the template from such 
pockets2 and hence, it was by this method that we investigated the imprinting of amlodipine.3  
Amlodipine is a calcium channel blocker, commonly used in the treatment of angina pectoris and 
hypertension. It was extracted from 10mg amlodipine besylate tablets and then bound to Merrifield resin. 
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Such a resin was chosen as its surface functional groups could be modified resulting in a bifunctional resin. 
Half of the chloromethyl functional groups already existing on its surface were converted to amine groups. 
These amine groups allowed binding of amlodipine. The remaining chloromethyl groups were bound to 
iniferter, sodium diethyldithiocarbamate. Resins with a full conversion or no conversion of functional groups 
were used as controls.  
Polymerisation studies concluded that crosslinker, ethylene glycol dimethacrylate and monomer, methacrylic 
acid resulted in polymer growth when exposed to UV light for 2 hours. Bound to amine groups, amlodipine 
was successfully immobilised on the resin via crosslinker dithiobis[succinimidyl propionate] and the ability to 
then remove it was investigated using a cleaving agent dithiothreitol (DTT) with analysis by HPLC. A sample 
of amlodipine modified resin reacted with DTT contained four times the amount of amlodipine than the same 
resin without DTT.  
Whilst amlodipine and the iniferter were not imprinted simultaneously they were successfully immobilized 
onto the resin independently and together, it would be hoped they would give controlled polymerisation.4 
1. Hillberg A, Tabrizian M. Biomolecule imprinting: Developments in mimicking dynamic natural recognition systems. IRBM. 2008;29(2-
3):15. 
2. Turner N, Jeans C, Brain K, Allender C, Hlady V, Britt D. from 3D to 2D: A Review of the Molecular Imprinting of Proteins. 
Biotechnology Progress. 2009;22(6):15. 
3. Cunliffe D, Alexander C. Surface Imprinting. Molecularly Imprinted Materials:Science and Technology. 2004;1:752. 
4. Hilt J, Byrne M. Configurational biomimesis in drug delivery: molecular imprinting of biologically significant molecules. Advanced 
Drug Delivery Reviews. 2004;56(11):21. 
 
Novel thienopyrimidine derivatives as anti-HCV agents 
Azyan Kamarudin, M Bassetto and A Brancale 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
It was estimated that 2-3% of the world’s population were chronically infected with HCV in 2012.1 The current 
treatment available is non-specific with significant side effects and high susceptibility to resistance,2 NS3 
helicase is an important enzyme in HCV life cycle that is essential in viral replication,3 thus inhibiting this 
enzyme may prevent the progression of the disease. This project aims to design and synthesise a series of 
novel thienopyrimidine derivatives that is potentially involved in the inhibition of NS3 helicase by rationally 
modifying the lead compound obtained from previous screening. 
Several modifications of the lead compound were done and the resulting compounds were analysed through 
docking studies to observe their interactions in the binding pocket. The best compounds were synthesised 
through a five-step synthesis involving Gewald reaction, pyrimidinone ring condensation, pyrimidine ring 
chlorination and aromatisation, hydrazine formation and production of final compounds hydrazones and 
hydrazides. 
The docking studies showed that the newly designed compounds interacted with the key amino acid 
residues within the binding pockets. Ten designed compounds were then synthesised successfully with 
acceptable yields. The production of the pyrido groups were complicated by its high polarity. However, 
different approaches of the second step of the synthesis were found and could be used for further work to 
improve the yield.  
As a conclusion, the replacement of hydrazones linker with hydrazides revealed an improvement in the 
binding modes of the compounds in the pocket. The yield of the products depends on the structure and 
polarity of the compounds. The compounds synthesised were sent for biological tests including cell-based 
HCV replicon assay and mutational studies to determine their antiviral activity. If any of the compounds were 
more active than the lead, further modifications needed to be done to optimise the activity such as using 
molecular docking studies to identify alterations. 
1. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the. Clin Infect Dis. 
2012; 55(1):S10-5. 
2. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for 
initial treatment of chronic hepatitis C: a randomised trial. The Lancet. 2001 9/22/;358(9286):958-65. 
3. Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in 
the 3' nontranslated region are essential for virus replication in vivo. Journal of Virology. 2000 //;74(4):2046-51. 
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Actions of trace amines in the isolated rat ileum and oesophagus 
Xin Kan, AA Herbert and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
β-phenylethylamine (β-PEA), tyramine and octopamine are collectively known as “trace amines”(TAs). TAs 
are structurally and chemically related to monoaminergic neurotrasmitters including noradrenline, dopamine 
and 5-hydroxytryptamine (5-HT). TAs are also abundant in our diet, such as cheese, sausage and 
chocolate.1 The mechanism of their action has been traditionally accepted as the displacement of 
endogenous classical amines from neuronal storage vesicles into synaptic cleft. The hypothesis of this study 
is the responses to TAs in rat gastrointestinal tract may be mediated by an indirect action on 5-HT2A 
receptors.  
Sections (2cm) of oesophagus or ileum were allowed to equilibrate in tissue baths containing Krebs solution 
warmed to 37°C and aerated with 5% CO2 in O2. Cumulative dose-response curves (DRC) to methacholine 
(MCh) were constructed at the beginning of each study. Repeat DRCs to trace amines were then 
constructed in the absence or presence of 5-HT2A receptor antagonist, ritanserin (1µm).Results were 
expressed as a percentage of the maximum MCh response in the tissue. 
β-PEA and tyramine contracted the oesophagus at high concentrations (1-10miliM, n=6). The response to β-
PEA in oesophagus was reduced by ritanserin, although this was not significantly different (Emax without 
and with ritanserin, 101.8±28% and 26.8±18.3% respectively). Tyramine brought about dose-dependent 
relaxation in the tissue initially, which were converted to a contraction in the repeat curve (n=4). Octopamine 
induced relaxant effect in ileum and oesophagus which were not modify by ritanserin (n=1-2). There were no 
significant differences in the maximum response or pD2 between any of the groups studied.  
Based on our findings, we propose that the actions of TAs are not mediated through 5-HT2A receptors. The 
responses may be mediated by other amine receptors (eg adrenoreceptors). Other possible candidate for 
the responses is the newly identified trace-amine-associated receptor family (TAAR)2. This can be tested by 
using a selective TAAR 1 antagonist, EPPTB4.3 
1. Broadley KJ, Akhtar Anwar M, Herbert AA et al. Effects of Dietary Amines on the Gut and Its Vasculature. Br J Nutr. 2009;101: 
1645-52. 
2. Lindemann L, Ebeling M, Kratochwil NA, Bunzow JR, Grandy DK, Hoener MC.Trace Amine-Associated Receptors Form Structurally 
and Functionally Distinct Subfamilies of Novel G Protein-Coupled Receptors. Genomics. 2005;85: 372-85. 
3. Stalder H, Hoener MC, Norcross RD. Selective Antagonists of Mouse Trace Amine-Associated Receptor 1 (Mtaar1): Discovery of 
Epptb (Ro5212773). Bioorg Med Chem Lett. 2011; 21:1227-31. 
 
Characterisation of cannabinoid responses on the isolated guinea-pig ileum 
Karrar Karrar and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Cannabinoid compounds (CBs), such as the synthetic agonist Win 55,212-2 have been thought to inhibit 
electrically evoked contractions of isolated ileum preparations by reducing excitatory enteric cholinergic 
transmission mediated via a prejunctional CB1 receptor.1 Previous studies have also suggested the 
involvement of other novel receptor signaling mechanisms. The aim of this study was to confirm the 
involvement of the CB1 receptor in mediating the inhibitory effects of cannabinoids on the isolated ileum. 
Contraction in ileum obtained from male Dunkin-Hartley guinea-pigs, was stimulated using electrical field 
stimulation (EFS).2 Concentration response curves (CRC’s) were constructed using Win 55,212-2 (1x10-6 M 
– 3x10-5 M) in the absence or presence of: SR141716A (CB1 selective), AM281 (CB1 selective), AM630 (CB2 
selective) and an endothelial cannabinoid receptor antagonist, O-1918 (n=3). Vehicle controls were carried 
out concomitantly for agonist and antagonist studies using ethanol and DMSO. This allowed for a Students 
paired t-test to be utilised in determining statistical significance. 
Win 55,212-2 (non-selective) and ACEA (CB1 selective) were found to cause concentration dependent 
decreases in the amplitude of electrically evoked contractions to 38.4 % and 55 % of the initial EFS response 
respectively. This was found to be statistically insignificant (p< 0.05) against an ethanol vehicle control apart 
from at a final bath concentration of 3x10-5 M. The use of CB1 selective antagonists, SR141716A or AM281 
alone or any combination of ‘AM281 (CB1)+ AM630 (CB2)’ or ‘Am281+ AM630 + O-1918 (CBe)’ failed to 
antagonise the effects of Win 55,212-2 when tested against their respective controls (p<0.05). 
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The results strongly suggest that Win 55,212-2 is acting via non CB1 - non CB2 receptors to mediate this 
inhibitory effect on motility in the isolated ileum. Cannabinoids have been shown to interact with proteins of 
the endocannabinoid system and other targets, in particular the Transient Receptor Potential Vanilloid type-1 
(TRPV1) channel.3 
1. Abalo R, Vera G, López-Pérez AE, Martínez-Villaluenga M, Martín-Fontelles MI. The gastrointestinal pharmacology of 
cannabinoids: focus on motility. Pharmacology. 2012; 90(1-2): 1-10. 
2. PATON WD.The response of the guineapig ileum to electrical stimulation by coaxial electrodes. J Physiol. 1955; 127(2): 40-41. 
3. Di Marzo V, Piscitelli F. Gut feelings about the endocannabinoid system. Neurogastroenterol Motil. 2011; 23(5): 391-398. 
 
The antibacterial activity of black seed oil against Mycobacterium smegmatis and its 
potential use in tuberculosis therapy 
Baljit Kaur, J Blaxland and L Baillie 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Black seed oil (BSO) is oil extracted from Nigella sativa and is a natural product.1 Natural products have 
been used in traditional medicine and are used increasingly in early drug discovery, as the primary sources.2 
Tuberculosis (TB) is a worldwide major health problem.3  
BSO was tested against M. smegmatis, which was used as a model for M. tuberculosis as they share some 
identical genomic sequences.4 The zone of inhibition test was used to see if BSO possessed 
antimycobacterial activity and synergy tests were performed to see if BSO and antibiotics had greater effects 
when used together.  
The zone of inhibition test proved that certain BSOs do possess antibacterial activity. The synergy tests 
showed that BSO potentiates the antibiotic effects of ethambutol and isoniazid.  
It was shown that BSO has potential to be used in combination with the antibiotics to enhance their effect. 
Further investigations would be required before BSO was to be approved for use in TB treatment.  
1. Shifa Lifeherbs International. Black seed, the magical herb. UK; 2005 [Accessed: 29 March 2013]. Available from: 
http://www.shifalife.com/etrading/black_seed.jsp 
2. Shibata MA, Khan IA, Linuma M, Shirai T. Natural products for medicine. Journal of Biomedicine and Biotechnology. 2012. 
3. Global Tuberculosis Report 2012. World Health Organisation, 2012. 
4. Thi BTN, Maura RB et al. Evaluation of the potential of Mycobacterium smegmatis as vaccine Candidate against tuberculosis by in 
silico and in vivo studies. VacciMonitor. 2010; 19(1). 
 
Isolation of an antimicrobial compound from Humulus lupulus 
Rachel Lloyd, J Blaxland and AW White 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Anti tubercular antibiotics are becoming increasingly ineffective due to the development of bacterial 
resistance mechanisms. Plants generate organic compounds called secondary metabolites which have been 
identified as key components in their defence mechanisms and have exhibited considerable activity against 
Mycobacterium tuberculosis, the causative agent in tuberculosis (TB) infection.1, 2 M. tuberculosis is now one 
of the most significant microorganisms to have developed multi-drug resistance and extensive-drug 
resistance.3 The preservative action of the Hop plant, known botanically as Humulus lupulus, has been 
exploited in the beer brewing industry since the Middle Ages and has been shown to exhibit anti-tuberculosis 
activity.4 
Organic solvents of varying polarities were used to extract compounds from two hop variants: Magnum and 
Amarillo. A bioautographic assay was used to analyse extracts for their antibacterial activity against 
Staphylococcus aureus. Column chromatography was used to separate extracts into their substituents which 
were also analysed for their antibacterial activity. Analysis by NMR and mass spectrometry analysis lead to 
limited characterisation and confirm the potential drug-like properties of compounds extracted. 
A compound from the non-polar Amarillo extract was found to exhibit the most significant antibacterial 
activity. Five unknown compounds were obtained from column chromatography. NMR analysis did not yield 
comprehendible results due to concentrations of samples being too low. Mass spectrometric analysis 
revealed an almost drug-like compound with molecular weight (M+H)= 589. 
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The success of the non-polar extract to inhibit bacterial growth could be due to its ability to penetrate the 
lipophilic bacterial cell wall. The compounds could not be fully characterised due to the unsuccessful NMR 
analysis. An almost drug-like compound that is potentially novel (its measured mass does not correspond to 
known hops constituents) has been isolated from the Amarillo variant of Humulus lupulus. Further 
investigation is necessary to assess its drug-like properties, characterise its structure and to quantitatively 
determine its antimicrobial activity to compare it to currently used antibiotics. 
1. Cheng M, Wu M, Yanai H et al. Secondary metabolites from the endophytic fungus Biscogniauxia formosana and their 
antimycobacterial activity. Phytochemistry Letters. 2012; 5(3): 467-472. 
2. Wu H, Cheng M, Peng C et al. Secondary metabolites from the stems of Engelhardia roxburghiana and their antitubercular 
activities. Phytochemistry. 2012; 82: 118-127. 
3. Zhang Y, Yew WW. Mechanisms of Drug Resistance in Mycobacterium Tuberculosis. Int J Tuberc Lung Dis. 2009; 13(11): 1320-
1330. 
4. De Almeida NEC, Do Nascimento ESP, Cardoso DR. On the Reaction of Lupulones, Hops β-acids, with 1-hydroxyethyl Radical. 
Journal of Agricultural and Food Chemistry. 2012; 60(42): 10649-10656. 
 
Synthesis of an [18F]-FAU precursor for PET imaging 
Mutheerah Mahmud, J-P Meyer and AD Westwell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
PET tracers are a huge demand in today’s market. [18F] tracers are usually the choice of preference due to 
its compromised half-life of 109.8 minutes and its low positron energy (633 KeV).1 [18F]-FAU (2’-deoxy-2’-
[18f]fluoro-1-β-d-arabinofuranosyluracil) is a pyrimidine nucleoside tracer which has a huge potential, not 
only as a diagnostic tool for cancer, but also in monitoring levels of thymidylate synthase enzyme.2 The aim 
of this research project is to develop a precursor of [18F]-FAU for PET imaging via a five steps process using 
uridine as the starting material. 
The first step involved protection of the 3’ and 5’ hydroxyl group of the nucleoside. The protecting group used 
was a TIPDS (tetraisopropyldisiloxane) protecting group. The second step involved the protection of the 2’-
hydroxyl group using TMS (trimethylsilyl) chloride. The third step involved the N-Boc (tert-Butyloxycarbonyl) 
protection as well as the deprotection of TMS group on the 2’ hydroxyl group. The fourth step involved the 
introduction of a good leaving group, which is a tosyl group at the 2’ position. The final step was the removal 
of the TIPDS protecting group and replacing it with a THP (2-tetrahydropyranyl) group.  
A clean precursor was successfully synthesised. Each reaction was monitored using TLC followed by NMR. 
NMR spectrum for each reaction has come clean indicating the completion of each step. The yield for each 
reaction varied between 47% to 88%. The precursor would be brought to the PETIC (Positron Emission 
Tomography Imaging Center) in Heath Hospital, Cardiff for the removal of the remaining protecting group 
after the radio-fluoridation with [18F] at the 2’ position is placed.  
The precursor synthesised has never been reported in any journal article or used for radio-fluorination 
before. The success of synthesising this precursor opens the window of opportunity for further research on 
this precursor to be carried out.  
1. Alauddin M. Positron emission tomography (PET) imaging with 18F-based radiotracers Am J Nucl Med Mol Imaging. 2012;2(1):55-
76. 
2. Eiseman J, Brown-Proctor C, Kinahan P, Collins J, Anderson L. Distribution of 1-(2-Deoxy-2-fluoro-D-arabinofuranosyl) Uracil in 
Mice Bearing Colorectal Cancer Xenografts: Rationale for Therapeutic Use and as a Positron Emission Tomography Probe for 
Thymidylate Synthase. Clinical Cancer Research. 2004;10:6669–76. 
 
Analysis of the kinetics of vasoconstrictor responses to amphetamines in isolated 
aorta 
Sarah Matthews and KJ Broadley 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Amphetamines and structurally related trace amines including tyramine and β-phenylethylamine (β-PEA) 
behave as indirectly acting sympathomimetics producing vasoconstriction causing an increase in blood 
pressure.2,3 However it is more recently suggested that they are also able to cause vasoconstriction via 
activation of trace amine associated receptors (TAARs).1  
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Male Sprague-Dawley rats (150-250g) thoracic aorta was removed, endothelium-denuded and cut into ring 
sections (approx. 0.5cm). The aortic tissue was suspended in a 50ml organ bath containing Krebs 
bicarbonate buffer. KCl (60mM) was added at the beginning of each experiment and used as a reference 
contraction. Concentration-response curves (CRCs) were constructed in the presence (except β-PEA) and 
absence of α1-adrenoceptor antagonist, prazosin (1μM). Successive concentrations of agonist in half log 
increments were used. Also a single dose of β-PEA (100μM) was added in the presence and absence of the 
“inhibitors” (1μM, Prazosin; 10μM, Pargyline; 1μM, ICI-118,551 hydrochloride; 10μM, cocaine hydrochloride). 
Tyramine partial agonist activity in rat aorta was investigated with β-PEA. All Contractions were expressed 
as a percentage of KCl maximum (% KCl) in each experiment.  
All three amines produced powerful vasoconstriction in rat aorta. The α1-adrenoceptor antagonist, prazosin, 
failed to inhibit amphetamine, however significantly inhibited tyramine. Tyramine was a partial agonist 
compared with amphetamine. The order of potency (EC40KCl μM) of the vasoconstrictors is as follows: 
amphetamine> β-PEA>tyramine. The “inhibitors” failed to alter β-PEA, whereas tyramine significantly 
antagonised the β-PEA response.  
Trace amines it seems are able to cause vasoconstriction of isolated rat aortic rings via a mechanism 
independent of α- and β-adrenoceptors, or indirect sympathomimetic stimulation. Therefore the contractile 
responses to trace amines are probably based on the activation of recently proposed TAARs. However it is 
still not established that trace amine activation of the TAAR receptors effectively cause vasoconstriction, only 
that there is capacity of these amines to activate them.1,4 
1. Branchek TA, Blackburn TP. Trace amine receptors as targets for novel therapeutics: legend, myth and fact. Current opinion in 
pharmacology. 2003;3(1): 90-97. 
2. Broadley KJ. (1996). Autonomic Pharmacology. London: Taylor & Francis. 
3. Broadley KJ. The vascular effects of trace amines and amphetamines. Pharmacology & therapeutics. 2010; 125(3): 363-375. 
4. Fehler M, Broadley KJ, Ford WR, Kidd EJ. Identification of trace-amine-associated receptors (TAAR) in the rat aorta and their role in 
vasoconstriction by β-phenylethylamine. Naunyn-Schmiedeberg's archives of pharmacology. 2010; 382(4): 385-398. 
 
The views of Cardiff undergraduate students on the community pharmacy 
placement scheme 
Nicole Morrow and E Mantzourani 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The GPhC requires pharmacy undergraduate students to obtain practical experience during each MPharm 
degree course.1 The Cardiff School of Pharmacy and Pharmaceutical sciences aims to meet these 
requirements through providing the community pharmacy placement scheme. As part of this scheme 
students undertake a community pharmacy placement experience during years one, two and three. The aim 
of this study is to explore the views of undergraduate students at Cardiff University on their community 
pharmacy placement scheme. The objectives of this study are to explore the views of the undergraduate 
students on the organisation of the placement, the information received beforehand and the methods of 
assessing the placement. 
To achieve these objectives a qualitative approach was chosen due to its exploratory nature.2 Semi-
structured interviews were conducted with participants in first, second and third year of the Cardiff School of 
Pharmacy and Pharmaceutical Sciences and thematic analysis was used. 
Ten students took part in the project which was a response rate of 2.8%. Five themes emerged from the 
analysis. Organisation, with university organisation and student organisation as subthemes. Student 
preparation with feelings and outcomes as subthemes. Preparedness of supervisor, exchange of 
experiences and finally methods of assessment with pharmacist supervisor marking, manual and reflective 
entry as subthemes. 
The aims and objectives of this research project were met through the use of qualitative analysis. Overall the 
placement scheme is valuable to undergraduate students in line with the literature.3 However there are a 
number of aspects of the scheme which participants felt could be improved e.g. more and longer 
placements, and better communication between the university and placement supervisor. 
1. General Pharmaceutical Council, 2011. Future pharmacists: Standards for the initial education and training of pharmacists 
[online]Available at: http://www.pharmacyregulation.org/education/education-standards [Accessed on: 2nd April 2013] 
2. Browne J, Green J. 2005 Principles of Social Research. Maidenhead: Open University Press  
3. Ting KN et al.. Contributions of Early Work-based Learning: A case Study of First year Pharmacy Students. International Journal of 
Teaching and Learning in Higher Education. 2009; 22(3): 326-335. 
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Investigation into the factors affecting community pharmacists’ engagement with 
spontaneous reporting of ADRs 
Cara Murdock and ML Hughes 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Adverse drug reactions are an important health problem in terms of morbidity, mortality and costs. In the UK 
6.5% of all hospital admissions are related to ADRs, 0.15% of patients admitted to hospital die from an ADR 
and the projected annual cost to the NHS is £466 million.1 The UK's spontaneous adverse drug reaction 
reporting scheme, called the Yellow Card Scheme is fundamental to drug safety surveillance but under-
reporting is a major limitation.2 This study aimed to investigate community pharmacists’ experiences of ADR 
reporting and explore barriers and facilitators to reporting. 
Preliminary semi-structured interviews with a purposive sample of community pharmacists were conducted 
and transcribed. Themes were identified to aid in the development of a confidential pilot questionnaire which 
was mailed to a random sample of 140 pharmacists in North East England. Resulting data was analysed 
using SPSS. 
Twenty-five percent (n=35) of the questionnaires were returned by the closing date. Thirty-nine percent of 
the pharmacists had previously reported an ADR and 97% agreed that it was a pharmacists’ responsibility to 
report an ADR. Although none of the results were statistically significant, they suggested that pharmacists 
who had received training were more inclined to report ADRs. Furthermore 83% of respondents agreed that 
reporting was a part of their professional duty. The interviews (n=7) suggested that perhaps it was more 
accessible for a GP to report an ADR as they have access to patient medical records. 
Although the numbers were low the knowledge and attitudes of pharmacists were explored, allowing an 
insight into the barriers and facilitators to reporting. This revelation may be useful in terms of patient safety 
as attitudes and knowledge are factors that can be modified. Additional research will be undertaken to 
support and further explore the findings of this study. 
1. Pirmohamed M et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004. 
[Online]. Available at: http://www.bmj.com/content/329/7456/15 [Accessed: 16 November 2012]. 
2. Lopez-Gonzalez A et al. Determinants of Under-Reporting of Adverse Drug Reactions - A Systematic Review. Drug safety. 2009 ; 
32 (1): 19-310114-5916/09/0001-0019. 
 
Characterisation of Transferrin as a targeting ligand in the blood-brain barrier 
Elaine Myo, G Al-Jayyoussi and M Gumbleton 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
CNS therapeutic drugs must be able to gain entry into the brain parenchyma to achieve pharmacological 
activity. The most sought for approach is to traverse the Blood Brain Barrier (BBB), thus avoiding risky 
surgically invasive methods.1 In this study, the efficacy of transferrin as a targeting ligand, for brain drug 
delivery was investigated using the immortalised murine BBB b.END3 cells as an in-vitro model.  
To characterise human Transferrin (hTf) uptake and recycling in b.END3 cells, we developed fluorescently 
labelled hTf protein and characterised its cellular internalisation using Fluorescence Activated Cell Sorting 
(FACS) and confocal microscopy. Further investigation of endocytic fate of hTf in BBB cells was 
characterised through co-localisation studies with fluorescently labelled lysosomal marker, dextran, using 
confocal microscopy. We further developed hTf - poly (acrylic acid)-chitosan nanoparticle (PAA-CS NP) 
conjugates and studied the effect of hTf – NP coupling upon the cellular uptake and internalisation of these 
NPs by b.END3 cells.  
hTf cellular internalisation studies, performed using FACS and confocal microscopy, strongly suggest a very 
rapid active process of uptake and recycling of hTf from the BBB cell line b.END3. Furthermore, co-
localisation studies give evidence that hTf can bypass lysosomal degradation when internalised in the cells.  
NP uptake studies show that PAA-CS NP cannot be actively internalised in the cells even when coupled to 
the rapidly internalised protein hTf, NPs displayed high levels of non-specific binding to cell membranes as 
evidenced from studies performed at 4oC. The results suggest that hTf although achieving high active 
cellular internalisation levels in the BBB, might not be capable of delivering large cargo (>200nm) across this 
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tenacious barrier. Further studies are needed to show capability of hTf in delivery of smaller cargo across the 
BBB.  
1. Gabathuler R. Approaches to Transport Therapeutic Drugs Across the Blood-brain Barrier to Treat Brain Diseases. Neurobiology of 
Disease. 2010;37: 48-57. 
 
Validity and reliability of the Family Reported Outcome Measure (FROM-16©) in 
urology 
David O’Donovan, H Joshi1 and MS Salek 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 
3NB, Wales, UK and 1University Hospital of Wales, Cardiff and Vale University Health Board, Cardiff, CF14 4XW, Wales, 
UK 
The Family Reported Outcome Measure is a generic family quality of life instrument that measures the 
quality of life of the families of patients with chronic conditions.1 FROM-16© comprises two domains: 
emotional domain (EM - 6 items) and personal and social life domain (PSL - 10 items).2 The aim of this study 
was to examine the psychometric properties of FROM-16© in families of patients with urological conditions.  
The study was carried out in the urology clinic at the University Hospital of Wales over a nine week period. 
Patients completed the SF-36 (n=125) and family members completed the FROM-16© on two separate 
occasions (Assessment 1, n=99; Assessment 2 n=30), 5 days apart. Internal consistency of the FROM-16© 
was assessed using Cronbach alpha. Test retest reliability was assessed using ICC. Convergent validity was 
assessed by correlating FROM-16© and SF-36 domain scores. FROM-16© scores of family members and 
patient perceived health status were compared using analysis of variance. 
The mean age of patients (male=104, female=21) was 65 years (SD= 16.2) and the mean age of family 
members (male=14, female=85) was 61 years (SD=14.22). Reliability of the FROM-16© total score was high 
(Cronbach α= 0.892; ICC=0.915). Similarly, the domains of FROM-16© showed high reliability (EM, α=0.80; 
PSL, α=0.89). Correlations between the SF-36 and FROM-16© domains were weak to moderate (-0.148 to -
0.469). Similarly, analysis of variance between the general health state of the patients and the FROM-16© 
demonstrated significant differences between patients quality of life and family quality of life (Chi- 
squared=13.176; p=0.01), suggesting that the patients’ quality of life does not necessary reflect that of the 
family members. 
This study indicates that the FROM-16© is both valid and reliable in families of patients with urological 
conditions. This provides confidence for the use of this measure in urology when developing care plan and 
management strategies. 
1. Golics C, Basra MK, Salek SS, Finlay AY. The Family Reported Outcome Measure: initial validation of a generic QoL measure for 
family members of patients with chronic medical conditions. Journal of Investigative Dermatology. 2012;132(72). 
2. Golics C, Basra MK, Salek SS, Finlay AY. The development and content validation of a novel generic family quality of life 
instrument: the family reported outcome measure. Quality of Life Research. 2012; 21(59). 
 
Exploring the role of c-Met in drug resistant breast cancer 
Matthew Pitman and S Hiscox 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The c-Met receptor is a receptor tyrosine kinase activated exclusively by its ligand HGF.1 Deregulation of c-
Met has been implicated in both tumour progression and resistance to breast cancer therapy. Tamoxifen-
resistant (‘TamR’) breast cancer cells show upregulation of EGFR signalling, and are sensitive to anti-EGFR 
therapy.2 However, prolonged treatment results in doubly-resistant cells (‘DubR’), resistant to both tamoxifen 
and anti-EGFR treatment. Microarray analysis of the c-Met gene shows progressive amplification during the 
transformation from TamR to DubR cells. Consequently, the aim of this project was to investigate the role of 
c-Met in resistance to anti-EGFR therapy.  
Western blotting was undertaken to compare the expression/activation of c-Met and related proteins 
between TamR and DubR cells. The cell samples analysed had been treated with HGF, crizotinib (c-Met 
inhibitor) gefitinib (EGFR inhibitor) or combination treatments. Secondly, MTT assays were conducted to 
observe the effects of these treatments on cell growth.  
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Surrogate markers of c-Met increased in response to HGF in both TamR and DubR cells. A dose dependent 
increase in MAPK activity was observed, with normalisation indicating this response was larger in DubR 
cells. DubR cells showed accompanying increases in Src signalling. Interestingly, crizotinib treatment 
resulted in increased EGFR and MAPK signalling in TamR cells. In terms of cellular growth, HGF treatment 
induced no significant changes, whereas crizotinib and gefitinib were growth inhibitory in both cell lines.  
Results suggest a role of c-Met in both cell lines, although this may be larger in DubR cells. In TamR cells 
cross talk between c-Met and EGFR was identified, whereby EGFR activity increases in response to c-Met 
inhibition. Similar cross talk between these two receptors has been widely reported.3,4 The role of c-Met in 
cell growth isn’t clear from these findings, suggesting further study on alternative end points such as 
migration or invasion.  
1. Organ SL, Tsao MS. An overview of the c-Met signalling pathway. Therapeutic Advances in Medical Oncology. 2011; 3:S7-S19. 
2. Knowlden JM et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth 
regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology. 2003;144(3):1032-1044. 
3. Engelman JA et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.Science. 2007 ;316: 
1039-1043. 
4. Velpula KK et al. EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells. Translational 
Oncology 2012; 5(5):379-392. 
 
Differential expression of natriuretic peptide receptors in rat myocardium 
Lauren R Pitt, JS Bice, DS Burley and GF Baxter  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Ischaemia-reperfusion (I/R) injury describes the paradoxical injury from the restoration of blood flow to the 
myocardium, during the clinical treatment of an Acute Myocardial Infarction (AMI).1 Natriuretic peptides (NPs) 
attenuate I/R injury in animal models,2,3 although the precise signalling cascade remains unclear. Emerging 
evidence suggests that NP signalling does not proceed via the classical natriuretic peptide receptor 
(NPR)-A/particulate guanylyl cyclase pathway and appears to require the nitric oxide/soluble guanylyl 
cyclase component,2-4 which could potentially be coupled to NPR-C. This study examines NPR expression, 
in particular NPR-C, in cardiomyocytes to assess its contribution to NP signalling in limiting I/R injury.  
Western blotting was used with rabbit anti-NPR-A, anti-NPR-B and anti-NPR-C antibodies to determine the 
differential expression of the respective NPRs in rat crude myocardial ventricular tissue extracts (n=4) and 
rat left ventricular isolated cardiomyocytes (n=4). The expression of mRNA coding for the NPRs was 
investigated in the same population of cardiomyocytes by utilising reverse transcriptase-polymerase chain 
reaction (RT-PCR).  
Western blot analysis revealed a band for NPR-A (~118 kDa), NPR-B (~117 kDa) and NPR-C (~64 kDa) in 
crude myocardium and isolated cardiomyocytes. The NPRs were expressed in the rat myocardium in the 
rank order: NPR-C>NPR-B>NPR-A; and, in the cardiomyocytes: NPR-B>NPR-C>NPR-A. Using RT-PCR, 
DNA species were detected for each target by observing the appropriate base pairs (bp): NPR-A: 172 bp; 
NPR-B: 234 bp; and NPR-C: 158 bp. The isolated cardiomyocytes expressed mRNA for all NPRs in the rank 
order: NPR-B>NPR-C>NPR-A.  
The results provide the biochemical confirmation that the NPRs are expressed in cardiomyocytes. In part, 
this indirect observation suggests that NPR-C may couple to the signal transduction pathway in NP-mediated 
infarct limitation in I/R injury. Further investigation into the full signalling pathway and functional regulation of 
cGMP is required prior to the effective therapeutic exploitation of NPs. 
1. Piper HM, Garcia-Dorado D, Ovize M.A fresh look at reperfusion injury. Cardiovasc Res. 1998; 38:291-300. 
2. Burley DS, Baxter GF. B-type natriuretic peptide at early reperfusion limits infarct size in the rat. Basic Res Cardiol. 2007; 102:529-
541. 
3. Yang XM, Philipp S, Downey JM, Cohen MV. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit 
hearts. Basic Res Cardiol. 2006; 101:311-318. 
4. D'Souza SP, Yellon DM, Martin C et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP. Am J Physiol 
Heart Circ Physiol. 2003; 284:1592-1600. 
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Towards an ex vivo method for monitoring changes in eicosanoids in skin: 
application to the investigation of anti inflammatory effect of topically applied 
pomegranate rind extract 
Kyle W Price and CM Heard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
When under stress, skin will inflame. This happens due to the transient up regulation of cyclooxygenase-2 
(COX-2) and 12/15 lipoxygenase1 (LOX) in keratinocytes within the viable epidermis. These enzymes will 
oxidise linoleic and arachidonic acid to produce inflammatory signalling molecules, known as eicosanoids. 
These cause vasodilation fever and pain sensitisation. Uncontrolled inflammation can lead to autoimmunity 
and disease states such as psoriasis and eczema. This project concerned a novel approach to monitoring 
the eicosanoids found in ex vivo porcine skin following treatment with topical antiinflammatories.  
LCMSMS was utilised to determine the aptness of various skin preparation methods for use in determining 
modulation of eicosanoid levels. By analysing levels of direct LOX and COX-2 metabolites found in full 
thickness and epidermal skin samples,2 the effect of different epidermal separation techniques on 12- & 15-
HETE, 9- & 13-HODE, PGE2 and PGD2 was determined using LCMSMS also. The findings were applied to 
the effect of pomegranate rind extract (PRE) on cutaneous eicosanoids, as PRE polyphenols have been 
shown to reduce COX –2 levels in porcine skin.3 
COX-2 metabolites were significantly greater in full thickness skin tissue; however, LOX metabolites were 
considerably less than when compared with epidermal samples. Heat separated and frozen heat separated 
epidermis produced greater LOX metabolites but less COX-2 products than that of enzymatic dispase 
separation. Samples treated with ibuprofen4 showed reduced eicosanoids in both LOX and COX. PGE2 
levels were less in PRE treated epidermis than control.  
The structure of the dermis can be used to rationalise reduced LOX metabolites in full thickness skin, and 
thermodynamic differences in separation technique will effect enzyme kinetics and change eicosanoid 
profiles. Auto oxidative species are reduced in the presence of DTPA /BHT buffer solutions. Finally, in silico 
modelling can be useful in rationalising components of PRE that are responsible for anti-inflammatory 
responses. 
1. Black AK, Barr RM, Wong E et al. Lipoxygenase products of arachidonic acid in human inflamed skin. British Journal of clinical 
pharmacology. 1985;20(3):185-190. 
2. Yamamoto S. Purification and assay of PGH synthase from bovine seminar vesicles.Methods in Enzymology 1982; 86:55–60. 
3. Schubert SY, Lansky EP, Neeman I. Antioxidant 14 and eicosanoid enzyme inhibition properties of pomegranate seed oil and 
fermented juice flavonoids. J Ethnopharmacol. 1999; 66:11-17. 
4. Matsuoka T, Ueta M, Kabashima K et al. Prostaglandin E(2)-EP(3) signaling suppresses skin inflammation in murine contact 
hypersensitivity. J. Allergy Clin. Immunol. 2009; 124(3):809-818. 
 
End point testing of total parenteral nutrition (TPN) – an exploration into current 
thoughts and practices within the NHS 
Karan Punni and AG Cosslett 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Total Parenteral Nutrition (TPN) is a means of intravenously delivering nutrients to patients who cannot 
utilize the GI system.1 As with any medicinal product delivered directly into the bloodstream, there are risks 
inherent to TPN: microbial contamination, particulate matter and compositional errors. In the past, illness and 
even fatalities have occurred as a result of these risks.2 The aim of this study was to ascertain the current 
testing practices used by hospitals, for the quality control of TPN and whether a BP monograph for TPN is 
needed. 
A list of 11 NHS regional QA pharmacists was provided by an NHS contact, Dr. Julian Smith, for inclusion in 
the study. It was decided that an email questionnaire would be the most appropriate data collection tool; it 
being cheap, fast and convenient to return.3 The questionnaire was developed through literature searching 
and supervisor interaction. Pilot studies helped to refine the questionnaire, ensuring face and content 
validity. Participants were sent the questionnaire and given one week to reply, after which reminders were 
sent. 
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Initial response rate was 27.3%, though some participants were able to forward the questionnaire onto 
individual aseptic production unit staff, bringing total responses to 6. The majority of responses were 
localized to southeast England. Two participants had encountered TPN related issues, the majority of which 
were compositional errors. Frequency and methods of testing vary widely between participants. The major 
testing parameter is electrolyte composition, of which sodium and potassium are most frequently measured. 
Common consensus was that end point testing is not always needed; participants were equally split on the 
need for a BP monograph. 
Frequency and methods of end point testing varied wildly between participants. Common opinions were 
seen, such as in process checks preferred over use of end point testing, but the study was limited by poor 
response rate and responder bias. 
1. Dunnett JS. 2003. Parenteral Nutrition. In: Walker, R. and Edwards, C. eds. Clinical Pharmacy and Therapeutics. 3rd ed. Churchill 
Livingstone, pp. 67-90. 
2. Puntis JW et al. Hazards of parenteral treatment: do particles count? Archives of Disease in Childhood 1992; 67(12): 1475-1477. 
3. Jones R, Pitt N. Health surveys in the workplace: Comparison of postal, email and World Wide Web methods. Occupational 
Medicine. 1999; 49(8):556-558. 
 
Evaluation of pharmacist independent prescribing in Wales 
Olivia Rees and KL Hodson 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The concept of other health care professionals prescribing was introduced after the publication of the Crown 
Report 1999, titled ‘Review of Prescribing, Supply and Administration of Medicines’.1 Supplementary 
prescribing was first introduced in 2003 followed by pharmacist independent prescribing in 2006.2,3 An 
evaluation of pharmacist independent prescribers (PIPs) was conducted in England in 2010 with many 
positive results.4 No such evaluation on PIPs has been conducted in Wales. The aim of this study was to 
evaluate Pharmacist Independent Prescribing in Wales. 
A piloted questionnaire, covering letter and pre-paid return envelope was mailed to registered PIPs working 
in Wales. After 10 days a reminder mail out was sent. After a further 10 days the data was analysed using 
the SPSS for Windows version 18.0. 
An overall response rate of 59% (n=75/128) was achieved. Only 64% (n=48/75) of the registered PIPs were 
practising; of those not using the PIP qualification, 3 were working as supplementary prescribers, and 11 
(15%) had never used the qualification. The majority (73%) were working in a hospital environment, with 
n=26/51 prescribing at ward level. Advantages indicated were increased job satisfaction, improving services 
to patients and improving relations with Doctors. Perceived barriers included lack of time (n=10/51) and lack 
of funding (n=9/51).  
Only around two-thirds of PIPs are using the qualification; further exploration of the reasons for this should 
be included in Phase II of the study. It was unexpected that so many PIPs are prescribing at ward level and 
further work will identify the exact model of prescribing e.g. how their prescribing is being checked. Barriers 
do need to be addressed and the future work proposed is to interview prescribing leads in Health Boards to 
explore their prescribing strategies and issues surrounding sustainability of PIPs.  
1. Crown J. 1999. Final Report: Review of Prescribing, Supply & Administration of Medicines. London: Department of Health 
2. Department of Health. 2012. Nurse and pharmacist independent prescribing changes announced. London: Department of Health. 
3. Department of Health. 2005. Nurse and pharmacist prescribing powers extended. London: Department of Health. 
4. Blenkinsopp A et al. 2010. Evaluation of Nurse and Pharmacist Independent Prescribing. London: Department of Health Policy 
Research Programme Project 016 0108 
 
An evaluation of the provision of monitored dosage systems to patients on 
clozapine 
Lowri Roberts, ML Hughes, E Bond1 and A Jones2 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 
3NB, 1Ysbyty Glan Clwyd Hospital, Betsi Cadwaladr University Health Board, Rhyl, Denbighshire, LL18 5UJ and 2Ysbyty 
Maelor Hospital, Betsi Cadwaladr University Health Board, Croesnewydd Road, Wrexham, LL13 7TD, Wales, UK 
Clozapine is an atypical antipsychotic that is uniquely effective in refractory Schizophrenia.1 It is supplied and 
monitored through the hospital under strict regulations. Wrexham Maelor Hospital supplies a large proportion 
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of its Clozapine in a compliance aid whilst Glan Clwyd Hospital does not. The aim of this study was to 
explore the views and experiences of staff and patients at both hospitals with regard to the use of monitored 
dosage systems (MDS) for Clozapine. 
This study adopted an exploratory approach2 using both quantitative and qualitative research methods. 
Patients’ views were explored through the administration of a face-to-face questionnaire and the views of 
staff were explored through one-to-one interviews. The resulting patient responses were analysed using 
descriptive statistics and interviews were transcribed verbatim and analysed thematically. 
Twenty eight patients (n=28) participated, 14 of whom received a compliance aid. From the statistical 
analysis, it was not possible to conclude that compliance aids improved compliance in these patients. 
Despite this, the majority of patients using the compliance aid found it to be ‘very useful’. Comparable views 
were identified by the six healthcare professionals interviewed. All were in favour of using the MDS service 
but emphasised that the aid should only be given to those who genuinely need it and to determine this, a 
common patient assessment tool is required throughout the Trust. 
No formal evaluation of the service has been undertaken in this area and although this study did not show 
that the MDS service improved compliance, a recent, larger scale study has shown that compliance aids 
improved compliance in those with a mental illness.3 This exploratory study has shown that the MDS service 
is supported by both patients and staff but further work with a larger sample size is required before the 
service can be optimised and expanded across the Trust. 
1. Taylor DM. 2006. Schizophrenia in Focus. London: Pharmaceutical Press.  
2. Babbie E. 2009. The Practice of Social Research. Twelfth Edition. USA: Wadsworth.  
3. Valenstein M et al. Using a Pharmacy-Based Intervention To Improve Antipsychotic Adherence Among Patients With Serious 
Mental Illness. Schizophrenia Bulletin. 2011; 37(4): 727-736. 
 
Is Src kinase a potential target in luminal B versus luminal A breast cancer? 
Izyan Rosman and S Hiscox 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The oestrogen receptor (ER) is expressed in around 70% of breast cancers diagnosed and characterise the 
‘luminal’ breast cancer subtype. A proportion of these tumours will also express the HER2 receptor and this 
has led to ER+ tumours being defined as luminal A (ER+/HER2-) and luminal B (ER+/HER2+) with the latter 
having a poorer prognosis and treatment outcome as compared to luminal A.1 The objective of this study is 
to investigate if the non-receptor tyrosine kinase, Src, known to be involved in ER activity and growth factor 
receptor signalling including the HER2 receptor, represents a potential target in luminal B tumours.2 
Changes in cell proliferation (MTT assay) and signalling pathway activation (Western blotting) in luminal A 
(MCF7, T47D) versus luminal B (BT474, MDA361) breast cancer cell models were determined in response 
to the novel Src inhibitor, AZD0530, endocrine therapy (tamoxifen) or both agents in combination.  
Tamoxifen was found to induce p-Src in most of the cell lines and only works in luminal A while Herceptin 
was effective only in luminal B and induced p-HER2 in low t-HER2 cell lines. AZD0530 was modestly 
effective in all cell lines with MDA361 being the most sensitive in terms of cell growth suppression. The 
combination treatment of AZD0530 and tamoxifen is better than single agents in all cell lines, however is 
only better than the current combination treatment of Herceptin and tamoxifen only in MDA361. 
Tamoxifen induced p-Src may be due to involvement of the non classical pathway involving cytoplasmic ER 
while P-HER2 induction is due to formation of EGFR-HER2 or HER2-HER3 dimers, and Herceptin acting as 
HER2 partial agonist.3,4 In luminal A, targeting both ER and Src kinase suppresses cell growth better than 
the current treatment of tamoxifen alone in MCF7. In luminal B, Src inhibitor improves tamoxifen response in 
Herceptin insensitive MDA361 cell line. 
1. Eroles P et al. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012; 38: 698-707. 
2. Goldhirsch A. Strategies for subtypes--dealing with the diversity of breast cancer: highlights. Ann Oncol. 2011; 22(8):1736-1747. 
3. Agrawal A et al. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocrine-related Cancer. 2005;12(1):135-144.  
4. Argiris A et al. Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin). Clinical Cancer Research. 2004;10: 1409-
1420.  
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Development and presentation of a Computer - Assisted Learning (CAL) package on 
food allergy 
Sarah Jayne Ryan and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Recently emerging technologies have opened up possibilities for providing pharmacy education through 
innovative strategies1 such as Computer Assisted Learning (CAL) as a supplement to teaching. In this 
project, a CAL package was developed and evaluated using an online GoogleDocs® questionnaire.  
The package content is summarised below. The questionnaire consisted of 23 closed statements using a 5-
point centre-weighted Likert scale with space for free text comments. The package and questionnaire were 
piloted leading to some minor changes. 
Table 1: Contents of the CAL Package on Food Allergy. 
Pharmacist’s Role Immune Mechanism 
Types of Sensitivity Symptoms 
Food Allergy Diagnosis 
Most Common Allergens Food Intolerance 
Childhood allergy Other Food Reactions 
Prevalence Treating allergy 
Current Research Immunotherapy 
Food Allergens Anaphylaxis 
 
Of 124 questionnaires, a response rate of 22% (28) was achieved. The majority agreed with the positively 
and disagreed with the negatively worded statements.2 Most agreed that the package was well presented. 
72% (20) thought the package was of appropriate length with only 4 agreeing that some slides contained too 
much information. Ninety-six per cent responded that the content fitted the purpose and only 4% (1) thought 
more information was needed. All students agreed that the package benefitted them and 82% agreed that 
the use of CAL was effective. Regarding the statement, “The use of CAL should not replace traditional 
learning methods,” 36% had no opinion. However, qualitative comments suggested an overall preference for 
the use of both methods simultaneously. Seventy-eight per cent (22) replied that they would use the package 
for continuing professional development, but only 29% (8) would rather complete a CAL package than attend 
a lecture. Again however, qualitative data suggested a preference for using both together. 
The overall response rate provided a representative view of third year pharmacy students on the use of CAL. 
It can be concluded from the questionnaire evaluation that the package was well-received and accepted 
overall as a beneficial tool to supplement lectures and aid revision. This reflects the findings of previous 
studies3 concluding that the purpose of CAL is not to replace lectures, but to assist in learning.  
1. Hall D et al. 2007. Instructional Design And Assessment: A Web-based Inter-professional Diabetes Education Course [online]. 
American Journal of Pharmaceutical Education 71(5) Article 93. Available at: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2064891/pdf/ajpe93.pdf [accessed 16 Feb 2013] 
2. Boynton PM. Administering, analysing and reporting your questionnaire. British Medical Journal. 2004; 328: 1372-1375.  
3. Gabriel Y. Against the Tyranny of PowerPoint: Technology-in-Use and Technology Abuse. Organization Studies. 2008;29(2): 255-
276 
 
Permeability of the renal pelvis, ureter and bladder to locally delivered terazosin 
Noratiqah Sauddi, NA Williams and CJ Allender 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
At present, there is little knowledge about drug absorption across urothelium in renal pelvis, ureter and 
urinary bladder. Therefore, it is complicated to target localized therapies to treat conditions like ureteral stent 
related pain. The aim of this study is to investigate the relative difference of permeability across urothelium of 
renal pelvis, ureter and bladder using terazosin hydrochloride as a model drug. 
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Organs were freshly obtained from porcine models and kept in iced-cold Krebs buffer to maintain viability. 
Franz-diffusion type cells were used in the bladder experiment. Terazosin 100 μg/ml stock solution was 
directly instilled into the renal pelvis and lumen of the ureter via a cannulating pipette. Tissues were 
incubated at 37°C for 90 minutes. Tissues were separated from underlying tissue layer and extracted in 
methanol overnight. Sample extracts were analysed using HPLC-UV detector at 250 nm wavelengths. 
Results showed that permeability of terazosin was the highest in renal pelvis and least in the bladder. 
Terazosin permeability was significantly different between bladder and ureter, and between bladder and 
renal pelvis. There was no significant difference between ureter and renal pelvis. Urothelium/lamina propria 
shows rate-limiting absorption of terazosin across bladder wall. Small amount of terazosin in medulla/cortex 
suggests that the drug may have permeated across muscle in renal pelvis. The amount of terazosin found 
bladder, renal pelvis and ureter may be sufficient to cause clinical effect. 
The difference in permeability between organs may be explained by the difference in anatomical distribution 
of uroplakin protein1 and thickness of urothelium2 between bladder, ureter and renal pelvis. In conclusion, 
results from this experiment could improve our understanding about permeability across urothelium. 
Therefore, more effective local drug delivery can be developed in the future for treating ureteral stent related 
pain and other similar complications such as urothelial cancers. 
1. Liang FX, Bosland MC, Huang H et al. Cellular basis of urothelial squamous metaplasia: roles of lineage heterogeneity and cell 
replacement. J Cell Biol. 2005;171: 835-44. 
2. Kehle WL, Helmut Platzer, Werner. Color Atlas and Textbook of Human Anatomy. Germany: Georg Thieme Verlag Stuttgart; 1976, 
1991. 
 
Does modafinil enhance cognition in healthy non-sleep deprived individuals? 
Moalosi B Seno and M Smith 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Modafinil is a novel wake-promoting Central Nervous System stimulating agent that has been licensed for 
excessive sleepiness associated with narcolepsy with or without cataplexy1-3 and as adjunctive treatment of 
obstructive sleep apnoea or hypopnea syndrome.1,2 There are myriad off-label uses of modafinil particularly 
for increasing brain performance and memory i.e. cognition enhancement. However, the empirical evidence 
from the literature is equivocal with a lack of data addressing the long-term use of this agent.2 The aim of this 
study then was to undertake a systematic review to determine whether modafinil increases cognition in 
healthy, non-sleep deprived individuals. 
Using a range of electronic databases four randomized placebo controlled trials were identified as meeting 
eligibility criteria and were analysed to determine the effect of modafanil on emerging common cognitive 
domains such as learning and problem solving. Data extracted from the articles was inputted into RevMan 
5.2 software4 for statistical analysis. The primary outcome was to assess the effect of modafinil, compared to 
placebo, on cognition. 
Modafinil did not display any improvements in working memory compared to placebo in tests of reaction 
times (Standard mean difference (SMD) 0.09[-0.36, 0.54]; p > 0.05,) and error rates (SMD -1.70[-5.62, 2.23]; 
p > 0.05). However, modafinil did show limited enhancement in executive function as demonstrated by 
improvements in elements of the Stockings of Cambridge test particularly the ability to plan (SMD -0.55[-
0.97,-0.14] p < 0.05) although there was no significant difference in pattern recognition tests (SMD 0.38[-
0.03, 0.79]; p > 0.05).  
Despite the wide-spread use of modafinil off-license for cognition enhancement, the number of rigorous and 
robust trials on its effect remains limited. However notwithstanding, these data suggest that modafinil has 
limited utility in cognition enhancement in non-sleep deprived individuals.  
1. Randall DC, Fleck NL, Shearson JM, File SE. The cognitive-enhancing properties of modafinil are limited in non-sleep-deprived 
middle-aged volunteers, Pharmacology, Biochemistry and behaviour. 2004; 77:547–555. 
2. Kumar R. Approved and investigational uses of modafinil. Drugs. 2008; 68 (13):1803-1839. 
3. Müller U, Rowe JB, Rittman T, Lewis C , Robbins TW, Sahakian BJ. Effects of modafinil on non-verbal cognition, task enjoyment 
and creative thinking in healthy volunteers. Neuropharmacology. 2013; 64: 490-495. 
4. Review manager (RevMan) [Computer program]. Version 5.2, Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2012. 
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Investigating the effects of the cell permeating peptide EY1068 on cell proliferation 
Jennifer Smith, E Sayers and AT Jones 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The binding of Epidermal Growth Factor (EGF) to its receptor triggers many signalling pathways, ultimately 
resulting in cell proliferation.1 The peptide EY1068 has been developed to competitively inhibit docking sites 
on the EGF receptor, thus stopping proliferation signals. The binding sequence is attached to an octa-
arginine cell penetrating peptide in order to allow access to the intracellular target. Repeating arginine chains 
have proven cell permeating properties.2 This study aims to investigate the effects of EY1068 on cell 
proliferation. 
Cell proliferation will be measured using the CellTiter-Blue assay for cell viability. This method uses the 
respiratory process of living cells to convert the reagent to a fluorescent compound. The intensity of 
fluorescence is proportional to number of viable cells.3 HeLa and A431 cells will be incubated with EGF in 
the presence and absence of EY1068 to determine whether there is a reduction in cell viability, indicating the 
suppression of cell proliferation. Microscopy will also be used to determine proliferation with and without 
peptide. Cells are stained with fluorescent dyes to label the nucleus and actin of the cell.  
Viability assays show that the presence of EY1068 in the growth medium tends to reduce viability. This 
inhibitory effect is most pronounced after 48 hours incubation. Microscopy reveals that cell division is 
increased at increasing concentrations of EGF. Addition of EY1068 reduces both the total number of cells 
and the number of cells undergoing replication. 
EY1068 is thought to inhibit cell proliferation by interfering with EGF signalling. A reduction in cell viability is 
observed when cells are incubated with the peptide, suggesting that cell proliferation is inhibited. Images of 
the cell nuclei show that the proportion of dividing cells is reduced in the presence of EY1068. It can 
therefore be inferred that the peptide is involved in preventing cell replication. 
1. Normanno N, De Luca A, Bianco C, Strizzi L. Epidermal Growth Factor Receptor (EGFR) Signalling In Cancer. Gene. 2006; 366; 2-
16. 
2. Jones AT, Sayers EJ. Cell entry of cell penetrating peptides: tales of tails wagging dogs. Journal of Controlled Release. 2012; 
161(2): 582-91. 
3. Cell Titer-Blue Cell Viability Assay Madison, Wisconsin, United States: Promega; 2013 [cited 2013]. Available from: 
http://www.promega.co.uk/~/media/Files/Resources/Protocols/Technical%20Bulletins/101/CellTiter-
Blue%20Cell%20Viability%20Assay%20Protocol.pdf. 
 
What types of medicines-based calculations are currently being performed in 
pharmacy practice settings? 
Mui Hoon Tan, SA Coulman, AJ Nicholson1 and DN John 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales, UK and 1Pharmacy, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, Wales, UK 
Medicines-based calculations (MBCs) are commonly used in the healthcare setting. Poor numeracy of some 
healthcare staff has resulted in a number of medication errors.1,2 The aim of this project was to identify 
examples of MBCs that are currently used in pharmacy practice settings. These will be used to review and 
update existing and develop new learning, teaching and assessment materials for pharmacy students and 
professionals, and possibly other healthcare professionals.  
Research ethics approval was obtained from Cardiff School of Pharmacy and Pharmaceutical Sciences 
Ethics Committee. Emails were sent to all MPharm III and MPharm IV students at Cardiff, to three pre-
registration pharmacists known to the researchers and to a number of hospital and community pharmacists 
asking for examples of MBCs performed in practice. A number of academic staff were also approached to 
gather information on the teaching and assessment on MBCs. Data relevant to this study were extracted 
from previous interview transcripts on MBCs.3 A literature search was performed to identify medication errors 
arising from calculation errors.  
Responses were obtained from 56 participants (24 students, 22 pharmacists, 4 pharmacy technicians and 6 
academic staff). MBCs identified in this study were categorized into eight themes, namely dosage 
calculations, quantity (including volume), infusion dose & rate, creatinine clearance, dilution, body surface 
area & weight-related, unit conversion and molarity. MBC errors that resulted in death were also identified 
from the literature. 
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The types of MBCs performed in pharmacy practice were successfully explored. Some differences between 
the MBCs performed in community and hospital settings were established. The findings of this study have 
already informed the teaching of MBCs in the MPharm course. Further work is required due to the small 
sample size.  
1. Lesar TS. Errors in the use of medication dosage equations. Archives of Pediatrics & Adolescent Medicine. 1998; 152(4):340-4. 
2. Warburton P, Sherrington S, Kirton J et al. An evaluation of an online numeracy assessment tool. Nursing Standard. 2010; 24(30): 
62-68. 
3. John DN, Taylor DJ, Okeke A, Thomas CM, Nicholson AJ, Coulman SA. “If I was the patient I don’t think I want any calculation done 
wrong.” Reflections from pharmacy, nursing and medicine staff in a hospital setting regarding medicines-based calculations. Int J 
Pharm Pract. 2013; 21(S1): 31-32. 
 
eBooks to Enhance Learning in the Pharmaceutical Sciences 
Tengku AJ Tengku Zawawi and M Smith 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The Cardiff School of Pharmacy utilises CAL packages to supplement classroom learning. These packages 
are hosted on the Universities’ intranet requiring students to visit a campus computer lab and do not afford 
flexible learning. This project seeks to identify whether the CAL content may be better channelled through 
interactive eBooks that provide a flexible learning environment. Given the mixed data in the educational 
literature1, a meta-analysis was conducted to understand the potential benefits of technology within 
healthcare education. The aim of this project was to create a Cell Biology eBook; supported by the outcomes 
of a meta-analysis. 
Meta-analysis outcomes were: knowledge and skills acquisition following technology enhanced learning 
(TEL). Data was extracted from the literature (n = 4 trials) and summary statistics were generated to 
determine the effect of TEL. A technology appraisal selected Apple’s iBook Author for eBook development 
as it is free, has rich interactive features and a shallow learning curve. 
The meta-analysis showed that TEL did not improve knowledge acquisition (Correlation and 95% CI= -0.070 
[-0.145, 0.006]; P=0.071) but did improve skill acquisition (Correlation and 95% CI= -0.274 [-0.354, -0.190]; 
P=0.0001,). Subsequently, the content of original Cell Biology CAL package was thoroughly analysed. For 
the eBook, 70% of the content was retained and original interactive features were improved such as the 
navigation and multimedia files. Enhanced features such as PowerPoint presentation and survey widgets 
were also included.  
Despite the mixed results for TEL described in the pedagogic literature, the meta-analysis conducted here 
provides evidence, at least for skills acquisition, that TEL improves student learning. These data combined 
with the increasing penetration of eBooks in the marketplace2 have supported the design of a multimedia rich 
interactive eBook which may be utilised by the School, following testing within the student body, to enhance 
the quality of learning experience.  
1. Jenkinson J. Measuring the effectiveness of educational technology: what are we attempting to measure? Electronic Journal of e-
Learning. 2009; 7:273 – 280.  
2. Dahlstrom E. 2012. ECAR Study of Undergraduate Students and Information Technology, 2012. Louisville, CO: EDUCAUSE Center 
for Applied Research.  
 
The views of supervising pharmacists on the community pharmacy placement 
scheme 
Bethan E Thomas and RE Deslandes 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Many studies have been conducted into the impact of experiential placements on university students, with 
most finding them to be an important aspect of many university courses.1 Cardiff School of Pharmacy (SoP) 
have incorporated work placements into their curriculum and have recently developed their placement 
scheme further. The aim of this project was to investigate the views of supervising pharmacists on the 
community pharmacy placement scheme.  
Firstly, the research proposal was submitted and permission was gained from Cardiff SoP Research and 
Ethics Committee. Non-probability convenience and purposeful sampling methods were then adopted. The 
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participants in this research were pharmacists listed on the placement scheme database. Semi-structured 
interviews were carried out and audio recorded, with consent to gain an in-depth understanding of the 
participant’s views and opinions.2 Once interviews were transcribed, common themes were identified via 
thematic analysis. 
Ten participants were interviewed and audio recorded. Most interviews were conducted face to face as 
pharmacies were within the Cardiff area. Pharmacists mentioned that the manual was important in providing 
structure for the placement but suggested that its flexibility could be increased. The reflective task was seen 
as an effective way to assess the students on the placement scheme but some thought this may be difficult 
for students. Formal feedback on each student from the pharmacist was deemed to be a possible future 
assessment method.  
Only individual interviews were used for this project. Using both qualitative and quantitative methods would 
increase reliability of the results. Due to the small sample size (n=10) the results gained may not be 
representative of the larger population. In conclusion, experiential placements are an essential part of 
pharmacy degree scheme and the pharmacists interviewed agree with this. Overall, pharmacists were 
satisfied with the scheme and thought that the placements would help prepare the students for their futures 
as pre-registration pharmacists. 
1. Little B, Harvey L. 2006. Learning through Work Placements and Beyond [Online]. Available at: 
http://ww2.prospects.ac.uk/downloads/documents/HECSU/Conferences%20and%20events/Changing%20Student%20Choices/Wor
k_based_learning_LH_BL.pdf [Accessed: 7th April 2013]. 
2. Royal Pharmaceutical Society, 2010. Pharmacy Research and Evaluation Resource [Online]. Available at: 
http://rpharms.com/science-and-research-pdfs/seriesone-articlethree.pdf [Accessed: 7th April 2013]. 
 
Adaptation and testing of the self-medication scale (SMS) for flu, coughs and colds 
Sam Thomas and DH James 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Flus, coughs and colds are common minor ailments and self-medicating to these is important1 and is 
encouraged by the government.2 The self-medicating scale (SMS) was developed to measure the beliefs 
and behaviour in response to the symptoms of pain.3 A previous qualitative study explored patients’ self-
medicating beliefs and behaviours in response to a flu, cough or cold.4 The study aimed to adapt the original 
12-item SMS to measure self-medicating beliefs and behaviours in response to the symptoms of a flu, cough 
or cold. 
A quantitative research methodology was used following ten qualitative interviews that were thematically 
analysed and built upon previous data4 to inform the questionnaire design. The final questionnaire contained 
sixteen SMS statements and questions to measure self-medicating behaviours. All staff and MPharm 
students at the Cardiff School of Pharmacy and Pharmaceutical Sciences were eligible for inclusion into the 
study. 
Of the 328 respondents, 275 (83.8%) reported having experienced symptoms relating to flu, coughs or colds 
in the last six months, with 208 (63.4%) choosing to self-medicate. A blocked nose (n=216, 78.5 %) was the 
most common symptom. Of those who self-medicated, headaches were the most commonly self-treated 
symptom (n=143, 68.3%), with paracetamol being the most frequently used (n=158, 76.0%).The three scales 
(‘Reluctance’, ‘Run its course’ and ‘Don’t think twice’) demonstrated good internal reliability (Cronbach’s 
alpha = 0.78, 0.85, 0.80 respectively). Statistical differences were found between the SMS scores between 
demographic variables (i.e. gender, ethnicity, sub-groups) and various self-medicating behaviours (i.e. 
number of symptoms experienced or self-medicated for and the number of medications and non-
pharmacological methods used). 
In conclusion, the modified SMS for flu, cough or colds shows good internal validity and reliability and can 
measure patients’ self-medicating beliefs and behaviours. Further research is needed in the wider general 
public with the potential for further modification of the SMS for other minor ailments. 
1. Armstrong D. 1989. An Outline of Sociology as applied to Medicine. Cambridge: Wright.  
2. Hughes CM et al. Benefits and Risks of Self-Medication. Drug Safety. 2001; 24(12):1027-1036. 
3. James DH, French DP.  The development of the Self-Medicating Scale (SMS): a scale to measure people’s beliefs about self-
medication. Pharmacy World Science. 2008; 30: 798-800. 
4. Evans L. 2012. Measuring patients’ self-medicating beliefs and behaviours in response to symptoms of a cough, cold or flu. 
MPharm project, The Cardiff School or Pharmacy and Pharmaceutical Sciences. 
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Investigation of whether serine residue 276 is fundamental for the activity of zinc 
transporter ZIP7 
Lowri Tonge and KM Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Zinc transporters operate to tightly control cellular levels of zinc. There are two main classes, ZnT and ZIP 
transporters.1 An increase in intracellular zinc has been associated with the activation of downstream 
signalling pathways that regulate cell growth and proliferation and an increased expression of zinc 
transporters, especially ZIP7, has been found in breast cancer cells.2 The activation of ZIP7 is thought to 
release a zinc wave due to phosphorylation by CK2 of two serine residues S275 and S276.3 This study looks 
at whether or not both S275 and S276 need to be phosphorylated order to activate ZIP7, looking specifically 
at the S276. 
MCF7 cells were transfected with wild-type ZIP7, ZIP7 S276A and ZIP7 S276D. With S276A, the serine 
residue was substituted with an alanine and therefore is unable to be phosphorylated and with S276D, the 
residue was phosphomimetic having the same confirmation as the activated/phosphorylated serine. Cells 
were exposed to exogenous zinc and probed for pZIP7, pMapK and pAKT proteins via western blotting. 
Results correspond with published data for wild-type3, but the main increase of activation was seen at 10 
minutes, not 5. The S276A mutant showed activation of ZIP7, MapK and AKT, suggesting importance of 
S275. The S276D mutant was also investigated for effect on activation of MapK and AKT compared to wild-
type and S276A mutant.  
Data does not truly confirm that the phosphorylation of S276 alone would be sufficient to activate ZIP7, but 
does suggest that one active residue present is adequate to cause minor activity. When both residues were 
active, the results achieved were much greater suggesting, if this mechanism was going to be a target for 
breast cancer, to see a greater reduction in the growth and spread of the cancer both residues must be 
inactivated.  
1. Cousins RJ et al. Mammalian Zinc Transport, Trafficking, and Signals. The Journal of Biological Chemistry. 2006; 281: 24085–
24089. 
2. Taylor K et al. Zinc in Cancer. In: Zinc in Human Health. iOS Press, 2011; 76: 283-304. 
3. Taylor KM et al. Protein Kinase CK2 Triggers Cytosolic Zinc Signaling Pathways by Phosphorylation of Zinc Channel ZIP7. Science 
Signalling. 2012; 210(5): 11. 
 
Design and synthesis of novel allosteric inhibitors against Dengue Virus 
Ha T Trinh, I Trist and A Brancale 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Dengue fever is the most common mosquito-borne viral infection. Classically found in tropical and 
subtropical regions, prevalence of dengue fever has recently spread to America and Europe.1 The disease 
characterised by influenza-like symptoms is normally mild and self-limiting. Infected individuals however may 
develop severe conditions namely Dengue Haemorrhagic fever (DHF) and Dengue Shock Syndrome (DSS) 
which are fatal if untreated. Concern arose over the increased risk of developing DHF/DSS upon secondary 
infection with different serotypes of DENV.2, 3 Yet drugs and vaccine are currently unavailable and treatment 
remains symptomatic.4 NS5 RNA-dependent RNA polymerase (RdRp) is an enzyme responsible for 
conversion of positive-sense RNA to double-stranded RNA during viral infection.5 Inhibiting RdRp 
theoretically prevents RNA replication and hence viral spread. 
Previous homology modelling and virtual screening resulted in a complete 3D structure of RdRp and two 
lead compounds with different binding mode to RdRp. The investigated site was near the priming loop known 
to involve in de novo initiation of RNA synthesis.6 Over 200 compounds structurally based on N-(3,5-
dimethylphenyl)-3-ethoxy-4-fluorobenzenesulfonamide (1) and N1,N5-bis(2-carbamoylphenyl)glutaramide (2) 
were docked and analysed using Glide and MOE. Newly-designed compounds demonstrated improved 
docking while retaining critical interactions with key residues Trp795 and Arg737 of the priming loop. 
Four compounds, two from each class, were selected for synthetic development based on docking score, 
orientation within the binding pocket and ease of synthesis. The chosen analogues of 1 were successfully 
synthesised with varying yield whereas several attempts were made to synthesise analogues of 2 yet 
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unsuccessful. Difficulty encountered was due to by-product formation and solubility of compounds in 
purifying solvents. 
The study has demonstrated potential for development of effective anti-DENV drugs. Designed analogues 
have shown promising inhibitory activity in silico. Further work nevertheless is required including biological 
testing of synthesised compounds and synthetic improvement of chosen analogues.  
1. World Health Organisation. Dengue Guidelines for diagnosis, treatment, prevention and control. Geneva: WHO Press; 2009. 
2. Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nature Reviews Immunology. 
2011; 11(8):532-43. 
3. Halstead SB. In vivo enhancement of dengue virus infection in Rhesus monkeys by passively transferred antibody. Journal of 
Infectious Diseases. 1979; 140(4):527-33. 
4. World Health Organisation. Handbook for Clinical Management of Dengue. Geneva: WHO Press; 2012. 
5. Malet H, Massé N, Selisko B et al. The flavivirus polymerase as a target for drug discovery. Antiviral Research. 2008; 80(1):23-35. 
6. Yap TL, Xu T, Chen Y-L, et al. Crystal Structure of the Dengue Virus RNA-Dependent RNA Polymerase Catalytic Domain at 1.85-
Angstrom Resolution. Journal of Virology. 2007;81(9):4753-65. 
 
Does magnesium affect salbutamol-induced bronchodilator responses? 
Ross A Wardle and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Magnesium is known to cause relaxation of a number of smooth muscle preparations; various mechanisms 
for this have been proposed. The main mechanism of action of magnesium is reported to be the blockage of 
calcium ion influx, but other roles of magnesium are also reported.1 IV MgSO4 has been shown to be 
clinically effective as an adjuvant to β2-adrenergic agonists in vivo, and has been used for years, as an 
emergency treatment of the most severe cases of acute asthma.2 The aim of the study was to investigate the 
effect of additional MgSO4 on bronchoconstrictor and bronchodilator responses. 
The lungs of male Dunkin-Hartley guinea pigs, weighing 300-500g, were split into two half-lungs. 
Cannulating the bronchi enabled one half of the lung to be perfused with Krebs containing 1.2mM MgSO4 
and the other half to be perfused with Krebs containing 16.2mM MgSO4. Bronchodilator drugs were added to 
methacholine-induced (10-5M), pre-constricted lungs via serial addition; then bronchoconstrictor drugs were 
added to relaxed lungs via the same method. 
Raising the concentration of magnesium, from 1.2mM to 16.2 mM MgSO4, had no statistically significant 
effect on the bronchodilator or bronchoconstrictor responses in ‘normal’ guinea pigs. Paired, 2-tailed, 
Student’s t tests were used to determine if there were significant differences in the data between the control 
group and test groups, and no significant statistical differences are considered when P>0.05. 
Additional MgSO4 did not cause any statistically significant effect on bronchodilator or bronchoconstrictor 
responses in vitro, but it has been shown to do so in vivo.3 This suggests that magnesium may not augment 
its effects by direct actions on the airway smooth muscle. This leads to idea that MgSO4 may produce its 
effects via different mechanisms, such as actions on the parasympathetic nervous system and inflammatory 
cells.1  
1. Blitz M, Blitz S, Beasely R, et al. 2005. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of 
Systematic Reviews [Online]. Available: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003898.pub4/abstract. 
2. Gallegos-Solórzano MC, Pérez-Padilla R, Hernández-Zenteno RJ. Usefulness of inhaled magnesium sulfate in the coadjuvant 
management of severe asthma crisis in an emergency department. Pulm Pharmacol Ther. 2010; 23: 432-7. 
3. Spivey WH, Skobeloff EM, Levin RM. Effect of magnesium chloride on rabbit bronchial smooth muscle. Ann Emerg Med. 1990; 19: 
1107-12. 
 
Pharmaceutical potential of two specimens of Aplysina aerophoba harvested from 
competitive and isolated environments 
Ceri W Wilkes, C Hatton and AW White 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Studies have shown that numerous factors can contribute to variation of natural product biosynthesis in 
marine sponges,1,2 the details accounting for such variations are not fully understood. Further research into 
the factors that regulate compound variation could potentially streamline the selection of organisms with a 
high yield of bioactive natural products. The aim of this study was to determine whether the marine sponge 
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Aplysina aerophoba produced different natural products when growing in competition with other sponges 
compared to when growing in isolation. 
Crude extracts were obtained from isolated sponges and those growing in a competitive environment 
surrounded by other species. Dried sponge samples were extracted using hexane, ethyl acetate and 
methanol, then analysed by thin layer chromatography (TLC). Several compounds were isolated from the 
ethyl acetate extracts and further purified using preparative TLC. A bioautographic3 technique was used to 
determine if any of the sponge extracts possessed antibacterial activity against Staphylococcus aureus. 
Isolated compounds underwent proton NMR, carbon-13 NMR and low resolution mass spectrometry (MS). 
High resolution MS was performed by the EPRSC National Mass Spectrometry Service Centre, Swansea 
University. 
 
Only the compounds extracted using ethyl acetate demonstrated variation between the sponge samples. 
NMR data for 2C1 suggested this compound had between 26 and 29 hydrogen atoms. Contradictory MS 
data for 2C1 suggested a molecular weight of 662 as well as the molecular formulas C30H15O9N7 or 
C28H58O8N10. MS data for 2C2 and 2C3 suggested both had relatively high molecular weights (662.3 and 
853.5 respectively). These compounds provided some evidence to support the hypothesis of this study as 
both were solely present in samples obtained from sponges growing in a competitive environment. None of 
the extracted components showed any conclusive antibacterial activity. 
In conclusion this study showed that compound production in Aplysina aerophoba varies when the sponge is 
growing in a competitive versus an isolated environment. Due to time constraints the absolute identity of the 
isolated compounds remains uncertain. 
1. Green G. Ecology of toxicity in marine sponges. Marine Biology. 1977; 40(3):207-15. 
2. Sacristan-Soriano O, Banaigs B, Becerro MA. Temporal trends in the secondary metabolite production of the sponge Aplysina 
aerophoba. Marine Drugs. 2012; 10(4):677-93.  
3. Valgas C, Souza S, Smânia EF, Smânia A. Screening methods to determine antibacterial activity of natural products. Brazilian 
Journal of Microbiology. 2007; 38(2):369-80. 
 
An evaluation of the provision of monitored dosage systems to patients on 
clozapine 
Emma L Williams, LA Roberts and ML Hughes 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Clozapine is an atypical antipsychotic drug used in treatment-resistant schizophrenia.1 Within BCUHB, 
clozapine dispensing differs. Wrexham supplies a large proportion in compliance aids to simplify self-
administration and improve compliance.2 Current knowledge of providing clozapine in MDS is limited. The 
project aims to identify reasons for clozapine non-compliance and to investigate the role of MDS by exploring 
patient and staff opinions. 
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Ethical approval from CSPPS REC was obtained. A mixed methods approach was adopted combining an 
exploratory semi-structured interview3 and a structured questionnaire.4 Purposive sampling recruited six 
health professionals with clozapine experience from Wrexham and Glan Clwyd hospitals including 
pharmacists, technicians and clinic nurses. The interviews were audio-recorded, transcribed verbatim and 
analysed thematically. The questionnaire was constructed around patient compliance and MDS experiences. 
After four weeks at each site, 28 responses were collected and input into SPSS for analysis. 
A response rate of 29.2% was obtained for the questionnaire. 96.4% view taking clozapine as important. A 
significant negative correlation (-0.436) was found between importance and frequency in forgetting. 88.9% 
either never forget or forget less frequently. Main reasons for non-compliance were forgetting and side-
effects. 93% of patients using a compliance aid and 50% not currently using one commented on their 
usefulness. Overall professionals were positive of the service and noted particular usefulness in those with a 
complex regimen or a history of poor compliance. Issues such as cost, equal access and hospital policies 
would need to be addressed. It was suggested an assessment tool should be introduced. 
Patients and staff commented on the usefulness of the service in the right patients. An important feature was 
identifying patients’ need with an assessment tool. This study of small numbers was successful in identifying 
issues to inform the development of the service. Further work in larger populations across the trust is needed 
before standardisation. 
1. IVAX, 2012. Zaponex (Clozapine): Summary of Product Characteristics. Available at: http://www.ztas.co.uk/pdf/02-
ZaponexSmPC_January2013.pdf (accessed 16 April 2013). 
2. Bond E, 2011. Review of Clozapine service Delivery for BCUHB patients. Wales: NHS BCUHB. 
3. Kvale S, 2009. Interviews. 2nd Edition. London: Sage. 
4. Smith FJ, 2010. Conducting Your Pharmacy Practice Research Project: Second Edition. London: Pharmaceutical Press. 
 
Hydrogels containing pomegranate rind extract: active release and antimicrobial 
activity 
Katherine J Williams, CM Heard, DM Houston and SP Denyer 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
There is a current need for new topical antimicrobial products, due in part to increased microbial resistance.1 
Generally, there is a preference among patients for medicines of natural origin, and the demonstrable 
antimicrobial activity of the fruit of Punica granatum L. (pomegranate) has received much attention 
accordingly. Recent research has demonstrated remarkable broad spectrum anti-microbial activity of 
pomegranate rind extract (PRE)2 when co-administered with potentiating agent, X.3  
GMP-grade hydroxypropyl methylcellulose (HPMC) was sourced from two manufacturers (K100 and 90SH) 
and used to prepare hydrogels containing PRE and X. Firstly, these were tested for spontaneous release 
across a minimal-resistance membrane, followed by the analysis of punicalagin (major antimicrobial of PRE) 
by HPLC and X by ICPMS. The antibacterial activities of the eluates released were then used to challenge 
two common skin bacteria: S. aureus and S. epidermidis. 
The greatest release was seen within the first hour, essential for efficacious topical formulation. The 90SH 
gels released more punicalagin, whereas K100 gels released larger amount of X. The most appropriate ratio 
(punicalagin: X) was shown by 90SH 5% w/v at 0.058: 1, although all the gels released more the initial ratio 
applied. The bacterial log reduction data followed the trend observed in the release ratios, as 90SH 5% gave 
greater than 99% kill after 2 h, followed by 90SH 2.5% with more than 90% kill. K100 2.5% and 5% showed 
a plateau in activity. The K100 2.5% showed the smallest zone of inhibition, concurring with the lowest 
release ratio, 0.016: 1M. There were differences noted between the zones of inhibition of S. aureus and S. 
epidermidis. 
In conjunction with data obtained previously, the results obtained in this project support the further 
development of a hydrogel product containing PRE and X as a broad-spectrum topical antimicrobial.  
1. Lambert P. Bacterial resistance to antibiotics: Modified target sites. Advanced drug delivery reviews. 2005; 57 (10):1471-1485. 
2. Dahham S, Ali N, Tabassum H. Studies on Antibacterial and Antifungal Activity of Pomegranate (Punica granatum L.). American-
Eurasian J. Agric. & Environ. Sci. 2010; 9(3): 273-281. 
3. Houston D. 2011. Towards a nanomedicine-based broad -spectrum topical virucidal therapeutic system. PhD Thesis, Cardiff 
University. 
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The role of GABA and nitric oxide in M1-receptor mediated relaxation of isolated 
duodenum 
Tristan Williams and KJ Broadley 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
M1 are a subtype of muscarinic receptor found in autonomic ganglia, glands and the cerebral cortex where 
they typically mediate excitatory responses.1 They also cause relaxation in rat duodenum.2 It is proposed 
that following M1 stimulation relaxation occurs due to a number of indirect mechanisms. This study aimed to 
confirm the role of M1-receptors in relaxation of duodenum and investigate the roles of GABA and nitric oxide 
as mediators. It is thought that following M1 stimulation GABAergic nerves release GABA which bind GABAA 
receptors. This leads to chloride influx which hyperpolarises the cell.1,2 Nitric oxide may also be released 
which activates guanylyl cyclase, increasing cGMP concentration. This decreases intracellular calcium, 
inhibiting smooth muscle contractions.1,3 
Isolated rat duodenum was suspended in an oxygenated 50ml organ bath of Tyrode’s solution at 37.5°C, 
under 1.5g of tension. Dose-response curves to GABA and the M1-selective agonist McN-A-3434 were 
carried out in the absence and presence of a number of drug additions: the GABA uptake inhibitor nipecotic 
acid, the nitric oxide synthase inhibitor L-NAME and the M3 antagonist darifenacin. 
GABA and McN-A-343 both caused relaxation in rat duodenum. Darifenacin enhanced relaxation and 
duration of the response of McN-A-343, especially at lower doses. Nipecotic acid significantly enhanced the 
response of GABA, but there were no significant differences with McN-A-343. Addition of L-NAME had no 
significant effect on GABA or McN-A-343. 
McN-A-343 causes relaxation suggesting it is via M1 receptors. Darifenacin enhanced McN-A-343 relaxation 
at lower doses suggesting McN-A-343 has contractile M3 activity. At higher doses the larger relaxation 
responses mask this contraction. There is some evidence to suggest GABA may be released following M1 
stimulation. Nipecotic acid blocked GABA uptake leading to an increase in GABA available to bind GABAA 
receptors. There is no evidence to suggest nitric oxide is released following M1 or GABAA stimulation. 
1. Rang HP, Dale MM. 2012. Rang and Dale's pharmacology. Student consult. New York: Elsevier/Churchill Livingstone  
2. Micheletti R et al. Muscarinic M1 Receptors Stimulte a Nonadrenergic Noncholinergic Inhibitory Pathway in the Isolated Rat 
Duodenum. The Journal of Pharmacology and Experimental Therapuetics. 1988; 244(2): 680-684. 
3. Hamrouni AM et al. Investigation of the mechanism for the relaxation of rat duodenum mediated via M1 muscarinic receptors. Auton 
Autacoid Pharmacol. 2006; 26(3): 275-284. 
4. Broadley K. Autonomic Pharmacology. Taylor & Francis, 1996, pages153 and 343.  
 
A study of the effects of trace amines on the contractile function of the ileum 
Nicholas S Wong and KJ Broadley 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Trace amines are found at very low concentration in the body1 and in the diet.2 They are traditionally thought 
to cause relaxation of the gut via indirect sympathomimetic pathway.3 Primary aim is to clarify the main 
effects of the trace amine on guinea-pig ileum. Secondary aim is to examine whether trace amines exert 
effects on other receptors directly, independent of indirect sympathomimetic activity. 
Isolated guinea-pig ileum was used. Cumulative CRCs were obtained for -PEA, tyramine, tryptamine and 
octopamine either in the absence or presence of ritanserin or prazosin and propranolol. Two phases of 
contraction, initial and secondary contractions were seen and measured separately. Non-cumulative CRCs 
were obtained for -PEA and tyramine in the absence or presence of prazosin and propranolol, with dose 
exposure time of (30min). Initial and secondary contractions or number of spontaneous contractions were 
measured. 
-PEA and tryptamine caused dose-related contractions of the ileum, but tyramine contractions were not 
concentration-related. A 5-HT2 receptor antagonist inhibited 5-HT contractions, but did not inhibit -PEA or 
tyramine contractions. The degree of contraction was not potentiated by 1 and -adrenoceptors antagonists. 
Spontaneous contractions for -PEA and tyramine did not increase with time but were increased by 1 and 
-adrenoceptors antagonists. Tryptamine initial contractions were inhibited by 5-HT2 receptor antagonist and 
tryptamine secondary contractions were potentiated by 1 and -adrenoceptors antagonist. No apparent 
responses were elicited by octopamine. 
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-PEA, tyramine and tryptamine cause contraction rather than relaxation of the guinea-pig ileum. Tryptamine 
exerts action mainly via the 5-HT2 receptors. -PEA and tyramine contractions are independent of 5-HT2 
receptors. -PEA, tyramine and tryptamine exert opposing relaxation effect on the gut that were blocked by 
1 and -adrenoceptors antagonists to reveal a larger contraction. The contraction is the dominant effect that 
masks the relaxation. Octopamine does not cause contraction of the gut.  
1. Burchett S, Hicks S. The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain. Progress 
in Neurobiology. 2006; 79: 223-246. 
2. Gloriam D, Bajarnadottir T, Yan Y, Postlethwait J, Schioth H, Fredriksson R. The repertoire of trace amine G-protein-coupled 
receptors: large expansion in zebrafish. Molecular Phylogenetics and Evolution. 2005; 35: 470-482. 
3. Zucchi R, Chielline G, Scanlan TS, Grandy DK. Trace amine-associated receptors and their ligands. Br J Pharmacol. 2006; 149: 
967-978. 
 
The effects of zeta potential and particle size of polyelectrolyte nanoparticles on 
their diffusion through GI mucus 
Amber Wynne, M Abelkareem, G Al-Jayyoussi and M Gumbleton 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Proteins and peptides cannot be given orally due to degradation in the GI tract.1 Nanoparticles can overcome 
this by protecting these drugs from harsh physiological conditions.2 A barrier to oral nanoparticle delivery is 
the mucus lining covering the small intestine, in which nanoparticles can become entrapped.3 This is due to 
the presence of hydrophobic and hydrophilic regions of mucus2,3 which can interact with the nanoparticles. 
Cationic nanoparticles cannot diffuse through mucus due to electrostatic attraction with the negatively 
charged mucus. Anionic nanoparticles will be repelled by the same charge in mucus. Uncharged 
nanoparticles will bind the lipophilic regions in mucus through hydrophobic interactions. It is hypothesised 
that ‘Polyelectrolyte’ nanoparticles which are highly charged nanoparticles with both anionic and cationic 
charges, but possess a net neutral charge will achieve high diffusion rates across the mucus barrier as they 
would avoid electrostatic attraction and repulsion whilst being highly hydrophilic and hence avoiding 
hydrophobic interactions too. 
Polyelectrolyte nanoparticles were produced by overnight mixing of different ratios of Chitosan and Poly 
(acrylic acid) (PAA) at pH6.5. The nanoparticles produced in the study were characterised by measurement 
of key physical attributes, namely, zeta potential and particle size. Subsequently the effects that these 
parameters had on diffusion of Lumogen Red® loaded nanoparticles through GI mucus were observed by 
confocal microscopy and the determination of diffusion coefficient through mucus. 
At a ratio of 1 part PAA to 2.2 parts Chitosan the zeta potential was approximately 0mV. These particles 
were also the largest, due to aggregation. These neutral nanoparticles diffused through mucus at a much 
faster rate than either cationic or anionic nanoparticles. 
PAA Chitosan nanoparticles with a high charge density, but a net neutral charge have been shown to be 
excellent candidates for exploitation as vehicles for protein and peptide delivery across the GI tract. 
1. Park K, Kwon IC, Park K. Oral protein delivery: Current status and future prospect. Reactive and Functional Polymers. 2011; 71(3): 
280-287. 
2. Yun Y, Cho YW, Park K. Nanoparticles for oral delivery: Targeted nanoparticles with peptidic ligands for oral protein delivery. Adv 
Drug Deliv Rev. 2012. 
3. Ensign LM, Cone R, Hanes J. Oral drug delivery of polymeric nanoparticles: The gastrointestinal mucus barriers. Adv Drug Deliv 
Rev. 2012; 64(6):557-70.  
 
Development and evaluation of a computer-assisted learning (CAL) package on 
evidence-based rationales for the management of substance abuse 
Siew Sien Yaw and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Computer Assisted Learning (CAL) is a useful supplementary teaching aid which provides interactive 
learning.1 Additionally, CAL can be utilised as Continuing Professional Development (CPD) for healthcare 
professionals.2 This study aimed to evaluate the potential of a CAL package on Management of Substance 
Abuse for teaching and CPD purposes among MPharm undergraduates and postgraduate pharmacists.  
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The CAL package consisted of an up-to-date and evidence-based management for alcohol abuse and opioid 
abuse.3,4 Information was presented with animation, diagrams and colours to aid understanding as well as 
retaining students’ interest. Role of pharmacists was included to make the package relevant to pharmacy 
practice. Quizzes and case-studies were included to test students’ understanding. A questionnaire-based 
survey was conducted on MPharm II students to receive feedback on the CAL package presentation, content 
and overall impression. GoogleDocs online questionnaire was used, with a 5-point-Likert scale and a facility 
for comments.  
Twenty-three questionnaire responses were received (19%). Overall feedback towards the CAL package 
was positive. Most respondents agreed that the package was well-presented (91%, n=21). Content was 
viewed as relevant and respondents agreed that information could be understood easily, especially with the 
aid of diagrams (91%, n=21). Many positive comments were received about the role of pharmacists and the 
case-studies. Most students would use CAL for their course (78%, n=18). Respondents confirmed that the 
package complemented MPharm course (74%, n=17); and would benefit their practice as a pharmacist 
(91%, n=21). However, use of CAL for CPD showed varied responses.  
Majority believed the package was comprehensive and would benefit as a revision aid. However, several 
improvements were suggested: inclusion of hyperlinks, audio or video and more case studies examples. In 
conclusion, the package was a useful supplementary teaching aid. The value of CAL for CPD needs to be 
further clarified by future study on postgraduate pharmacists. 
1. Hudson JN. Computer-aided learning in the real world of medical education: does the quality of interaction with the computer affect 
student learning? Medical Education. 2004; 38(8):887-895. 
2. Pirashanthie VS et al. The evaluation of multimedia learning packages in the education of health professionals: experience of a 
musculoskeletal examination package. Nurse Researcher. 2001;11(3):43-55. 
3. National Institute for Health and Clinical Excellence (NICE) Guidelines. Alcohol-use disorders: Diagnosis, assessment and 
management of harmful drinking and alcohol dependence; 2011. [Accessed 15 Feb 2013] Available from: 
http://www.nice.org.uk/nicemedia/live/13337/53191/53191.pdf  
4. NICE. Methadone and buprenorphine for the management of opioid dependence; 2010. [Accessed 15 Feb 2013] Available from: 
http://www.nice.org.uk/nicemedia/pdf/TA114Niceguidance.pdf  
 
Evaluation of FDA approved small molecule anticancer drugs in the last 5 years 
Yutian Zhao and AD Westwell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Natural products have played a vital role in the history of anticancer drugs, however the arrival of X-ray 
crystallography and high-throughput screening have revolutionised the field of anticancer drug discovery, 
allowing researchers to conduct researchers much more efficiently.1 In this project, small molecule 
anticancer drugs that were approved by the FDA between 2008 and 2012 have been investigated. This 
project evaluated the whether if structural diversity of small molecule anticancer drugs have narrowed, along 
with the consensus towards target-based high-throughput screening, and whether if there is a decline in the 
popularity of natural products.  
First, small molecule anticancer drugs that were approved by the FDA between 2008 and 2012 were isolated 
from the FDA website. Details of each drug such as structure, approved indication, year of the indication 
being approved, drug class, their mode of action and origin of discovery were obtained from various sources 
of information. The number of drugs approved from each origin of discovery is then compared with past 
literatures. The structures of the drugs are evaluated to determine whether if the structural diversity has 
narrowed. 
Total of 45 new indications between 34 small molecule anticancer drugs were approved. After comparing 
these data with that of the past literature, I have found that there is a significant increase in the percentage of 
first time approved drugs being totally synthetic and a significant decrease in drugs that are natural products 
and natural product derivatives.  
Despite this the number of new natural products and natural product derivatives approved each year has 
actually increased stating that there is no loss in popularity of natural products. It is simply the case of a 
significant increase in the popularity of totally synthetic drugs. The structural diversity has not narrowed 
judging on the wide range of structural motifs and drug modes of actions. 
1. Blundell TL et al. Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead 
discovery. Philosophical Transactions of the Royal Society of Biological Sciences. 2006; 361: 413-423. 
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The following abstracts have been withheld as they have been or will be published 
elsewhere, and/or due to intellectual property or confidentiality issues: 
 
Production and permeation of topical gabapentin formulations across various 
diffusion barriers 
Jessica Bennett, CJ Martin1, S Hiom1 and JC Birchall 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB and 1St Mary’s Pharmaceutical Unit, Cardiff and Vale University Health Board, 20 Fieldway, Cardiff, 
CF14 4HY, Wales, UK 
 
Design, synthesis and biological evaluation of potential anticancer drugs 
Man Hin Chung, M Slusarczyk, M Serpi and C McGuigan 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
The effects of modification of 5-HT and dopamine on their biological activity 
Abigail Farrell and AK Campbell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
Vitamin D and its association with cancer: selective inhibition of the CYP24A1 
enzyme 
Tomas Griffith and C Simons 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
The study of the effect of temperature on the aerosol performance of nebulised 
salbutamol sulphate 
Parvinder Hayre and G Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
Comparative in vitro assessment of salbutamol sulphate metered dose inhalers: 
consistency of delivered dose using different priming and shaking methods 
Mohd Fadhil Mohd Zaki and G Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
A study of growth factor impact on signalling in the presence of a pan-erbB inhibitor 
in tamoxifen resistant (TAM-R) cells 
Jenny Ng, RA McClelland, IR Hutcheson1, D Barrow, L Goddard and JMW Gee 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK and 1Department of Pharmacology, Therapeutics & Toxicology, Cardiff University School of Medicine, 
Heath Park, Cardiff CF14 4YU, Wales, UK 
 
 
 
MPharm 
55 
The efficacy of different wipe materials to remove bacteria from surfaces in a 
hospital environment 
Megan O’Hara, H Siani and J-Y Maillard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
Deducing the mechanism by which human insulin catalyses coelenterazine 
chemiluminescence 
Chris Peberdy, C Cox and AK Campbell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
Synthesis of Bcl3 inhibitors against HER2+ mammary tumours 
Sunaiya Varsani, AD Westwell, and J Soukupovà1 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK and 1School of Biosciences, Cardiff University, Wales, UK. 
 
Design and synthesis of novel inhibitor of Mycobacterium tuberculosis Cytochrome 
P450 CYP121 
Mandy HT Yu and C Simons 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
Is rectal administration an alternative route for melatonin? 
Nur Ili Nadiah Zulkiple and G Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
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Patients and providers views on the pain or discomfort experienced by women 
having the insertion of an intrauterine method of contraception 
Hannat Akintomide and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Intrauterine contraception is the most commonly used method of contraception worldwide. Pain and 
discomfort associated with the insertion of an intrauterine device is a known barrier to intrauterine 
contraception use in the West. There is no evidence that currently available analgesia and local anaesthesia 
are effective for pain experienced during the insertion procedure. Exploring health professionals’ (providers) 
and women’s (patients’) views on pain during intrauterine device insertion will facilitate an understanding of 
and further research on pain experienced during intrauterine device insertion and its management. 
This project aimed to determine the prevalence of and reasons for local anaesthesia use and non-use by UK 
health professionals during intrauterine device insertion, the pain and/or discomfort experienced by women 
who have the insertion of an intrauterine device, and to establish if this correlated well with pain health 
professionals perceived women to have experienced during their insertion procedure. 
Questionnaire surveys were undertaken to determine local anaesthesia use by UK health professionals that 
perform intrauterine device insertions, and to collect information on the patient experience of intrauterine 
device insertion from both health professionals and women. 
The majority of UK healthcare professionals did not routinely use local anaesthesia during intrauterine device 
insertions. Most women surveyed received local anaesthesia during their insertion and experienced mild 
pain or minimal discomfort. Health professionals had a tendency to perceive a lesser degree of pain than 
was actually experienced by their patients during insertions. Intrauterine device insertion may be associated 
with pain, even when available local anaesthesia is used. Health professionals perceive less pain than 
actually experienced by their patients during insertions. Healthcare professionals may better serve their 
patients and increase intrauterine contraception use by routinely offering local anaesthesia to women for 
intrauterine device insertion. 
 
An investigation of a new compound for the treatment of adrenal insufficiency 
Maria Collins and RDE Sewell  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
This was an original research study to investigate whether a modified release formulation of hydrocortisone 
(Chronocort®) could be used to replicate physiological cortisol release. Patients who are deficient in cortisol 
have to take life-long hydrocortisone replacement (the synthetic form of cortisol).  
Twenty eight health male volunteers were administered either 5 mg, 10 mg, 20 mg or 30 mg modified 
release formulations of hydrocortisone (Chronocort®). Blood samples were taken to examine the 
pharmacokinetic profile. The safety and tolerability of Chronocort® was assessed and was considered to be 
safe and well tolerated.  
The AUC demonstrated that twice daily dosing provided a similar AUC to the normative cortisol profile. A 
comparison of the time-segmented AUC parameter exemplifies the closeness of fit between DIURF-006 (20 
mg and 10 mg) versus normative data i.e., AUC0-8: 1824.18 versus 1338.65 hr*nmol/L, AUC8-18: 3391.36 
vs. 2690.81 hr*nmol/L and AUC18-24 501.53 vs. 827.32 hr*nmol/L. Hence, twice daily dosing with the 
modified release formulation of hydrocortisone was capable of replicating physiological cortisol release. 
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Pharmacovigilance and the prevention of adverse drug reaction at Guy’s and St 
Thomas’ NHS Foundation Trust: a retrospective observational study of ADRs to 
warfarin 
Paul Ian Cross, MS Salek and RDE Sewell  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Pharmacovigilance is vital for identifying adverse drug reactions (ADRs) to medicines. The aim of this 
research was to raise awareness of pharmacovigilance in order to aid in the prevention of ADRs at Guy’s 
and St Thomas’ NHS Foundation Trust. This investigation involved a study of the impact of the 
implementation of a quality management system on pharmacovigilance reporting, to the Kings Health 
Partners Clinical Trials Office (KHP-CTO). Warfarin is a drug often implicated in causing ADRs. A study of 
warfarin-related medication incidents reported via the Datix patient safety and risk management system 
(from April 2007 until March 2012) was also completed. Incident data were compared against a second 
dataset which was collected from a cohort of patients who were prescribed warfarin.  
This research produced a number of key findings: (1) the implementation of the KHP-CTO quality 
management system improved pharmacovigilance reporting frequency, due to increased training, awareness 
and improved competencies of clinical research personnel. (2) the most frequent warfarin-associated ADR 
was increased INR, sometimes resulting in over anticoagulation and haemorrhage. (3) The frequency of 
drug-drug interactions identified was limited; however two drugs were identified that may have been 
implicated: enoxaparin and metronidazole (an antibiotic). Enoxaparin was the root cause of two serious 
ADRs, including one case of retroperitoneal haemorrhage, a rare and serious ADR. The frequency of 
incident reporting was high; however the importance of ADR reporting via the Yellow Card Scheme should 
be reiterated to clinical personnel, as some suspected warfarin-related ADRs were not reported 
appropriately. On evaluation, medication errors accounted for 84.62% of warfarin-related ADRs as reported 
via Datix. (4) The warfarin prescribing and administration for inpatients requires the greatest focus for 
targeted quality improvement programs. (5) The Datix incident system is a valuable tool that should be 
developed further for pharmacovigilance purposes.  
Pharmacy could assist in improving the reporting of ADRs by performing pharmacovigilance audits. 
Important findings could then be reported Trust-wide in order to raise awareness. Future work could 
compare pharmacovigilance data between NHS Trusts to assess the implementation of other quality 
systems. It would be interesting to investigate the relationship between concurrent warfarin and enoxaparin 
use and the potential for ADRs in this group. Finally, it would be important to investigate issues related to the 
use of recently licensed drugs: if known events to licensed drugs such as warfarin are not reported 
appropriately, then unknown reactions to novel drugs may also be missed.  
 
Barriers and influences on recruitment and retention in paediatric clinical trials: a 
parents’ perspective 
Laura Crowther and RDE Sewell  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Paediatric research is necessary to ensure that the medicines given to children are safe and efficacious. The 
importance of research in this population has been recognised in recent EU legislation, with the inclusion of 
a Paediatric Investigation Plan now mandatory in all marketing authorisation applications. Parents play a key 
role in recruiting children to clinical trials since they have the responsibility of making the decision as to 
whether their child can participate. Consequently, in order to inform the design of future trials for 
maximisation of recruitment, it is essential to obtain the opinions of parents and guardians regarding 
influences on their decisions.  
The study was conducted in two phases: In phase I a questionnaire was designed to assess the views and 
opinions of parents regarding their child’s participation in research; Phase II involved distribution of the final 
questionnaire to parents in a single tertiary centre in the UK.  
98 completed questionnaires were analysed. One of the main findings was that there is a failure to meet the 
expectation of parents in terms of the information they are given about research, and the opportunities to 
take part. Key barriers to recruitment were: unknown side effects of new treatments; additional tests that may 
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be uncomfortable to the child; and the child not wanting to take part. Motivating factors were benefit to the 
child and access to the latest treatments. Differences were identified in the opinions of subsets of the 
population with regard to certain barriers, for example in different ethnic and disease groups.  
More needs to be done to engage with parents, as the vast majority of participants were not only happy to be 
contacted about relevant trials, but expected to be informed of any studies that may be appropriate for their 
child. Involvement of the child in the decision making process is important to families. Further investigation of 
the differences in the opinions of subsets of the population is needed to inform design of trials, in order to 
ensure that participation in clinical trials is as simple as possible for families. 
 
Do Polish patients prefer the virtual clinical trial or the standard clinical trial where a 
clinic must be attended? 
Patrycja Doba, RDE Sewell and WR Ford  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
75-85% of clinical trials fail to make their timelines due to insufficient patient enrolment and retention. Slow 
patient recruitment and poor patient retention within ongoing clinical trials is thought to be caused by 
limitations and inconvenience of a standard clinical trial. The virtual clinical trial introduced by Pfizer holds 
promise of improving patient recruitment and retention by opening up trials to a larger patient population and 
making trial participation more convenient. 
As the virtual clinical trial is carried out is totally different to a standard trial, it would be imperative to know 
whether patients would like to participate in such a trial and whether they would prefer this type of trial over a 
standard clinical trial where a clinic must be attended.  
Questionnaires (120) were sent out to five Investigators across Poland for distribution among patients that at 
least one time in their lives had participated in a standard clinical trial.  
117 patients completed the questionnaire. The results indicated that Polish patients do not prefer virtual 
clinical trials over standard clinical trials as 82% of Polish patients, when given the opportunity to choose 
between a standard and virtual clinical trial chose the first one. Statistical analysis of the answers given by 
the patients showed that patients’ preference for participation in a standard clinical trial over virtual clinical 
trial did not depend on any of the socio-demographic factors or actual use of the Internet by patients. 
The results of this research study have some significant implications for the pharmaceutical industry. Firstly, 
virtual clinical trials might not be attractive to some patients despite their convenience. Secondly, virtual 
clinical trials might not resolve recruitment and retention problems and thirdly, a hybrid version of the 
standard clinical trial and virtual clinical trial might be the best solution towards patient recruitment and 
retention problems.  
 
An investigation into a new compound for the treatment of type 2 diabetes mellitus 
Oliver Knott, WR Ford and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
This thesis reports the findings of an investigational study into a potential new oral capsule treatment for type 
2 diabetes mellitus (T2DM). PSN821 is an agonist at the G protein-coupled receptor GPR119 and has 
shown to substantially lower glucose and cause meaningful weight loss in animal studies. The compound 
has so far been tested in 2 clinical trials as a suspension and has been shown to be safe and well tolerated. 
The primary objective of the study was to compare the bioavailability of PSN821 administered as a 
suspension with two novel oral capsule formulations and assess the effect of food (high fat and if necessary 
a light breakfast) on bioavailability.  
This was a randomised, open-label, crossover study in 18 healthy volunteers. Group 1 (9 subjects) received 
PSN821 capsule formulation 1 fasted and following a high fat meal, plus PSN821 suspension fasted. Group 
2 (9 subjects) received PSN821 capsule formulation 2 fasted and following a high fat meal, plus suspension 
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fasted. Based on the interim safety and PK data collected from Periods 1 and 2, Group 2 were asked to 
return to receive capsule formulation 2 following a light meal. During the study 3 subjects requested early 
discontinuation in Group 2 and were replaced to ensure 18 completed the study. PSN821 capsule 
formulation 1 and 2 were found to be markedly less bioavailable than the reference suspension when 
administered to fasted subjects. Administration of capsule formulation 1 after a high fat meal and capsule 
formulation 2 after a light breakfast increased bioavailability, but both were still lower than that of the 
suspension. Exposure to PSN821 following administration of capsule formulation 2 after a high fat meal 
increased when compared to the reference suspension, although the rate of absorption was delayed and 
Cmax reduced.  
The low bioavailability seen in the capsules following fasted administration was the likely result of slower 
capsule disintegration, drug dissolution and drug transit through the GI tract. The increase in bioavailability 
following food may be the result of a greater residence time and fluid volume, producing better disintegration 
and dissolution of the capsule. Additional work will need to be performed in order to develop a capsule 
formulation that has better bioavailability, especially if bioequivalence with the suspension is to be achieved. 
Additional clinical trials may be necessary to investigate this possibility.  
 
An examination of administration of antibiotics to patients with a blood stream 
infection 
Helen Lewis and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Blood born infections are known to have one of the worst outcomes of any infection, both clinically and 
financially. Prompt and effective treatment is the primary determinant in a positive outcome. Meanwhile 
administering medication is a fundamental nursing activity. The focus of this study was to establish how well 
the Trust performed against national standards in prescribing and administering anti-microbial agents in this 
patient group. It also assessed whether patients prescribed antibiotics (ABx) were administered it correctly 
and where prescriptions were not administered, was appropriate documentation completed and the relative 
risks evaluated between a critical care facility and an acute medical ward? 
A retrospective audit of medical notes was undertaken to evaluate administration versus prescriptions of 
antibiotics and the documentation to explain discrepancies. All data were recorded on a database with a 
combination of fixed and free text data fields. Results were described in terms of percentages and relative 
risk. 
Thirty per cent of prescriptions for ABx prescribed were not administered. There was no difference in risk 
across ICU or an acute medical setting. There was a significant difference in whether ABx were administered 
on time RR of 3.21 (95% Confidence interval: 2.989 – 3.43) between ICU and the acute medical setting, 
patients on ICU were three times more likely to receive their medication on time. While documentation 
pertaining to omissions were less likely to occur on ICU than the acute medical wards; RR 0.44 (95% 
Confidence interval: 0.237 – 0.882) 
While rates of prescriptions administered were disappointing, they were comparable to other prospective 
studies. Reasons for this poor delivery of nursing care are discussed, along with the limitation of the study. 
While the reasons can be speculated; the issue for nurses is how to ensure that while technology is 
embraced to reduce these issues, nurses do not become devoid of personal contact in this most human of 
professions. 
 
An educational research project to determine the level of understanding of the 
informed consent process from the perspective of the healthy volunteer 
Deirdre McCollam and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The Participant Information Sheet, which forms the main part of the informed consent process has evolved 
into a lengthy narrative document. Designed to inform participants of trial details, it has become complex, not 
easily or readily understood. Much research has been documented on content and length of the participant 
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information sheet, but little on comprehension. The primary objective of the research was to ascertain the 
level of understanding of the informed consent process from a healthy volunteer perspective. Secondary 
objectives were: (a) To determine factors that influence people to participate in clinical trials; (b) the male : 
female ratio.  
Method was by means of a quantitative questionnaire for clinical trial participants to complete immediately 
after consenting. Section 1 determined sex, age, demography, language, employment & marital status and 
any previous experience of consenting. These responses allowed for comparisons & correlations, answering 
the secondary objectives. Section 2 was designed to answer the primary objective. A healthy volunteer 
population was chosen based on the type of phase 1 studies being conducted in the study unit in which the 
researcher was employed. Questionnaires were collated, coded and complete datasets analysed. Results 
were in the form of visual representations, pie charts/bar graphs.  
In the primary outcome measure it was established that as many participants had a high understanding as 
those who had a low understanding. (High 23%, Low 21%). In the secondary outcome measure it was 
established that - correlations between and personal circumstances and reason for participation were as 
follows:  
1. The majority participated for financial reward.  
2. The employed outnumbered the unemployed.  
3. Those with previous experience of consenting for participation in a clinical trial had a poor level of 
understanding compared to those participating for the first time.  
4. Demography was not an influencing factor and any difference between rural and urban areas were 
minimal.  
5. More males than females participated.  
6. The age range was reflected by the type of studies that were conducted.  
Complete comprehension could not be established, so further research studies should be performed to 
determine if there are alternative options for testing comprehension. 
 
The Impact of ICH GCP on clinical trial procedures operationally within the USA, EU 
and Japan 
Mia Romijn, MS Salek and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Historically there have been differences in the regulation and law between the USA, EU and Japan on 
conducting clinical trials. Following the introduction of the ICH GCP Guidelines, one of the primary aims was 
to harmonise these three regions, but although standards of quality have been harmonised, it is still unclear 
whether operational procedures and efficiency within the pharmaceutical industry (sponsors as well as 
Contract Research Organisations) have been standardised globally. 
The aim of this dissertation was to fully understand how ICH GCP has impacted clinical trial procedures 
within USA, EU and Japan operationally with regards to regulation and law by reviewing the following 
objectives; 
Examining if the differences in interpretation affect the management and running of clinical trials today from a 
sponsor and CRO perspective; 
To determine what could be done differently to aid the management and running of clinical trials today; 
To explore what changes could be implemented in the future to improve operational delivery of clinical trials 
The ICH GCP guidelines encompasses all aspects of clinical trials, but this dissertation will focus only on the 
main regulations and law that affect the initial phase of clinical trials, commonly described as “Start Up”. For 
the purposes of this dissertation, ‘Start Up’ was defined as the time period between protocol finalisation until 
the first subject has been enrolled.  
Emerging countries such as Asia and India are attracting a growing number of large-scale clinical trials, as 
they have access to large subject populations required to run these trials. The shift to running clinical trials 
within these markets has increased in recent years which could lead to a drop in clinical research activities 
within the 3 main regions (USA, the EU and Japan). However, ICH GCP regulations have been firmly 
entrenched over the USA, EU and Japan for a number of years and this is reflected within the current 
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regulations in place. This allows for assurances from different countries that clinical trials have been 
performed in a robust manner and that subject safety and the data collected from these clinical trials are of a 
deliverable quality. This ultimately provides reassurance to the subject population and general public that the 
drugs that the pharmaceutical industry are bringing to market are safe and efficacious.  
 
The socioeconomic impact of HIV/AIDS in Zimbabwe 
Lavender Tembo, WR Ford and RDE Sewell  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The Human Immunodeficiency Virus/Acquired Immuno-Deficiency Syndrome (HIV/AIDS) is the epidemic that 
has aggrieved many countries in Sub-Saharan Africa for over 30 years. Sub-Sahara is home to only 12% of 
the world’s population yet, it accounts for 22.9 million of HIV-infected individuals. This thesis investigates the 
hypothesis that there is a negative relationship between HIV/AIDS and economic growth. This disease is 
nothing like other diseases, because it largely affects the healthiest and most reproductive and productive 
populations (individuals between the ages of 15-49). Thus, the effects on households, industries, farming, 
governments and the health sector can be critical and far-reaching. Consequently, such an analysis is 
fundamental in framing public decision-making concerning resource allocation and policy interventions and 
placing HIV/AIDS as a national priority. 
The research makes use of secondary source of data in the form of published data from the World Bank 
Report (2012) and World Development Indicator (WDI) and also source data from Joint United Nations 
Program on HIV/AIDS (UNAIDS), (2011). Analyses are based on data from 10 southern African countries for 
the period 1996-2009. The study used Gross Domestic Product (GDP) per capita as a proxy for economic 
growth and HIV prevalence rate as the independent variable. A Spearman rank analysis was conducted to 
determine the nature of the correlation between the GDP per capita and HIV prevalence rate.  
The analysis concluded that there is a significant correlation between HIV prevalence rate and economic 
growth. The correlation coefficient (0.336) is positive, denoting that there is a positive relationship between 
HIV prevalence and GDP per capita. The results, therefore, show an opposite relationship from the one the 
study hypothesised.  
 
PhD 
62 
Acquired tamoxifen resistance and promotion of angiogenic responses in breast 
cancer 
Edward Hayes and S Hiscox 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
In the treatment of pre-menopausal women with oestrogen positive (ER+) breast cancer, tamoxifen 
represents a first line of adjuvant treatment with demonstrable benefits. Despite this, resistance is frequently 
acquired to tamoxifen with an associated poor prognosis. Breast cancer cell models have revealed the 
importance of growth factor signalling networks in sustaining growth of endocrine-resistant cancers and, 
more recently, their ability to promote a highly migratory and invasive phenotype, together with the 
expression of genes with pro-angiogenic ontology. The potential of endocrine-resistant cells to elicit 
angiogenic responses, however, remains unknown. Real-time PCR was used to validate results from 
preliminary Affymetrix-based gene profiling of pro-angiogenic gene expression in endocrine-sensitive 
MCF7wt cells and their endocrine resistant counterparts. The expression of pro-angiogenic factors in 
conditioned media (CM) from these cells was assessed by ELISA. The proliferative and migratory effects of 
conditioned media on vascular endothelial cells (HUVEC and HECV cells), was determined by MTS cell 
proliferation assay, wound closure assays and Matrigel tubule formation assays. Changes in endothelial cell 
migration following co-culture with endocrine-resistant cells were examined using Boyden-chamber 
chemotaxis assays. Growth factor signalling and migration pathway activation in endothelial cells in 
response to CM was determined by Western blotting. TamR cells were found to express high levels of IL-8 
and VEGF at an mRNA level compared with expression in MCF7wt cells. High levels of VEGF protein were 
also confirmed in the conditioned media from TamR cells versus their endocrine-sensitive counterparts. 
TamR conditioned media promoted in vivo and ex vivo endothelial cell proliferation, as well as in vitro 
endothelial cell migration and the formation of tubules to a greater extent than that seen in MCF7wtCM 
treated cells. TamR conditioned media was found to stimulate VEGFR2 phosphorylation and downstream 
activation of MAPK and Akt in endothelial cells compared to MCF7wt CM. Pharmacological inhibition of 
VEGFR2 activity in endothelial cells suppressed TamR-induced endothelial cell proliferation and VEGFR 
phosphorylation. Further pharmacological manipulation of Src kinase in TamR cells revealed a Src kinase 
dependent mechanism of VEGF production in these cells. In addition, in vivo examination of TamR 
xenografts illustrated higher presence of endothelial cells in these tissues than in MCF7wt xenografts. These 
data suggest acquired tamoxifen resistance is accompanied by development of a Src kinase-dependant pro-
angiogenic phenotype which, if recapitulated in vivo, may promote tumour progression. Therapeutic targeting 
of Src signalling may prove beneficial in such cases. 
 
Understanding the interactions of hydrogen peroxide with macromolecules and 
microbial components 
Ezra Linley, SP Denyer, C Simons, G McDonnell 1 and J-Y Maillard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK and 1Steris Corporation, Mentor, Ohio, USA 
The bactericidal mechanism of hydrogen peroxide is poorly understood, with most evidence being obtained 
from studies involving greatly reduced concentrations aimed at investigating the effects of stress. Current 
theory suggests that this mechanism is based on the oxidation of protein, DNA and lipids within the cell by 
the production of free hydroxyl radicals through the interaction of hydrogen peroxide and intracellular iron. 
The mechanism of vapour phase hydrogen peroxide treatment remains unstudied, despite evidence that it 
may be different to the liquid phase. 
This study aimed to investigate the effects of bactericidal treatments of liquid and vapour phase hydrogen 
peroxide on the macromolecular components of a model organism, Escherichia coli strain K12. A set of 
treatment conditions producing a range of reductions in colony forming units was identified, and the effects of 
these conditions on the protein, DNA and lipid constituents of the cells assayed. 
No effect on the lipid contents and membrane integrity of treated cells was found. Liquid hydrogen peroxide 
was found to reduce the thiol content of cytoplasmic protein, but this was not found to be a major mechanism 
of bactericidal action. Extensive fragmentation of DNA was found to result by treatment with both phases, the 
degree of which was correlated with a reduction in colony forming unit counts. No effect on bactericidal 
action was found on addition of a hydroxyl radical scavenger or an inhibitor of protein synthesis, showing that 
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DNA damage was due to the primary action of hydrogen peroxide, and that this damage was not caused by 
the production of free radicals within the cell. 
A modified mechanism of hydrogen peroxide bactericidal action is proposed, whereby lethality is due solely 
to DNA damage caused by the production of ferryl radicals by the interaction of hydrogen peroxide and iron 
associated with the DNA backbone. 
 
The involvement of CaMKII in myocardial ischaemia-reperfusion injury 
Osian Llwyd and GF Baxter 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
CaMKII acts as a second messenger to Ca2+ signals within the cardiac myocyte. Cellular stresses such as 
ischaemia and subsequent reperfusion perturb the normal physiological oscillations of Ca2+ to cause an 
escalating concentration which damages the cell. CaMKII has been implicated as an injury signal during 
such cellular conditions. However, there are discrepancies as to whether CaMKII is a possible mechanism of 
ischaemic preconditioning as its inhibition can abrogate or improve the protective effect of preconditioning. 
This thesis investigated the effects of CaMKII inhibition in models of ischaemia-reperfusion (I-R) injury. It was 
hypothesised that CaMKII promotes irreversible injury caused by acute myocardial infarction (AMI), but 
would also have a beneficial role in mediating cardioprotection by ischaemic preconditioning. This work has 
demonstrated that: i) in an ex vivo rat heart model of regional I-R injury, CaMKII promoted irreversible injury 
but is not a feasible target for reperfusion therapy as only a pre-ischaemic intervention reduced myocardial 
infarction; ii) CaMKII activation was not a pre-requisite for protection with ischaemic preconditioning, 
although an additive protective effect of CaMKII inhibition and ischaemic preconditioning was possible; iii) 
models of simulated I-R or oxidative stress in the H9c2 cells did not involve CaMKII activity; iv) isolated 
cardiac myocytes paced at 1Hz and subjected to simulated I-R do not engage a significant amount of 
CaMKII activity. These studies substantiate the involvement of CaMKII during ischaemic injury and establish 
that it does not play a substantial role in ischaemic preconditioning. It highlights the characteristics of the 
kinase within in vitro models of I-R injury. Understanding CaMKII role in I-R may underpin the development 
of future therapeutic strategies for the management of AMI. 
 
The role of viral and bacterial infections in asthma exacerbations and corticosteroid 
resistance 
Alexander PP Lowe, WR Ford, EJ Kidd and KJ Broadley 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Asthma is a chronic inflammatory disease of the airways characterised by early and late asthmatic 
responses (EAR & LAR) to allergen, airways hyperresponsiveness (AHR) to inhaled spasmogens, airway 
inflammation and airway oedema. Viral infections and lipopolysaccharide (LPS) from bacteria and 
environmental sources contribute to exacerbations of asthma and the development of insensitivity to 
corticosteroids. Complete insensitivity to oral corticosteroids is rare and most patients lie on a continuum of 
steroid responsiveness. This thesis aimed to examine the effect of viral infection and LPS in a guinea-pig 
model of asthma and determine the sensitivity to inhaled and systemic corticosteroids. 
Sensitised guinea-pigs challenged with ovalbumin displayed EAR, LAR, AHR to histamine, airways 
inflammation and airway oedema. Inoculation of guinea-pigs with parainfluenza-3 virus alone induced AHR 
to histamine and airway inflammation. However this response was not consistent. Inhaled LPS alone 
induced an immediate bronchoconstriction, AHR, airway inflammation and oedema and goblet cell 
hyperplasia. LPS co-administered with ovalbumin exacerbated the allergen response by lengthening the 
EAR, prolonging the bronchoconstrictor response to histamine, increasing airway inflammation and oedema 
and goblet cell hyperplasia.  
In guinea-pigs challenged with ovalbumin alone, treatment with inhaled fluticasone propionate (FP) and 
inhaled and systemic dexamethasone decreased the LAR, abolished AHR, airway inflammation and 
oedema. Responses to LPS alone were not reduced by inhaled dexamethasone or FP but partially reduced 
by systemic dexamethasone. Ovalbumin and LPS combined responses were insensitive to inhaled 
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corticosteroids, except lavage fluid protein. These responses were partially sensitive to systemic 
dexamethasone, with the prolonged EAR, inflammation and airway oedema all reduced.  
The data in this thesis suggests that LPS inhalation exacerbates ovalbumin-induced functional and 
inflammatory responses rendering them insensitive to inhaled corticosteroids but partially sensitive to 
systemic corticosteroids. Thus, the experimental combination of ovalbumin with LPS might represent a useful 
preclinical model of corticosteroid-insensitive airway inflammation. 
 
Liquid loaded microneedles for the intradermal delivery of botulinum toxin for 
Primary Focal Hyperhidrosis 
Barbara Maria Torrisi, JC Birchall and SA Coulman 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Primary focal hyperhidrosis (PFHH) is a medical condition characterised by over-activity of the eccrine sweat 
glands, primarily occurring on palmar, plantar and axillary regions. PFHH can have a significant adverse 
impact on a patient’s quality of life. Multiple intradermal injections of a commercial formulation of botulinum 
toxin A (BTX A) (Botox®) is the most effective non-surgical treatment currently licensed in the UK for cases of 
severe PFHH. Although effective, intradermal BTX A injections are associated with considerable pain and 
discomfort for the patient and are time-consuming for the administering clinician. This study aims to evaluate 
the potential of using pocketed microneedle devices for minimally invasive intradermal delivery of BTX A, as 
a liquid formulation, into human skin.  
Pocketed microneedles, metallic 700 μm-long needles containing a cavity within the needle shaft, were 
selected as an appropriate and relatively untested intradermal delivery device. Pocketed microneedle 
devices (PMDs) were liquid loaded by immersion into a ‘Botox® like’ formulation that mimicked the 
composition of the commercial Botox ® formulation, with the exception of BTX A, which was replaced by the 
model macromolecular protein β-galactosidase (~465 kDa). A water-soluble dye was also included to enable 
visualisation. Microneedles were assessed for loading uniformity by light microscopy and the formulation 
residency time was evaluated by monitoring evaporation using a digital camera. The microneedle loading 
capacity was determined using an established quantitative assay for β-galactosidase. Studies using excised 
human breast skin, maintained in organ culture, examined delivery of the model β-galactosidase from liquid 
loaded PMDs and the time-dependent diffusion of the protein within the dermal tissue. A more clinically 
representative model of BTX A, formaldehyde inactivated BTX A, i.e., botulinum toxoid, was used to 
determine the deposition pattern of the therapeutic within the skin. Following skin delivery the toxoid was 
detected by immunohistochemical staining and fluorescence imaging, following its conjugation to an 
appropriate fluorophore.  
Immersion of the PMD into a ‘Botox® like’ formulation resulted in successful uptake and retention of the 
model protein solution. Quantitative studies indicated that nanogram quantities (~100 ng/microneedle array) 
of the β-galactosidase model can be loaded and retained on individual microneedles, in a liquid state. These 
results suggest that the loading capacity of the microneedle device is appropriate for therapeutic botulinum 
toxin formulations, although loading uniformity will need to be addressed. Histological analysis revealed 
effective delivery of the model β-galactosidase from a PMD to the epidermal and the dermal layers of the 
skin. Rapid and extensive diffusion of the protein within the deeper dermis was also demonstrated. Further, 
immunohistochemical and fluorescence studies indicated effective PMD loading and successful delivery of 
botulinum toxoid to the dermis of human skin. These data suggest that it should be possible for BTX A to 
access its therapeutic target (the eccrine sweat glands) following delivery via PMDs.  
This study has demonstrated for the first time that pocketed microneedle s represent a viable, minimally 
invasive alternative, for the intradermal delivery of botulinum toxin A (Botox®). Future pre-clinical and clinical 
studies are now required to test and optimize a microneedle - based delivery system that is most suited to 
clinical practice.  
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The following abstracts have been withheld as they have been or will be published 
elsewhere, and/or due to intellectual property or confidentiality issues: 
 
Antiviral drug design, synthesis and biological evaluation for treatment of Hepatitis 
C virus 
Claire Bourdin and C McGuigan 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
Design, synthesis and biological evaluation of acyclic nucleotide prodrugs as 
potential antiviral agents 
Davide Carta and C McGuigan 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
Pathogenicity & a bedside real-time detection assay for clostridium difficile in the 
faeces of hospitalized patients 
Lovleen Tina Joshi, J-Y Maillard and L Baillie 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
Design, synthesis and biological evaluation of novel anti-HCV nucleosides and 
nucleotides: from bench to the clinical trials 
Karolina Madela and C McGuigan 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
Development, characterisation and evaluation of sugar glass microneedles 
Christopher Martin, CJ Allender, KR Brain and JC Birchall 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
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